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Summary 
 
 
Mitochondrial genetics has been changing its focus during the last decade. Originally limited 
to describing effects of mutations of the mitochondrial DNA (mtDNA) research at present 
aims to understand circumstances of mutation generation and propagation in the context of 
mitochondrial genome maintenance. Key players of the mitochondrial DNA synthesis 
machinery have been thoroughly investigated by many research groups. However, little is 
known about the influence of other processes that are crucial for mtDNA maintenance. 
During my PhD study, I have been working on projects that seek to shed light on specific 
aspects of disturbances in mtDNA maintenance. (i) Investigating three families with an 
mtDNA maintenance disorder, we discovered a novel gene MGME1 that can process single 
stranded DNA molecules and flap structures, shows 5’-exonuclease activity, and probably 
plays a role in the process of replication and turn-over of replication intermediates, such as 
7S DNA. 
(ii) Different factors that affect mitochondrial biogenesis in general might also 
influence mtDNA maintenance. Mitofusin 2 is one of these factors playing a crucial role in 
fusion of mitochondria, and thus in achieving an appropriate balance of mitochondrial 
dynamics. Pathogenic mutations in the MFN2 gene lead to mitochondrial fragmentation. We 
were able to show that alteration of mitochondrial dynamic leads to respiratory deficiency 
through a disturbed mtDNA replication. 
(iii) Our group developed techniques to investigate complex mixtures of large mtDNA 
deletions that are known to be involved in several human diseases, such as Parkinson’s and 
Alzheimer’s, as well as, in normal aging. We demonstrate that TLE with AHS, a rather 
common neurological disorder, is also associated with pathological changes in the 
mitochondrial genome. Analyzing detailed spectra of deletions we are able to investigate 
alterations of deletion patterns that might provide hints about different mechanisms leading to 
deletion generation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
List of Tables 
 
iv 
List of Tables: 
 
Table 1 Oligonucleotides for the nuclear gene Kir4.1 32 
Table 2 Oligonucleotides used for linker synthesis 32 
Table 3 mtDNA primers in the D-loop 33 
Table 4 Primers in the mtDNA coding region 34 
Table 5 Enzymes 35 
Table 6 Chemicals 36 
Table 7 Solutions 37 
Table 8 Kits 37 
Table 9 Equipment 38 
Table 10 Software 39 
Table 11 Mixture for PAGE gel 44 
Table 12 TaKaRa LA Taq (HS) and JumpStart AccuTaq LA LR PCR mixture 44 
Table 13 LR-PCR program 45 
Table 14 TaKaRa LA Taq (HS) smPCR mixture 45 
Table 15 Single-molecule PCR program 46 
Table 16 SYBR® Green qPCR mixture 49 
Table 17 SYBR Green qPCR program 49 
Table 18 TaqMann® qPCR mixture 50 
Table 19 Ranger qPCR mixture 52 
Table 20 Linker annealing mixture and conditionsл 53 
Table 21 Quick Blunting Kit treatment 53 
Table 22 Mung Bean Nuclease treatment 54 
Table 23 S1 nuclease treatment 54 
Table 24 Linker ligation 55 
Table 25 LM-PCR mixture 55 
Table 26 LM-PCR program 56 
Table 27 Single-molecule LM-PCR mixture 56 
Table 28 Program for single-molecule LM-PCR 56 
Table 29 TaKaRa LA Taq (HS) multiplex PCR mixture 57 
Table 30 PCR program for multiplex PCR 57 
Table 31 LongAmp PCR mixture 58 
Table 32 PCR program for sequencing PCR 58 
   
  List of Tables 
  v                                                                                           
Table 33 Amount of deletions in MGME1 muscle biopsy (MB) samples, control   
 muscle and POLG muscle (PG) 65 
Table 34 Small direct multimers in the D-loop of MGME1 patients 68 
Table 35 mtDNA copy numbers determined in four CMT2A patients,   
 one diseased control patient with CMT1A and controls 83 
Table 36 mtDNA deletions mapped by smPCR in H2O2 treated human fibroblasts 88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of Figures 
 
vi 
List of Figures: 
  PAGE 
Figure 1 Micrograph image of mitochondria from rat kidney 1 
Figure 2 Schematic representation of mitochondrial structure 3 
Figure 3 Anterograde and retrograde transport of mitochondria 6 
Figure 4 Mitochondrial fusion and fission 7 
Figure 5 Circular mitochondrial DNA molecule by atomic force microscopy 8 
Figure 6 Scheme of the human mitochondrial genome 9 
Figure 7 Asynchronous model of mtDNA replication 12 
Figure 8 Bidirectional model of mtDNA replication 15 
Figure 9 RITOLS model of mtDNA replication 16 
Figure 10 mtDNA replication scheme 19 
Figure 11 Slipped-strand mechanism of deletion formation 24 
Figure 12 Mechanism of deletion formation during DSBs repair 25 
Figure 13 Single-molecule PCR 47 
Figure 14 Pedigrees of MGME1 patients  61 
Figure 15 LR-PCR amplification of mtDNA from MGME1 patients 63 
Figure 16 mtDNA rearrangements in MGME1 and POLG patients 66 
Figure 17 Relative mtDNA copy numbers in muscle and fibroblasts   
 of MGME1 patients 69 
Figure 18 Relative mtDNA copy numbers, with eleven primer pairs outside   
 and inside the 7S DNA region 71 
Figure 19 mtDNA copy number in fibroblasts from P1976, transduced with   
 a viral construct overexpressing MGME1, compared to control   
 and POLG patients 72 
Figure 20 Changes in mtDNA copy numbers during induced mtDNA depletion   
 and repopulation of fibroblasts from P1976, P4052 and a control 73 
Figure 21 Schematic representation of LM-PCR for detection of free mtDNA ends 75 
Figure 22 LM-PCR visualization of the 5’ end of the 7S DNA 77 
Figure 23 LM-PCR after T4-polymerase (T4), Mung Bean nuclease (MuB) and S1  
 treatment of fibroblasts from patients with MGME1 mutation and controls 78 
Figure 24 7S DNA ends mapped by single-molecule LM-PCR 79 
Figure 25 LM-PCR showing free end at the OL of MGME1 patients 81 
Figure 26 Partial sequences representing MFN2 mutations in four patients with  
 CMT2A 82 
  List of Figures 
  vii                            
Figure 27 Deletions in CMT2A patients 85 
Figure 28 Mapped mtDNA deletion breakpoints in CMT2A patients 86 
Figure 29 mtDNA damage upon oxidative stress by H2O2 88 
Figure 30 LR-PCR and semiquantitative analysis of mtDNA deletions content in  
 TLE patients 90 
Figure 31 mtDNA deletion amounts in AHS and lesion patients, dependent on age 91 
Figure 32 Comparison of relative deletion percentage in AD region, in AHS   
 patients, with two different primer pairs 92 
Figure 33 Multiplex PCR of AHS and lesion TLE samples 93 
Figure 34 Structure of the D-loop containing the 7S DNA 96 
Figure 35 Proposed function of MGME1 in mtDNA maintenance 101 
Figure 36 Replication fork at the mtDNA 102 
Figure 37 Proposed involvement of MGME1 in different processes of mtDNA   
 maintenance, mtDNA replication and repair, and consequences from   
 its dysfunction 103 
Figure 38 mtDNA mutagenesis 108 
Figure 39 Overview of the accumulation of mutated mtDNA, respiratory failure,  
 and insufficient ATP supply leading to disease 109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of Abbreviations 
 
 viii 
List of Abbreviations: 
 
AD area dentate 
ADP adenosine diphosphate 
adPEO autosomal dominant progressive external 
ophthalmoplegia 
AHS  Ammon’s horn sclerosis 
ALS amyotrophic lateral sclerosis 
APS ammonium persulfate 
ATP adenosine-5’-triphosphate 
BER base excision repair 
BL blood 
BSA bovine serum albumin 
CA1 cornu Ammonis 1  
CA3 cornu Ammonis 3 
CCCs covalently closed circles 
CMT1A Charcot–Marie–Tooth Neuropathy Type 1A 
CMT2A Charcot–Marie–Tooth Neuropathy Type 2A 
CoA coenzyme A 
COX cytochrome c oxidase 
CPEO chronic progressive external ophthalmoplegia 
CRAC calsium release activated channel 
CSB conserved sequence blocks 
Ctmito Ct value of mtDNA fragment 
Ctnuc Ct value of reference gene 
CYTb cytochrome b 
ddC 2’, 3’-dideoxycytidine 
ddH2O double-distilled water 
D-loop displacement loop 
DMEM Dulbecco's Modified Eagle's Medium 
DMSO dimethyl sulfoxide 
DNA2 DNA replication helicase/nuclease 2 
dNTP deoxyribonucleotide triphosphate 
DR direct repeat 
dRP deoxyribose phosphate 
DRP1 dynamin related protein 1 
DSB double-strand break 
DSBR double-strand break repair 
dsDNA double-stranded DNA 
EDTA ethylenediaminetetraacetic acid 
EM electron microscopy 
ER endoplasmic reticulum 
EtBr ethidium bromide 
F forward primer 
FB fibroblasts 
FBS fetal bovine serum 
FEN1 flap structure specific endonuclease 1 
FIS1 fission 1 
FRDA Friedrich’s ataxia 
FW forward primer 
GTP guanosine-5’-triphosphate 
HEK human embryonic kidney 
HEPES hydroxyethyl piperazineethanesulfonic acid 
HMG-box  high mobility group box 
  List of Abbreviations 
                            ix 
HR2 domain heptad repeat domain 2 
HSP heavy strand promoter 
H-strand heavy strand 
IMM inner mitochondrial membrane 
IMS inner membrane space 
Kir4.1 ATP-sensitive inward rectifier potassium channel 10 
KSS Kearn-Sayre syndrome 
LHON Leber’s Hereditary Optic Neuropathy 
LIG3 ligase 3 
LMP ligation-mediated PCR primer 
LM-PCR Ligation-Mediated PCR 
LR-PCR Long-range PCR 
LP-BER long patch base excision repair 
LSP light strand promoter 
L-strand light strand 
M muscle 
MAP microtubule associated protein 
MB muscle biopsy 
MDS mtDNA depletion syndromes 
MEF  mouse embryonic fibroblasts 
MELAS mitochondrial encephalomyopathy, lactic acidosis and 
stroke like episodes 
MERRF myoclonic epilepsy and ragged red fibers 
MFN1  mitofusin 1 
MFN2 mitofusin 2 
MGME1 mitochondrial genome maintenance exonuclease 1 
MMD mtDNA maintenance disorders 
MMR mismatch repair 
MP morbus Parkinson 
mtDNA   mitochondrial DNA 
MTERF1 mitochondrial transcription termination factor 1 
mtSSB mitochondrial single strand DNA binding protein 
MuB Mung Bean nuclease  
NADH nicotinamide adenine nucleotide 
NARP neuropathy, ataxia, and retinitis pigmentosa 
ND nicotinamide adenine nucleotide dehydrogenase 
NHEJ non-homologous end-joining 
NTP nucleotide triphosphate 
OD optical density 
OH heavy strand origin of replication 
OL light strand origin of replication 
OMM outer mitochondrial membrane 
OPA1 optic atrophy 1 
OXPHOS oxidative phosphorylation system 
P patient 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PEO progressive external ophthalmoplegia 
PH parahippocampus 
POLG polymerase gamma 
POLRMT mitochondrial RNA polymerase  
PS Pearson syndrome 
QBK quick blunting kit 
qPCR quantitative Real-Time PCR 
List of Abbreviations 
 
 x 
R reverse primer 
RC respiratory control 
RITOLS ribonucleotide incorporation throughout the lagging 
strand 
Rnase H1 ribonuclease H1 
ROI region of interest 
ROS reactive oxygen species 
RRF ragged red fibers 
RW reverse primer 
SDH succinate dehydrogenase 
smLM-PCR single-molecule ligation-mediated PCR 
smPCR single-molecule PCR 
SN-BER single nucleotide base excision repair 
SPMS secondary progressive multiple sclerosis 
SSB single strand break 
ssDNA single stranded DNA 
STIM1 stromal interaction molecule 1 
T4 T4 polymerase  
TAS termination associated sequence 
TBE tris borate EDTA 
TCA cycle tricarboxylic acid cycle 
TE tris EDTA 
TEMED tetramethylethylenediamine 
TERM mitochondrial transcription termination sequence 
TFAM mitochondrial transcription factor A 
TK2 thymidine kinase 
TLE temporal lobe epilepsy 
TM TaqMann probe 
TPR tetratrico-peptide repeats 
TWINKLE T7-like mitochondrial DNA helicase 
UR urine sediment 
wt wild-type 
y years old 
 
 
 
 
 
Introduction 
                                                                                                                                                       1 
1. Introduction 
 
1. 1 Brief history of mitochondria 
 
Mitochondria were first described by Richard Altmann in 1890; he called them ‘bioblasts’ and 
assumed that they are ubiquitous ‘elementary organisms’ living inside the cells (Altmann, 
1890), having the properties of free-living microbes. The name ‘mitochondrion’ was given by 
Benda in 1898, based on their appearance during spermatogenesis, from the Greek ‘mitos’ 
(thread) and ‘chondros’ (granule) (Benda, 1898; Ernster and Schatz, 1981). In 1900, 
Michaelis has visualized mitochondria actively engaged in cellular respiration, by Janus 
Green B staining, which was the single method used to stain mitochondria until their first 
electron micrographs (Palade, 1952) (Figure 1). Fifty years after Michaelis finding, Lazarow 
and Cooperstein have proven that the Janus Green B staining is possible due to reoxidizing 
of the dye by mitochondrial cytochrome oxidase (Lazarow and Cooperstein, 1953). 
 
 
 
Figure 1   Micrograph image of mitochondria from rat kidney. Made by Palade in 1953 (adapted from 
Palade, 1953); ‘ep’, ellipsoidal profile; ‘fc’, free channel; ‘nc’ cristae showing three-layered structure; 
‘oc’, christae showing dimmed three-layered structure. The bar indicates 0.1µm. 
 
Since the mitochondria were discovered, there is a vivid dispute over their origin. The 
researches of the Russian botanist Konstantin Mereschkowsky (1905) and the previous 
discoveries of Sachs (Sachs, 1882) and Altmann (Altmann, 1890) have given rise to the 
“serial endosymbiotic theory” of repeated discrete endosymbiotic events which led to the 
formation of the eukaryotic cells.  Its recent active populizer was Lynn Margulis who was 
strongly criticized by the research community for standing against the basic assumptions 
about evolution. Together with Dorion Sagan they stated: “Life did not take over the globe by 
combat, but by networking. Life forms multiplied and complexified by co-opting others, not by 
killing them” (Margulis and Sagan, 2001). In 1927, Ivan Wallin broadened the serial 
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endosymbiotic theory to mitochondria. According to it, mitochondria are result of a symbiotic 
relationship between primitive prokaryotic cell, able to perform oxidative phosphorylation 
(proteobacteria and for chloroplasts, cyanobacteria) and a proto-eukaryotic cell (Scheffler, 
2008). And indeed, phylogenetic analyses have accumulated evidences suggesting that 
mitochondria share a common ancestor, the α-proteobacterium, with the obligate intracellular 
parasite Rickettsia prowazekii (Andersson et al., 1998; Andersson et al., 2003; Emelyanov, 
2003; Gray, 2001).  
Eukaryotes missing mitochondria (from the kingdom of Archezoa) (Cavalier-Smith, 
1981), such as trichomonads, cilliates and chytrid fungi (Embley et al., 2003, Broers et al. 
1993; Fenchel and Finlay 1995; Roger and Silberman 2002) were shown to contain ancestral 
mitochondria-like organelles such as hydrogenosomes and mitosomes, or remnant 
mitochondria (Müller, 1993; Williams et al., 2002; Tovar et al., 1999; Zubáčová et al., 2013; 
Hjort et al., 2010; Shiflett and Johnson, 2010).  These organelles are surrounded by a double 
membrane; in most cases they have lost their DNA and oxidative phosphorylation function, 
but have kept other biochemical functions of the mitochondria (Honigberg et al., 1984); 
for example, the hydrogenosomes can perform fermentative metabolism of pyruvate and 
ATP synthesis through substrate-level phosphorylation, creating molecular hydrogen as a  
by-product (Lindmark and Müller, 1973; Hjort et al., 2010).  
 
1. 2 Structure and morphology of mitochondria 
 
The structure of mitochondria can be observed in detail by electron microscopy (EM). A 
traditional view on the inner structure of mitochondria is shown on Figure 2. Each 
mitochondrion has two separate membranes, the outer membrane, which draws the smooth 
boundaries of the mitochondrion and the inner membrane, which forms many invaginations 
and tubes spanning the mitochondrial lumen, called cristae. The inner membrane and the 
lamellar structures are connected by narrow tube-like connections, called the cristae 
junctions (Scheffler, 2008). The inner and the outer membrane have completely different 
protein content and are functionally distinct (Lodish et al., 2012). The most abundant protein 
of the outer mitochondrial membrane (OMM) is the protein porin. Ions and small molecules 
can pass easily through the pore of this transmembrane channel protein (Benz, 1985; Benz, 
1990). Mitochondrial porins have size of 30 to 35 kDa. The maximal molecular weight of 
uncharged molecules which can pass through the OMM porins is about 5 kDa (Benz, 1985; 
Benz, 1990; Shoshan-Barmatz and Mizrachi, 2012). The inner mitochondrial membrane 
(IMM), which has 76% protein content, more than any other cellular membrane (Gohil and 
Greenberg, 2009; Lodish et al., 2012), is a tight permeability barrier, with functional 
consequences.  
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Figure 2   Schematic representation of mitochondrial structure (adapted from Nelson and Cox, 
Lehninger Principles of Biochemistry, 3rd edition, 2000). 
  
The space closed between the outer and the inner mitochondrial membrane is named 
intermembrane space and the mitochondrial matrix is the lumen of the mitochondria, 
surrounded by the inner membrane. Due to its cristae the IMM has much larger surface area 
in comparison to the outer membrane. The cristae are containing the adenosine-5’-
triphosphate (ATP) synthesis complexes, protruding from the inner membrane to the matrix. 
The cristae number and size varies between the cells, and it is thought to be dependent on 
the energy demand of the cell. The more surface area is formed by the cristae, the more ATP 
synthase complexes are present in the mitochondrion. For example, the inner membrane 
area of a muscle cell contains three times as many cristae as a liver cell, presumably due to 
the greater energy (ATP) demand of the cell (Lodish et al., 2012). 
 
1. 2. 1 Biochemical reactions in mitochondria 
 
The biochemical reactions taking place in mitochondria are part of many metabolic pathways, 
that play central role in the cellular function. For example, the fatty acid oxidation (Lehninger, 
1945) and the Krebs cycle, also known as the tricarboxylic acid cycle (TCA cycle) (Krebs and 
Johnson, 1937; Svirbely and Szent-Györgyi, 1933; Scheffler, 2008) are taking place in the 
mitochondria. The process of aerobic oxidation of glucose and fatty acids starts in the 
cytosol, where the glucose is being converted to pyruvate and the fatty acids to fatty acyl 
Introduction 
 
 4 
coenzyme A (CoA). They then enter the mitochondrial matrix through the porin channels on 
the OMM and by transporters on the IMM. The pyruvate and the fatty acyl CoA are being 
converted to acetyl CoA and further oxidized until the release of CO2. Nine sequential 
oxidative reactions are turning the acetyl group of acetyl CoA into CO2, and they form the 
TCA cycle. The transfer of electrons from the coenzyme electron carriers to and between the 
complexes of the respiratory chain and the process of oxydative phosphorylation (OXPHOS) 
ends with reduction of O2 and release of water. The functional enzyme complexes of the 
OXPHOS system are NADH: ubiquinone oxidoreductase (Complex I), succinate: ubiquinone 
oxidoreductase (Complex II, succinate dehydrogenase, SDH), ubiquinol: cytochrome c 
oxidoreductase (Complex III, cytochrome bc1 complex), ferricytochrome c: oxygen 
oxidoreductase (Complex IV, COX) and the F1F0-ATPase (Complex V) (Chinnery and Schon, 
2003; Hatefi, 1985; Saraste, 1999). The transport of electrons through the electron transport 
chain is used to pump protons into the innermembrane space and out of the matrix, which 
consequently creates an electrochemical gradient or protonmotive force (Jastroch et al., 
2010) used from the F0F1 complex, called ATP synthase to produce ATP from ADP and 
inorganic phosphate (Pi). This theory of ATP synthesis was proposed by Peter Mitchell in 
1961 and is called the chemiosmotic theory (Mitchell P, 1961).  
Mitochondria are involved also in other major pathways such as the urea cycle in 
which ammonia (NH3) is converted to urea ((NH2)2CO) (Krebs and Henseleit, 1932 a, b, c); 
heme biosynthesis; partially, they participate in steroid, dolichol and ubiquitine biosynthesis, 
and in the synthesis of cardiolipin. Mitochondria are as well the origin of iron-sulphur (Fe-S) 
centers (Scheffler, 2008). They play a crucial role in maintenance of calcium homeostasis 
and programmed cellular death (Lee and Peng, 2008). 
 
1. 3 Distribution, motility and dynamics of mitochondria 
 
1. 3. 1 Mitochondrial distribution 
 
In the cellular cytosol mitochondria are forming networks, which depending on the 
mitochondrial number, size and position differ in the different cell lines and tissues. 
Generally, the mitochondria network is most dense around the nucleus and scatters to the  
periphery of the cell (Frazier et al., 2006). The cells can answer to their energy demands by 
inducing changes in mitochondria distribution. For example, mitochondria cluster in the 
presynaptic nerve terminal as result of local synaptogenic signals and play important role for 
the synapse formation by providing ATP needed for the actin cytoskeleton assembly of the 
presynapse (Lee and Peng, 2008; Peters et al., 1991). The correct positioning of the 
mitochondria is involved as well in the mobilization of the synaptic vesicles (Verstreken et al., 
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2005). Mitochondria were reported to be involved in the dendritic spine formation as well as 
in immunological response functions, such as podosome activations of the lymphocytes, and 
synapse formation in activated T-cells (Li et al., 2004; Sung et al., 2008; Campello et al., 
2006; Quintana et al., 2007). The local calcium concentration may depend on calcium uptake 
from the mitochondria; thereafter, mitochondria are distributed not only in subcellular regions 
with high metabolic requirements, but also at such with Ca2+ accumulation (Werth and 
Thayer, 1994; Zucker, 1999).  
 
1. 3. 2 Mitochondrial motility 
 
Organelles are often transported far away from the place of their biosynthesis in the 
cytoplasm reaching a goal location, for example, the nerve cell axons may be more then a 
meter in length. The well defined tracks on which the organelles slide to these locations are 
formed by microtubules, which can load different types of ‘cargo’. The microtubules are built 
up from αβ-tubulin dimers and are stabilized and aligned by different classes of microtubule 
associated proteins (MAPs). Such proteins characteristic for the neuronal cells are the tau 
protein and the MAP2 protein (Lodish et al., 2012). The transportation of different loads takes 
different time, from very slow as fraction of mm a day (microfilaments, metabolic enzymes, 
clathrin complex – 2 to 8 mm a day; neurofilaments and microtubules – 0.2 to 1 mm a day), 
to very fast as 200 to 400 mm a day (small vesiculotubular structures, neurotransmitters, 
membrane proteins and lipids). The mitochondria are trafficked at medium speed down the 
axons to the synapses with 50 to 100 mm a day (Morfini et al., 2012).  
There are two main motor protein families responsible for the transportation of the 
different ‘cargoes’ along the microtubules, the kinesins and dyneins. The transport 
proceeding from the cellular body to the axons and the synapses is named anterograde 
axonal transport (Lodish et al., 2012) and in the opposite direction, retrograde axonal 
transport (Figure 3). Along the microtubule network mitochondria are trafficked anterogradely 
by kinesin-1 (KIF5) or kinesin-3 (KIF1) (Nangaku et al., 1994; Tanaka et al., 1998) and 
retrogradely by cytoplasmic dynein, whose motor coordination is being supported by the 
binding of kinesin (Salinas et al., 2008) and microtubule associated protein 1B (MAP1B).  
Milton, Miro, syntabulin and a mitochondria specific isoforms of kinectin are protein 
adaptors serving as connection between mitochondria and kinesins (Salinas et al., 2008). 
The microtubule based transport is used for long-range movements and actin-based 
transport for short-range movements (Morris and Hollenbeck et al., 1995). Actin-based 
transport of mitochondria was suggested to participate in the docking of mitochondria (Sheng 
and Cai, 2012; Salinas et al., 2008).  
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Figure 3   Anterograde and retrograde transport of mitochondria (adapted from Salinas et al., 2008). 
 
The Miro protein family includes mitochondrial Rho GTPases participating in 
mitochondrial transport. In mammals there are two known proteins belonging to it, Miro-1 and 
Miro-2 (Liu and Hajnóczky, 2009). Cells lacking active Miro are having disrupted 
mitochondrial motility and networking, and higher apoptosis rates (Liu and Hajnóczky, 2009; 
Fransson et al., 2003). 
Milton 1 and 2 are proteins associated with mitochondrial motility in Drosophila 
melanogaster (Stowers et al., 2002). Their mammalian homologues are TRAK 1 and TRAK 2 
(Brickley and Stephenson, 2011). Miro interacts with Milton protein, which simultaneously 
binds to kinesin-1 and in this way this Miro-Milton interaction can affect the recruitment of 
Milton to mitochondria (Glater et al., 2006). 
The mitofusins MFN1 and MFN2, involved in mitochondrial fusion and fission, also 
were proven to interact with the Miro-Milton complex. Dysfunction of MFN2 leads to slower 
mitochondrial transport in both retrograde and anterograde directions, but does not affect the 
transport of other organelles. A dysfunction of the OPA1, protein also involved in the fusion 
of the IMM does not affect the motility of mitochondria, which points to MFN2 as specific part 
of the mitochondrial transport machinery (Misko et al., 2010). 
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1. 3. 3 Mitochondrial dynamics 
 
Beside their constant movement mitochondria are undergoing process of active fusion and 
fission (Figure 4) (Chan, 2006). Mitochondrial fusion is controlled by the mitofusins: mitofusin 
1 and mitofusin 2 (MFN1 and MFN2) for the OMM and by optic atrophy 1 protein (OPA1) 
involved in the IMM fusion (Hales and Fuller, 1997; Rojo et al., 2002). The mitofusins belong 
to the GTPase protein family (Hales and Fuller, 1997). MFN1 and MFN2 differ in their 
functions, for example, in their interactions with other proteins such as OPA1 (Cipolat et al., 
2004). In the absence of MFN2, MFN1 together with OPA1 are enough to mediate efficient 
fusion (Cipolat et al., 2004; Ishihara et al., 2004).  
Close to their N-terminal, the mitofusins have a GTPase domain and on their C-
terminal a coiled-coil domain facing the cytosol and followed by two transmembrane spans 
and another coiled-coil domain (Figure 4). During the process of fusion, two mitochondria 
dock through the mitofusins anchored into their OMM. The mitofusins bind to other mitofusin 
molecules in like-attract-like fashion on closely placed mitochondria and tether them. Once 
the mitofusins are bound to each other a GTP hydrolysis takes place. It is still unclear how 
this process changes the shape of membranes and provides their merging (Chen et al., 
2003; Hales and Fuller, 1997; Hermann et al., 1998) (Figure 4). MFN1 tethers more 
efficiently the mitochondrial membranes in comparison to MFN2 (Ishihara et al., 2004) and 
recently, it was suggested that only MFN2 is involved in endoplasmic reticulum (ER) 
tethering, but not MFN1 (de Brito and Scorrano, 2008). 
 
 
 
Figure 4   Mitochondrial fusion and fission (adapted from Youle and Karbowski, 2005). 
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The process of mitochondrial fission (Figure 4) is mediated by membrane-associated 
adaptor proteins fission 1 (FIS1), which recruits the large GTPase and dynamin homologue 
dynamin related protein 1 (DRP1) from the cytoplasm by using its tetratrico-peptide repeats 
(TPR). DRP1 participates at the final step of mitochondrial fission by forming spirals around 
constricted sites on mitochondria and pinching off the membrane stalk at the scission sites, 
between the two newly formed mitochondria (Youle and Karbowski, 2005; Koirala et al., 
2013). The mitochondria fission sites depend on the early interaction of mitochondria with the 
ER prior to DRP1 binding (Friedman et al., 2011).  
 
1. 4 Mitochondrial DNA 
 
1. 4. 1 Structure 
 
In 1963 Margit and Sylvan Nass have described for the first time the mitochondrial DNA 
(mtDNA) (Nass and Nass, 1963) and its circularity was discovered by electron microscope 
imaging by Nass, (1966). In mammals, mtDNA is a double-stranded circular molecule with 
size of approximately 16 kb (Figure 5), in human 16,569 base pairs (bp) (Anderson, 1981). 
On Figure 6 is shown the structure of the mtDNA. It has nucleotide composition with 44% 
(G+C) content. The mitochondrial strand with greater intrinsic buoyant density in alkaline 
cesium chloride gradients and respectively high content of guanine bases is called the heavy 
(H) strand (Figure 6, H-strand depicted in black) and its complementary strand, rich in 
cytosine is called the light (L) strand (Figure 6, L-strand depicted in gray) (Clayton, 1996).  
 
 
 
Figure 5   Circular mitochondrial DNA molecules by atomic force microscopy (provided from 
collaborative study with Prof. Kotlyar, George S Wise Faculty of Life Sciences, Tel Aviv, Ramat Aviv, 
Israel). 
 
Animal mtDNA is intronless and most of the genes are located on the heavy strand. 
Altogether, it is encoding 37 genes, from which 13 are protein coding for respiratory chain  
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and ATPase subunits (Figure 6, in green), 22 transfer RNAs (tRNAs) (Figure 6, in blue, the 
letters stand for the corresponding amino acids) and two ribosomal RNAs (rRNAs) (Figure 6, 
in purple), all crucial for the process of oxidative phosphorylation (Shadel and Clayton, 1997). 
The two rRNAs, 12 mRNAs, and 14 tRNAs are encoded from the H-strand, whereas the L-
strand encodes one mRNA and eight tRNAs (Figure 6). The genetic code of the mtDNA is 
different to the one in the nuclear DNA and it also varies between species (Lodish et al., 
2012). The process of replication and transcription of mtDNA is regulated by nuclearly 
encoded factors. Polymerase gamma (POLG), the only known polymerase located in 
mitochondria (Graziewicz et al., 2004), is also encoded in the nucleus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6   Scheme of the human mitochondrial genome (adapted from Bestwick and Shadel, 2013). 
The heavy H-strand in black and the light L-strand in gray encode for rRNAs (purple), mRNAs (green), 
and tRNAs (blue, letters mark allied amino acids). The H-strand genes are indicated outside and the 
L-strand genes inside the circle. ND, NADH dehydrogenase; COX, cytochrome c oxidase; ATP, ATP-
synthase; CYTb, cytochrome b. 
 
Since only 13 of the estimated proteins are encoded by the mtDNA, mitochondria are 
relying on the permanent interplay between the mtDNA and the nuclear DNA (Thorsness and 
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Weber, 1996). All but one protein complexes for the respiratory chain are encoded by both 
nuclear and mtDNA. The only enzyme complex exclusively encoded by nuclear DNA is the 
Complex II (Smeitink et al., 2001). The mtDNA contains a D-loop region, which is non-coding 
and contains essential sites for replication and transcription initiation (Taylor and Turnbull, 
2005) (shown expanded on Figure 6). It is called a displacement loop (D-loop) as the two 
strands are separated from each other, in a small stretch, by a third strand complementary to 
the light strand, called the 7S DNA (Doda et al., 1981).  The replication origins of both 
mtDNA strands are OH and OL, respectively for the heavy and the light strand (Figure 6). 
The H-strand transcription initiates from H-strand promoter 1 (HSP1) and 2 (HSP2), 
with HSP1 transcripts terminating at a termination sequence (TERM), within the tRNA-Leu 
(UUR) gene, to which a mitochondrial termination factor (MTERF)1 binds. The TERM region 
is strongly protected from methylations assuring the frequent and highly specific binding of 
the MTERF1 (Rebelo et al., 2009). The HSP2 transcripts are almost full length polycistronic 
transcripts. The L-strand transcription starts from an L-strand promoter site (LSP) that also 
generates near full-length polycistronic transcripts. Both transcripts from the H and the L-
strand, and the tRNA are later on processed into mRNA (Bestwick and Shadel, 2013). 
Transcription initiated at the light strand promoter (LSP) is suggested to be responsible for 
the formation of the RNA primer needed for the heavy strand replication. One hypothesis is 
that the primers are formed by the action of RNA endonuclease, which is cleaving primary 
transcript starting from LSP (Lee and Clayton, 1997; 1998; Wanrooij et al., 2010). Both LSP 
and HSP sites are protected as well from methylation (Rebelo et al., 2009). Downstream of 
the LSP are located three conserved sequence blocks (CSB), that show low variability in 
mammals (CSB I, II, III), CSB II is considered to support the formation of RNA-DNA hybrids 
transition (Pham et al., 2006).  
The mtDNA is organized into protein-DNA complexes called nucleoids (the name is 
derived from the bacterial nucleoids, comprising their chromosomes) (Kukat and Larsson, 
2013). The nucleoids have uniform mean size of approximately 100 nm in mammals. They 
are histone-free formations, containing prevalently single copies mtDNA (average of 1.4 
mtDNA molecules per nucleoid). The nucleoids contain as well proteins of mtDNA replication 
and gene expression machinery, and the process of fission and new mitochondrial tubule 
formation occurs adjacent to the nucleoids (Figure 4) (Tauber et al., 2013; Bogenhagen, 
2012). It was suggested that the fission process helps to prevent the nucleoid clustering 
(Ban-Ishihara et al., 2013). 
The nucleoids are packed by the mitochondrial transcription factor A (TFAM), 
belonging to the family of architectural high mobility group (HMG)-box proteins, binding to 
DNA.  TFAM can bind, wrap and bend DNA without DNA sequence-specificity (Fisher et al., 
1992) and is fully coating the mtDNA in human (Alam et al., 2003). Therefore, TFAM plays 
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important role in the nucleoid formation and mtDNA maintenance (Kukat et al., 2011;  
Ngo et al., 2011). In vivo, it is providing bending and looping of the mtDNA, which is shaping 
the nucleoids in spherical structures (Kaufman et al., 2007). Crystallographic experiments 
suggest that TFAM induces a 180° U-turn of the mtDNA when bound to it (Ngo et al., 2011). 
Knockout of TFAM in mice causes severe mtDNA depletion and is lethal to the fetus 
(Larsson et al., 1998; Mao and Holt, 2009).  
The mtDNA is a multicopy genome and its number varies between cells and tissues, 
and is dependent on the energy demands of the cells (Moraes, 2001). Usually, there are 
102–104 copies of mtDNA per cell (Ruhanen et al., 2011). Due to its polyploid nature, the 
mitochondrial genome can be homoplasmic, when all mtDNA copies are identical and 
heteroplasmic when two or more variants of the mtDNA exist together. A single mutation 
which affects all mtDNA copies is a homoplasmic mutation, and when it affects some mtDNA 
molecules it is a heteroplasmic mutation (Taylor and Turnbull, 2005). In difference to the 
homoplasmic mutations, which are transferred to all maternal offspring the transmission of a 
heteroplasmic mutations is much more complicated and depends on the mutation type and 
its segregation within the maternal tissues (Taylor and Turnbull, 2005). 
 All mtDNA encoded proteins are synthesized on ribosomes unique for the 
mitochondria, mitoribosomes, which are located in the mitochondrial matrix (Taanman, 
1999). In rat hepatocytes there are less then 100 mitoribosomes per mitochondrion 
(Cantatore et al., 1987). The mitoribosomes differ from the cytosolic ones; they have lower 
sedimentation coefficient and have lower RNA content. Their 12S and 16S rRNAs are 
encoded as well from the mtDNA (Attardi and Ojala, 1971). The process of translation is 
supported by 22 tRNAs that are also mitochondria specific, different from the cytosolic ones 
and encoded by the mtDNA. The genes encoding the mito tRNAs are highly prone to 
mutations and often are reason for different diseases and mitochondrial dysfunction (Suzuki 
et al., 2011). The heavy strand tRNA loops share high sequence homology with the OL loop. 
There is a suggestion that tRNA loops may serve as alternative origins of replication over the 
mtDNA (Seligmann, 2009). 
 
1. 5 mtDNA replication 
 
In 1968 Kirschner et al., have proven for the first time that the mtDNA is self-replicating in the 
mitochondrion. The replication of mtDNA takes about one to two hours (Berk and Clayton, 
1974; Clayton, 1982), it is independent from the cell cycle phase (Clayton, 1996) and 
happens at lower level in postmitotic cells (Magnusson et al., 2003).  
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1. 5. 1 Strand displacement model of replication 
 
The classical mtDNA replication model described in the literature is the strand displacement 
model, or the asynchronous replication model (Robberson et al., 1972), (Figure 7). The 
model is called asynchronous as there is spatial and time asymmetric way of replication of 
both strands – the leading (H-strand) and lagging (L-strand) strand of replication (Brown and 
Clayton, 2006).   
           
 
Figure 7   Asynchronous model of mtDNA replication (modified from Kasiviswanathan et al., 2012). 
 
According to Clayton (1996, 1982) in this model the replication begins at the H-strand 
origin of replication (OH) and continues for about 450±80 nucleotides and stops (Kasamatsu 
et al., 1971). The formed nascent H-strand fragment remains single stranded, bound to the 
light strand and displaces the parental H-strand, forming the D-loop. This fragment has a 
sedimentation coefficient of 7S and thereafter is called the 7S DNA. In this model, when the 
replication is to continue, the single stranded daughter H-strand is being synthesized and it 
displaces the parental H-strand unidirectionally (Berk and Clayton, 1974; Robberson and 
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Clayton, 1972). The formation of the 7S DNA fragment is a matter of dispute, it was 
suggested as well that it is formed as an end-step of the H-strand replication by the 
termination of the replication at the termination associated sequence (TAS) region (Chang 
and Clayton, 1985; Doda et al., 1981; Berk and Clayton, 1974). 
The replication of the mtDNA is coupled with the process of transcription, which is 
initiated from a single promoter on the light strand – LSP (Figure 6). The synthesized 
transcript forms RNA-DNA hybrid. RNaseMRP is an enzyme which processes the hybrid, by 
cutting the RNA into pieces that afterwards are being used as replication primers at the OH, 
by POLG (Brown and Clayton, 2002; Shadel and Clayton, 1997).  
After the H-strand replication has proceeded to two thirds of its total length, the L-
origin of replication (OL) becomes exposed and the replication of the L-strand begins from it 
(Wanrooij and Falkenberg, 2010; Wong and Clayton, 1985). OL is approximately 30 
nucleotides in size, it is highly conserved in vertebrates (Wanrooij et al., 2012), it is flanked 
by tRNA genes and has the potential of forming a stable stem-loop structure when being 
single stranded (Fusté et al., 2010; Clayton, 1996). The OL is being exposed to the action of 
a mitochondrial RNA polymerase called POLRMT, able to recognize it and initiate priming 
from a poly-dT stretch in the single-stranded loop region and to begin DNA synthesis 
(Clayton, 1996; Fusté et al., 2010). The primer for L-strand replication is an RNA sequence 
complementary to the T-rich loop structure of the OL and the switch from RNA to DNA 
synthesis is happening after about 25 nt near the base of the stem (Fusté et al., 2010; Wong 
and Clayton, 1985). 
The asynchronous replication of the two mitochondrial strands leads to the synthesis 
of two daughter molecules (Berk and Clayton, 1974). The newly synthesized mtDNA 
daughter molecules are having relaxed shape for about an hour and afterwards they pass 
into a super-coiled state with approximately 100 negative super turns (Bogenhagen and 
Clayton, 1977). The synthesis of new D-loop completes the replication cycle (Clayton, 1996). 
It has been suggested that the 7S DNA serves to relax the super helical turns of the super 
coiled mtDNA and might have role in the exposure of the parental H-strand (Clayton, 2003; 
Tapper and Clayton, 1981; Kang et al., 1997; Kasamatsu et al., 1971). The turnover of the 
7S DNA is rapid, but the mechanism of its degradation is not known and its full function 
remains unclear (Clayton, 2003; Bogenhagen and Clayton, 1977). There is no confirmation if 
the existing 7S DNA fragments are being used for initiation (as primers) of the H-strand 
replication, and are being elongated, or a novel process of replication initiation occurs 
(Clayton, 2003; Clayton, 1996). However, as the nascent H-strands and the 7S DNA 
fragments are having the same 5’ end it seems that each newly synthesized strand becomes 
either 7S DNA strand or a nascent strand. Doda et al., in 1981, has proposed that the 
premature termination process of the nascent strand is a template-sequence-directed event, 
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at TAS. TAS is 15 bp long conserved sequence, which is a potential cis-acting sequence and 
is present in multiple copies, upstream from the termination site (Doda et al., 1981). Kai et 
al., in 1999, have used Ligation-Mediated PCR (LM-PCR) (Kang et al., 1997) and site-
specific primers, to distinguish the nascent H-strands leading to 7S DNA formation from the 
total nascent H-strands. They claim that the premature termination has regulatory role in 
mtDNA replication and some of the 7S DNA molecules are temporarily terminated and re-
elongated for successful replication. In an experiment with proliferation stimulated cells, the 
termination of the nascent strands simply decreases and in this way the replication gets up-
regulated (Kai et al., 1999). In depletion experiments, directly after applying ddC, the nascent 
strand termination gets down-regulated, and this effect is strongest after ddC removal; these 
experiments suggest that the release of the elongation and the control of termination at the 
D-loop, are crucial for mtDNA copy number maintenance and recovery of depleted mtDNA 
(Brown and Clayton, 2002). It has been estimated that around 95% from the leading strands 
get terminated prematurely and the cells are capable of much greater replication capacity 
then demanded under normal circumstances (Bogenhagen and Clayton, 1978; Brown and 
Clayton, 2002).  
 
1. 5. 2 Bidirectional replication model 
 
After electron microscopy of mtDNA from rat hepatocytes and HeLa cells, which revealed 
mtDNA duplex replication intermediates (Koike and Wolstenholme, 1974; Crews et al., 
1979), a hypothesis raised for coupled leading and lagging strand replication, in opposition to 
the asynchronous model (Figure 8) (Holt et al., 2000). In this mechanism the replication is 
symmetrical, with leading and lagging strand synthesis progressing from multiple 
bidirectional replication forks. The initiation zone (ori-Z) was proposed to be a broad zone 
covering several kilobases in solid tissues (Bowmaker et al., 2003) with multiple origins of 
replication, and smaller zone in the non-coding region in cultured cells (Yasukawa et al., 
2005).  
The later investigation proposed a bidirectional origin of replication close to the 5’ end 
of the non-coding region, a replication starting from that point would be terminated at the 
TAS region and would be effectively unidirectional for the most part (Yasukawa et al., 2005). 
In this model the lagging strand is being the result of maturation of Okazaki fragments, that 
are joined to create the novel nascent strand. Ruhanen et al., (2011) have suggested that 
Ribonuclease H1 (RNase H1) is responsible for the removal of RNA primers from the lagging 
strand and DNA ligase III is responsible for the ligation of the newly synthesized Okazaki 
fragments.  
 
Introduction 
                                                                                                                                                       15 
 
  
Figure 8   Bidirectional model of mtDNA replication (modified from Kasiviswanathan et al., 2012). 
 
In 2002, Yang et al. claimed that the strand-coupled mechanism is exclusively the 
replication mechanism existing in the mitochondria, and that the single stranded replication 
intermediates observed previously from Holt et al., 2000, are an artifact of DNA extraction, as 
the strand-coupled mechanism includes mostly double-stranded replication intermediates but 
contains widespread regions of RNA-DNA hybrids which are formed by incorporation of 
ribonucleotides on the light strand, that afterwards are converted to DNA; exactly these 
ribonucleotide-rich regions can be easily degraded during mtDNA extraction and can result in 
single stranded replication intermediates. In the experiments performed by Yang et al., 
(2002) by the usage of an RNase H they could show the formation of single stranded 
replication intermediates (Yang et al., 2002). Brown et al., (2005) have performed atomic 
force microscopy, and their findings pointed towards the orthodox strand-displacement model 
of replication, but interestingly, it showed the existence of alternative lagging strand 
replication origins, which is in consistance with the earlier investigations of Robberson et al., 
(1972); Koike and Wolstenholme, (1974); and Pikó et al., (1984). As the observed replication 
intermediates included also single stranded ones, which can only be products from 
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asymmetric replication, Holt et al., (2000) suggested that both models of replication exist 
simultaneously in the cell and the switch between the mechanisms depends on the needs of 
the cell.  
 
1. 5. 3 RITOLS 
 
In 2006, Yasukawa et al. described a novel model of replication, the ribonucleotide 
incorporation throughout the lagging strand (RITOLS) model. In that model newly 
synthesized RNA can cover the parental H-strand prior to lagging L-strand synthesis. The 
RNA may build up the whole lagging strand before it is converted to DNA. The synthesis of 
the RNA was suggested to be a result of the activity of a primase or alternatively, it is laid by 
pre-existing processed transcripts (Figure 9, panel 1), in that way the RNA fragments are 
being hybridized to the parental strand with the advancing of the replication fork (‘bootlace' 
mechanism, Reyes et al., 2013).  
 
 
 
Figure 9   RITOLS model of mtDNA replication. Red line, RNA primers; blue line, newly synthesized 
mtDNA strand (adapted from Yasukawa et al., 2006). 
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In 2008, Wanrooij et al. described the POLRMT that can act as a lagging strand 
primase. The enzyme was shown to be able to synthesize RNA primers with length from 25 
to 75 nucleotides on a single strand template in vitro. These primers can be then used by 
POLG to initiate the lagging strand synthesis (Wanrooij et al., 2008). The degradation of the 
RNA and its substitution with DNA happens in the maturation phase, where a putative RNase 
fragments it. They suggested that this function might be performed by RNase H1 
mitochondrial isoforms. The slow degradation of RNA into fragments may release exactly the 
needed RNA primers for the lagging strand synthesis (Yasukawa et al., 2006). 
In the RITOLS model, replication is initiated in a unidirectional manner at the 
replication origin OR. OR is located either at OH or at an alternative site present in the non-
coding region, several hundred nucleotides away from OH, around nucleotide position 
16,197, close to the TAS region (Yasukawa et al., 2006; Yasukawa et al., 2005). In some 
molecules, as mentioned above, the RNA is laid all over the parental strand prior to its 
converting into DNA (Figure 9, panel 2A), in other molecules the maturation starts already 
when the incorporation of RNA has proceeded until the OL (Figure 9, panel 2B) or at 
dispersed sites (Figure 9, panel 2C). Such a model can generate all replication intermediates 
described till now (Yasukawa et al., 2006).  
2D agarose gel electrophoresis (2D-IMAGE) of intact mitochondrial DNA, performed 
by Kolesar et al., (2013), revealed broad range of double-stranded forms of the mtDNA, such 
as super coiled molecules (covalently closed circles, CCCs), nicked circles and multiple 
catenated species, as well as single-stranded DNA structures, which they suggest to be 
replication intermediates (Kolesar et al., 2013). By ethidium bromide (EtBr) depletion the 
same group has observed accumulation of high molecular weight mtDNA (under strong 
depletion conditions), and after the release of the replication arrest, firstly covalently closed 
circles and head-to-tail circular dimer formations were detectable, and their intensity was 
diminishing after 6 hours of released replication, therefore, it is possible that different mtDNA 
templates are being used in different conditions, speaking of multiple mechanisms of 
replication dependent on the cell conditions (Kolesar et al., 2013), which was also proposed 
by Holt et al., in 2000.  
 
1. 5. 4 Main participants in the mtDNA replication 
 
All proteins involved in the mtDNA replication are nuclear encoded. The POLG gene 
encodes the catalytic subunit of the mitochondrial DNA polymerase gamma (POLG). For its 
function, POLG requires the full activity of its subunits – POLG A and POLG B (Ropp and 
Copeland, 1996). POLG A is the catalytic unit of the polymerase and POLG B is its 
processivity unit (Gray and Wong, 1992). For the successful replication of the mtDNA, POLG 
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needs a mitochondrial replicative DNA helicase called TWINKLE (Spelbrink et al., 2001), the 
mitochondrial single-stranded DNA-binding protein (mtSSB) (Tiranti et al., 1993), and the 
mitochondrial RNA polymerase (POLRMT) (Tiranti et al., 1997) (Figure 10), that constitute 
the minimal replication machinery in vitro, defined by Korhonen et al., 2004.  
The POLG holoenzyme contains single A and two B subunits and it is an asymmetric 
245 KDa heterotrimer (Yakubovskaya et al., 2006). POLG has 5’→3’ polymerase activity and 
3’→5’ exonuclease proofreading activity. Both functions are fulfilled by subunit A. Subunit B 
has accelerating function for the processivity of the holoenzyme and increases the affinity of 
the A subunit for the mtDNA (Wanrooij and Falkenberg, 2010). POLG has as well 5’ 
deoxyribose phosphate (dRP) lyase activity, which is important for its participation in the 
repair of oxidative base lesions (Graziewicz et al., 2006). The POLG holoenzyme functions 
cooperatively with the mitochondrial helicase TWINKLE and the mitochondrial single strand 
binding proteins. 
TWINKLE (T7 gp4-like protein with intramitochondrial nucleoid localization) was 
discovered in 2001 by Spelbrink et al. and it is the replicative helicase in mitochondria. It has 
double-strand DNA affinity (Farge et al., 2008) and it unwinds it in a nucleotide triphosphate 
(NTP) dependent manner; it functions in 5’→3' direction. It has been speculated that 
TWINKLE participates in recombination; moreover, its helicase domain contains the same 
conserved organization as RecA involved in homologous recombination in bacteria (Wanrooij 
and Falkenberg, 2010). 
The mtSSB has protective role over the single stranded mtDNA by stopping it from 
refolding and being degenerated by nucleases. The human mtSSB is similar to the one 
existing in Escherichia coli (Tiranti et al., 1993). The single stranded mtDNA is wrapping 
around the mtSSB in electropositive channels (Yang et al., 1997). It was proposed that 
TFAM and mtSSB can influence the D-loop turnover and that they play crucial role for the 
stabilization of the D-loop and the mitochondrial DNA overall (Takamatsu et al., 2002). The 
mtSSB is enhancing the primer recognition and the processivity of POLG (Williams and 
Kaguni, 1995). Only in its presence POLG is able to synthesize longer then 16,000 bp 
products (Korhonen et al., 2004; Wanrooij and Falkenberg, 2010). 
POLRMT was discovered in a human cell line by Tiranti et al., in 1997. POLRMT 
initiates transcription with the help of TFAM and transcription factor B2. It is responsible for 
the RNA primer synthesis needed for replication initiation of both leading and lagging strand. 
It synthesizes primers with length of about 25 bp (Wanrooij and Falkenberg, 2010). 
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1. 5. 5 mtDNA replication machinery 
 
All components of the replication fork are shown schematically on Figure 10. The TWINKLE 
helicase (shown in blue) slides over the mtDNA in 5’→3’ direction and unwinds it. Right away 
the mtSSB protein (dark green) binds the single stranded mtDNA and supports the affinity of 
the POLG holoenzyme (red and gray) to process the synthesis of mtDNA. POLRMT (light 
green) is responsible for the RNA priming (yellow line) on the lagging strand, once the 
unwinding has reached the light strand origin of replication (OL). The single stranded OL 
adopts a stem-loop structure, which prevents the binding of mtSSB and thus the POLRMT 
can initiate primer synthesis from a poly-dT stretch in the OL. After the primer synthesis has 
taken place POLG performs the lagging strand synthesis (red line) (Wanrooij and 
Falkenberg, 2010). 
 
 
 
Figure 10   mtDNA replication scheme (adapted from Wanrooij and Falkenberg, 2010). 
 
1. 6 mtDNA damage and repair 
 
mtDNA mutations can arise form different factors such as DNA polymerase errors during the 
process of replication, exposure to environmental mutagens (Shokolenko et al., 2009) or 
oxidative damage, with the lattermost, being the most well studied damage (Alexeyev et al., 
2013). Mitochondria are the main source of endogenous reactive oxygen species (ROS) 
produced by the partial reduction of oxygen during the process of oxidative phosphorylation. 
High production of ROS leads to oxidative stress, resulting from the incapability of the 
cellular antioxidant defense system to handle its excessive production (Ray et al., 2012). The 
mtDNA, specifically, is highly exposed to ROS damage, because of its endogenous 
formation during mitochondrial respiration and close proximity of the mtDNA to the 
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respiratory chains (Wiesner et al., 2006). It is broadly assumed that the damages to the 
mtDNA caused by ROS are reason for the process of mtDNA mutations accumulation and 
mitochondrial damage, leading to respiratory chain dysfunctions and consequent further 
increase in ROS production. This ‘vicious circle’ might lead to the general damage of the 
whole cellular function, aging and cell death (Shokolenko et al., 2009; Wiesner et al., 2006; 
Miquel, 1992). 
ROS induces DNA strand breaks, via lesion formation in the DNA backbone, or 
causes oxidation of bases. Complex I is considered as main site for (ROS) formation, due to 
possible leakage of electrons and easy interaction with oxygen molecules. Between 0.2 and 
1.5% of the electron transport in the mitochondrial respiratory chain is ending with the 
formation of superoxide anion. The formation of superoxide anion as side product of the 
respiratory chain function is a normal ongoing process in the mitochondria. The superoxide 
anion is being dismutated into hydrogen peroxide by Mn-superoxide dismutase, and later on 
the hydrogen peroxide is converted into water and oxygen, by enzymes as catalase and 
glutathione peroxidase (Kudin et al., 2004; Chance et al., 1979; Liu et al., 2002). The 
hydrogen peroxide is relatively stable and can diffuse through the membranes and can 
spread in the entire cell. Through Fenton reactions (in the presence of redox-active metal 
ions such as Fe2+) it can generate reactive hydroxyl radical that can cause effective damage, 
such as single-strand or double-strand DNA breaks (Alexeyev, 2009; 2013; Henle et al., 
1996; Kudin et al., 2004). In support to the ‘vicious circle’ theory, higher amounts of hydrogen 
peroxide cause local elevation of hydrogen peroxide production in rat brain mitochondria 
(Kudin et al., 2004). DNA pyrimidine damage leads to the formation of the low mutagenic 
thymine glycol, which causes damage due to inhibition of polymerase activity (Wang et al., 
1998; Hanes et al., 2006; Alexeyev et al., 2013). The purine damage results in the production 
of the highly mutagenic 8-dihydro-8-oxo-2’-deoxyguanosine (8-oxoG), responsible for the 
formation of G to T transversions (Alexeyev et al., 2013; Hanes et al., 2006; De Bont and van 
Larabeke, 2004; Wang et al., 1998). Excessive amounts of ROS cause oxidative stress and 
predispose to development of different pathological conditions; therefore, the right balance of 
ROS production and degradation is very important. For example, reduced levels of 
glutathione were found in substantia nigra pars compacta of patients with Parkinson’s 
disease (Sian et al., 1994; Dringen et al., 1999). The main reason for mtDNA mutation 
accumulation is the failure of the mtDNA repair machinery or the unsuccessful degradation of 
damaged mtDNA molecules (Shokolenko et al., 2009).  
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1. 6. 1 Single strand mtDNA break and repair 
 
A single strand break (SSB) occurs when only one of the two mtDNA strands is affected, by 
loss of single nucleotide and damage of the 5’ end, the 3’ end or both termini at the break 
site (Alexeyev et al., 2013); in this case its complementary strand can be used as a template 
to remove the break. SSB can be converted in double-strand break (DSB) by an approaching 
replication fork or if SSBs are located close on opposing DNA strands. There are SSB nicks 
resulting from oxidative attack directly on the DNA sugar backbone, but also SSB (gaps) can 
occur indirectly as a result of base excision repair (BER) after oxidative damage (Friedberg 
et al., 2006). It was proposed that in mitochondria the BER process is analogous to the 
nuclear BER. There are two different types of BER, a single nucleotide BER (SN-BER) and 
multinucleotide repair patch or long patch BER (LP-BER) (Liu et al., 2008; Szczesny et al., 
2008). In case of LP-BER, POLG performs a strand displacement synthesis that results in 
the frequent formation of 5’-single-strand DNA (5’-ssDNA) flaps. In the nucleus the 
processing of this flap structures is being performed by flap structure specific endonuclease 
1 (FEN1) and DNA replication helicase/nuclease 2 (DNA2) with endonuclease activity 
(Copeland and Longley, 2008). DNA2 cannot cleave overhangs at junction between ssDNA 
and dsDNA, thereafter, it would rather leave a 5’ overhang that can be processed by FEN1 
(Sykora et al., 2012). Even though the function of DNA2 and FEN1 in the nucleus is very well 
studied, their existence and function in mitochondria is not clear. 
Zheng et al., (2008) have demonstrated that DNA2 in humans localizes to 
mitochondria and forms a complex with POLG and stimulates its activity, in opposite to other 
species. DNA2 has important role for the stability and maintenance of the mtDNA replication. 
Its association with POLG might be due to its function in RNA primer removal during the 
process of replication (Zheng et al., 2008).  
The functionality of FEN1 in mitochondria is still a matter of dispute, but its existence 
would lead to faster removal of the RNA primers during replication (Budd and Campbell, 
1997; Zheng and Shen, 2011; Zheng et al., 2008). In 2013 Kazak et al., discribed a 
shortened form of FEN1, which is mitochondrially targeted and translated from internal start 
codon, a mitochondrial FEN1 isoform. They named it FENMIT and represented results 
showing that FENMIT has an R-loop substrate preference, observed frequently in the D-loop 
region where replication starts at GC-rich sequences promoting this R-loop formation 
(Aguilera and García-Muse, 2012; Kazak et al., 2013). FENMIT has role in stabilizing these 
structures and is imported in mitochondria upon accumulation of RNA-DNA hybrids near the 
origin of replication (Kazak et al., 2013). Most probably the truncated version of FEN1 
participates in the process of mtDNA repair by using the lagging RNA strand as a template to 
fix or bypass lesions on the leading DNA strand, which might be possible only by reverse 
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transcriptase activity in the mitochondria. FENMIT might also play role in processing 
mitochondrial polycistronic transcripts as this process is occurring while the DNA is still 
hybridized with RNA (Kazak et al., 2013; Carré and Atardi, 1978).  
Another enzyme, EXOG, required for repairing of endogenous SSBs was shown to 
localize to the mitochondrial inner membrane space (IMS) and eventually plays similar role to 
FEN1 and DNA2 in LP-BER. EXOG has both exo and endonuclease activity and acts in 
5’→3’ direction (Cymerman et al., 2008). Its depletion leads to persistent SSBs 
accumulation, which is initiation signal for apoptosis. The mtDNA amplification is decreased 
when EXOG is depleted. EXOG precipitates together with POLG (Tann et al., 2011). 
Ligase 3 (LIG3) re-establishes the continuity of the mtDNA strand in both BER 
pathways. It has 5’-P to 3’-OH ligation activity as all other ligases in eukaryotes and is ATP 
dependent (Zheng et al., 2008; Stumpf and Copeland, 2011). LIG3 has putative zinc-finger 
motif (ZnF) which may help its attachment to DNA secondary structure elements, which can 
be met at sites of DNA damage (Martin and MacNeill, 2002). 
 
1. 6. 2 Double strand DNA break and repair 
 
Very hazardous is the situation in which both mtDNA strands are damaged and double-
strand breaks (DSBs) are formed and no intact complementary strand is available, because 
they can cause genome rearrangements (Watson et al., 2004). The DSBs can be result from 
ionizing radiation or the collapse of replication forks at a single strand break of the mtDNA. 
DSBs can occur also during replication, due to stalling of the POLG (in the coupled strand 
replication model). Prolonged formation of DSBs can lead to formation of multiple deletions 
and their accumulation, as well as to profound absence of full length mtDNA and mtDNA 
depletion (Song et al., 2011). The accumulation of damaged mtDNA leads to cellular 
heteroplasmy of the mtDNA pool, and when it reaches a threshold for deleted mtDNA 
molecules (Moraes et al., 1992; Mita et al., 1990; Greaves et al., 2012) and not enough 
functional mitochondria have remained the cell would fail maintaining the ATP production 
and the mitochondrial dysfunction might lead to cell death.  
DSBs can be repaired by homologous recombination (Krishnan et al., 2008) or 
nonhomologous end-joining (Graziewicz et al., 2006). The process of mtDNA homologous 
recombination in mammals is a matter of dispute and appears to be an event, detectable in 
mtDNA depletion models (D’Aurelio et al., 2004) and induction of multiple DSB (Bacman et 
al., 2009). Great number of mtDNA recombination junctions and catenation were described 
in adult heart mitochondria (Kajander et al., 2000); such formations seem to be missing in 
rodents and infant mitochondria (Pohjoismäki et al., 2009; 2010; Alexeyev et al., 2013). 
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Homologous recombination-dependent DNA repair was proposed to be involved in the 
formation of deletions with breakpoints flanked by direct repeats (Krishnan et al., 2008).  
 
1. 6. 3 mtDNA deletions 
 
According to the mitochondrial theory of aging, point mutations and deletions accumulate 
with age (Khrapko et al., 1999) and a single deletion can spread in the whole cell through its 
clonal expansion (Kowald et al., 2014). The clonal expansion is supported either by random 
genetic drift (Elson et al., 2001; Chinnery and Samuels, 1999) connected with random clonal 
expansion of mutations which occurred once in life, or because of the replicative advantage 
of the deleted molecule, as they are smaller in size (Diaz et al., 2002; Wallace, 1992b; Lee et 
al., 1998; Kowald et al., 2014). Simulation studies from Kowald et al., (2014) claimed that 
replication advantage due to smaller size is very unlikely to explain the clonal expansion of a 
single deleted mtDNA molecule, due to differences in the replication times and the half-life of 
the mtDNA. For example, a mutant which has lost 30% of its mtDNA would overtake the wild-
type mtDNA in 150 years.  
The formation of mtDNA deletions might result from failure in the function of mtDNA 
maintenance factors, maternal inheritance (generation in the mothers germ line) or stochastic 
formation. However, mtDNA deletetions are rarely inherited and are rather formed sporadicly 
(Fukui and Moraes, 2009). mtDNA deletions are being formed and accumulate naturally in 
the tissues during the process of aging (Wiesner et al., 2006). 
Many studies have shown that deletions often occur between direct repeats (DR) (up 
to 85% of the deletions (Bua et al., 2006; Samuels et al., 2004)) or stem-loop structures on 
the mtDNA (Lakshmanan et al., 2012; Solano et al., 2003) and appear mostly in the ‘major 
arc’ of the mtDNA (Kraytsberg et al., 2006). About 60% of the deletions are surrounded by 
perfect homologous direct repeats, forming Class I deletions. In approximately 30% of the 
deletions the flanking sequences are imperfect, imperfect repeats, and these deletions are 
classified as Class II. When formed between DRs, most of the deletions retain their 5’ end 
repeat (45% of the deletions in neurons and 75% of the deletions in muscle) (Samuels et al., 
2004; Krishnan et al., 2008).  Class III deletions represent 10% of the deletions and have no 
repeats (Samuels et al., 2004). Samuels et al., (2004) stated that there is no specific 
association between repeats and breakpoints distribution. All three classes of deletions share 
great similarity in the distribution of the breakpoints, which is pointing to a general underling 
deletion formation mechanism.  
Slip-replication (Shoffner et al., 1989), recombination (Schon et al., 1989; Mita et al., 
1990) and DSB repair (Krishnan  et al., 2008) are mechanisms associated with the deletion 
formation between DRs (Guo et al., 2010). The slipped-strand model of deletion formation 
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(Figure 11) (Krishnan et al., 2008) proposes that an upstream DR on the H-strand binds to 
downstream DR on the L-strand, during lagging strand replication (Figure 11a and b) and 
forms a light strand loop. A POLG error in the downstream repeat or single strand break in 
the loop (Figure 11c) leads to its degradation till double-strand region is reached (Figure 
11d). Ligation of these free ends of the heavy strand, followed by continuation of the 
replication leads to the formation of one wild-type molecule and one deleted molecule (Figure 
11d–f) (Eimon et al., 1996; Schon et al., 1989). The slipped-strand mechanism of deletion 
formation is strongly associated with the strand asynchronous model of replication and would 
result in large-scale deletion formation in the mtDNA major arc (Shoffner et al., 1989; 
Krishnan et al., 2008).  
A study by Krishnan et al., (2008), showed that only 12% of repeats larger then 10 bp 
and 21% of repeats with size of 5 to 9 bp are present in the minor arc, which would suggest 
that formation of deletions in the major arc is simply due to lower number of deletion 
formation sites present in the minor arc and the limiting effects of the two origins of 
replication (Samuels et al., 2004). 
 
 
 
Figure 11   Slipped-strand mechanism of deletion formation (adapted from Krishnan et al., 2008). 
 
Therefore, the slipped-strand model of deletion formation cannot be defined as the 
major way in which large scale deletions are formed. Hence, Krishnan et al., (2008) 
suggested that deletions can occur during DSB repair (Figure 12). After DSB formation, 
when under exonuclease activity at the DSB (Figure 12a–c) or due to mistakes in the POLG 
3’→5’ exonuclease repair activity, single strands are formed (Figure 12d) and they can 
anneal to other homologous single stranded mtDNA regions or the D-loop; further repair, 
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ligation and degradation of the left over single strand pieces (Figure 12e–f) leads to the 
formation of intact deleted mtDNA molecules. 
Samuels et al., (2004) addressed another issue of OL being a limiting factor for the 5’ 
deletion breakpoint. According to their studies and previous findings, deletions removing the 
OL are detectable in low levels and are amplifiable by PCR in post-mitotic tissues  
(Baumer et al., 1994; Moslemi et al., 1997; Kajander et al., 2000; Marzuki et al., 1997), or in 
connection with mtDNA duplications (Manfredi et al., 1997; Dunbar et al., 1993; Miyabayashi 
et al., 1991), and can influence the possibility of propagation of the deletion to high level, but 
does not influence the formation of the deletions themselves. 
 
 
 
Figure 12   Mechanism of deletion formation during DSBs repair (adapted from Krishnan et al., 2008). 
 
The distribution of the deletional breakpoints is probably dependent of the mechanism 
by which the deletions are formed. The 3’ end of the deletions often is in the region between 
16,000 np and 16,100 np, (Samuels et al., 2004) and the 5’ breakpoints lay in the region 
between 7800 and 8600 np. No deletions exceeding np 16,268 have been described 
(Samuels et al., 2004) and only four deletions at position above 16,085 are listed in the 
literature (Kajander et al., 2000; Barrientos et al., 1996; Samuels et al., 2004). For example, 
hippocampal samples from temporal lobe epilepsy (TLE) patients with Ammon’s horn 
sclerosis (AHS) contain 10-fold more deletions than a normal hippocampus and these 
deletions are containing a double-strand breakpoint hotspot at position 16,070, that is 
suggested as hot spot to the action of ROS (Zeviani et al., 1989; Srivastava and Moraes, 
2005; Imlay and Linn, 1988; Guo et al., 2010). Another study suggests that at that position a 
replication fork arrest might occur and DSB formation can be accelerated (Wanrooij et al., 
2004), also due to the possible existence of a replication fork barrier (Bowmaker et al., 2003). 
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Krishnan et al., (2008) claims that this hotspot might be due to the single stranded nature of 
this region in the mtDNA and its participation in deletions formation through single strand 
homologous annealing in their model of deletion formation by DSBs repair (Figure 12). It 
seems that deletions carrying no or small repeats tend to cluster at that region (Samuels et 
al., 2004). The most frequently detected deletion in human, the ‘common deletion’, is also 
formed between 13 bp long perfect DRs (Schon et al., 1989). The common deletion removes 
4977 bp from the mtDNA between np 8482 and np 13,459 (Holt et al., 2007; Schon et al., 
1989) and it was shown that it accumulates with the age in post-mitotic tissues (Kukat and 
Trifunovic, 2009) and is indicative trait for elevated oxidative damage (Lee and Wei, 2007). 
Samuels et al., (2004) suggested that the 13 bp long repeats, characteristic for the common 
deletion, are basic factor for the formation of most deletions and the exact breakpoint 
location is probably influenced by local sequence features. Guo et al., (2010) have performed 
deletional spectra analysis and have stated that the deletion formation is dependent mostly 
on secondary structures, such as long regions of up to 50 nt length with partial homology, 
that bring together distant parts of the mtDNA and participate in the deletion formation 
(Shoffner et al., 1989; Mita et al., 1990; Guo et al., 2010). The possibility of formation of 
deletions between these long regions is higher then only between simple perfect repeats 
(Guo et al., 2010).  
In difference to the homologous recombination end joining repair, the non-
homologous end joining (NHEJ) repair of DSBs can be much more hazardous and it is the 
mechanism in which deletions absent of DRs are formed (Gredilla et al., 2012). After DSB 
formation, POLG can remove single strand ends formed during the DSB and these 
intermediates can undergo NHEJ in a stochastic manner (Fukui and Moraes, 2009). Knock 
out mice absent of POLG proofreading activity also tend to form large scale deletions without 
DRs (Vermulst et al., 2008; Fukui and Moraes, 2009).  Some of these deletions have very 
small nucleotide homologies at the breakpoint position, which has been detected in aging 
and disease (Krishnan et al., 2008). However, these types of deletions are rarely detectable 
in comparison to the deletions formed between DR (Krishnan et al., 2008).  
 
1. 7 Alterations of mtDNA in disease 
 
The mtDNA molecules in a single cell coexist in heteroplasmic state with the mutated ones 
(Bua et al., 2006). The accumulation of mutated mtDNA fraction by clonal expansion is 
leading to heteroplasmic drift reaching certain threshold at which a biochemical phenotype 
occurs (Rossignol et al., 2003). At that stage the physiology of the cell might be severely 
impaired. As each cell reaches this threshold at a different time, these different 
heteroplasmic mtDNA levels in the cells lead to the mosaic pattern of the tissue, when 
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stained for mitochondrial enzymes activity (Lane et al., 1996). Muscle containing 
dysfunctional mitochondria often displays mitochondrial proliferation, visualized by staining 
with modified Gomori trichrome. Muscle fibers representing such phenotype are ragged-red 
fibers (RRF). Depending on the distribution and proportions of wild-type and mutated mtDNA 
molecules in different tissues, the patholgical manifestation of the mitochondrial disease can 
have different organ and age onset (Debrosse and Parikh, 2012). Lactic acidosis, myopathy, 
neurodegeneration and peripheral neuropathy are some of the symptoms connected with 
mitochondrial disorders. 
Defects of the respiratory chain subunits and mitochondrial disorders affect 1 in 5000 
live births (Skladal et al., 2003; Vafai and Mootha, 2012). More then 200 mitochondrial 
diseases are associated either with point mutations in mtDNA encoded respiratory chain 
proteins and tRNAs or single clonally expanded deletions (Chabi et al., 2003). Leber’s 
Hereditary Optic Neuropathy (LHON) and the Leigh Syndrome are examples of mitochondrial 
disorders based on point mutations in the mtDNA. Mutations m.11,778G>A in the ND4 gene 
(Wallace et al., 1988), m.3460G>A in the ND1 gene (Huoponen et al., 1991), m.14,484T>C 
in ND6 gene (Johns et al., 1992) and m.14,495A>G also in the ND6 gene (Chinnery et al., 
2001) are the mutations found most frequently in LHON patients and all of them are affecting 
Complex I of the respiratory chain. Point mutations in the ATPase domains are associated 
with the Leigh Syndrome (m.8993T>G or m.8993T>C, mutations in the ATPase 6 gene; de 
Vries et al., 1993) or Subacute Necrotizing Encephalomyelopathy. Its milder form with lower 
heteroplasmy causes neuropathy, ataxia, and retinitis pigmentosa (NARP) (Debrosse and 
Parikh, 2012; Leigh, 1951; Rahman et al., 1996). The mitochondrial tRNA genes frequently 
are found to carry point mutations in mitochondrial disease and are related to diseases such 
as MELAS and MERFF (myoclonic epilepsy with ragged red fibers) (Suzuki et al., 2011). 
MELAS patients suffer from mitochondrial myopathy, encephalopathy, lactic acidosis and 
stroke-like episodes, which give name of the disease. For example, MELAS is associated 
with mutations located in the mtDNA encoding for the tRNA Leu (m.3243A>G) but other 
tRNA mutations also can manifest in a similar way. The epileptic seizures in these patients 
are based on metabolic strokes, which often lead to focal or generalized epilepsy (Vafai and 
Mootha, 2012; Debrosse and Parikh, 2012). MERFF patients with mutation in the tRNA Lys 
(m.8344A>G) develop ataxia, hearing loss and peripheral neuropathy; they may represent 
generalized seizures and myoclonic epilepsy (Debrosse and Parikh, 2012).  
Mitochondrial single deletion syndromes are asscociated with the formation of a 
single deletion and its clonal expansion. They are usually characterized by large scale 
deletions from to 2 to 10 kb. In the different syndromes different tissues are affected, 
thereafter, the phenotype varies (Debrosse and Parikh, 2012). Such single mitochondrial 
deletion syndromes are the Pearson Syndrome (PS) (Williams et al., 2012; Debrosse and 
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Parikh, 2012) and the Kearns-Sayre syndrome (KSS) (Debrosse and Parikh, 2012; Harvey 
and Barnett, 1992; Berenberg et al., 1977). One of the most frequent mitochondrial disorders 
caused by single or multiple mtDNA deletions is CPEO or chronic progressive external 
ophthalmoplegia. Very often CPEO is accompanying other diseases such as MELAS and 
mitochondrial maintenance disorders. PS, KSS and CPEO symptoms and pathology often 
overlap in different patients (Debrosse and Parikh, 2012; Berenberg et al., 1977). 
Defects in the replication machinery and repair are broadly connected with the 
formation of multiple mtDNA deletions leading to ‘multiple mtDNA deletion disorders’, or 
mtDNA depletion represented with reduction of the copy number of mtDNA molecules and 
‘mtDNA depletion syndromes’ (MDS). Both the clinical and genetical phenotypes of these 
two groups of syndromes often are overlapping in the patients; therefore, they are called 
collectively ‘mtDNA maintenance disorders’ (MMD). MMDs have broad pathological 
manifestation.  Their phenotype may affect multiple organs in early childhood or they can be 
tissue specific pathologies appearing in later age. 
MMDs are associated with mutations in nuclearly encoded genes all of them coding 
for proteins involved in mtDNA replication or repair, or involved in the mitochondrial salvage 
pathway of deoxyribonucloside-5’-triphosphates (Nishino et al., 1999, Kaukonen et al., 2000; 
Ostergaard et al., 2007). One of the most frequent example for defects in the mitochondrial 
replication machinery are mutations in the POLG gene. The POLG patients are characterized 
with great diversity of phenotypes, that can be explained with the different kinetic 
mechanisms and unique enzymatic activities involved in each disease caused by different 
mutation in the same gene (Sohl et al., 2013). Mutations in POLG2, encoding for the 
accessory subunit of the POLG holoenzyme (Yakubovskaya et al., 2006) and a missense 
mutation in it, c.1352G>A (G451E) were found to be cosegregating with autosomal dominant 
form of progressive external ophtalmoplegia (adPEO) (Longley et al., 2006) and a 
heterozygous 24 bp insertion in its exon 7 leads to missplicing, late-onset ptosis and 
myopathy (Walter et al., 2010).  
adPEO is mainly associated with mutations in the nuclear genes POLG, TWINKLE or 
adenine nucleotide translocator 1 (ANT1). The patients represent multiple deletions and 
accumulation of point mutations, they show ragged red fibers and lowered respiratory 
capacity in muscle (Graziewicz et al., 2006; Bohlega et al., 1996; Copeland, 2008; Van 
Goethem et al., 2001; Zeviani et al., 1989; Spinazzola and Zeviani, 2005). More then 40 
mutations in C10Orf2 (TWINKLE ) have been reported (Young et al., 2011). Missense 
mutations in it cosegregate with adPEO, hepatocerebral syndrome with mtDNA depletion 
syndrome, and infantile-onset spinocerebellar ataxia (Longley et al., 2010). 
The Alpers-Huttenlocher syndrome is another MMD inherited in autosomal recessive 
way, characterized by depletion of the mtDNA and based on mutations in POLG, but in 
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opposite to the adult-onset adPEO, it has early childhood-manifestation (Huttenlocher et al., 
1976; Sandbank and Lerman, 1972; Naviaux et al., 1999; Zsurka et al., 2008).  
Except the dysfunction of the replication machinery, dysfunction of the mitochondrial 
deoxynucleoside triphosphates metabolism also leads to mtDNA depletion and subsequent 
mitochondrial disease (Leanza et al., 2008). Eight genes have been described in the 
literature in connection with impaired deoxynucleoside triphosphates metabolism, 
mitochondrial dysfunction and MDS; this group of genes includes, for example, the thymidine 
kinase 2 (TK2), leading to myopathic MDS (Götz et al., 2008; Saada et al., 2001) and the 
mitochondrial inner membrane protein MPV17 associated with hepatocerebral MDS (Götz et 
al., 2008; Spinazzola et al., 2006). The mitochondrial dNTP pools disbalance can be 
mutagenic, causing replication errors as A  T → G  C transitions. Low mismatch repair 
activities in mitochondria accelerate the replication errors (Song, et al., 2005; Mathews, 
2006).  
Emerging evidence shows that MMDs are tightly connected also to the mitochondrial 
dynamics, and the processes of active fusion and fission of mitochondria are responsible not 
only for the mitochondrial morphology and number, but obviously are also involved in the 
mitochondrial mtDNA maintenance (Wang et al., 2009). For example, mutations in Mfn2, 
involved in the process of fusion of the mitochondrial outer membrane, were found to cause 
autosomal dominant neuropathy, Charcot–Marie–Tooth Neuropathy Type 2A (CMT2A), that 
affects the long axons of motor and sensory neurons (Züchner et al., 2004). Its phenotypes 
were associated with mtDNA instability, which was not observed in CMT2A patients until 
recently. Mutations in OPA1, responsible for the merging of the IMM during fusion, are 
associated with autosomal dominant optic atrophy ‘plus’ phenotypes such as ataxia, chronic 
progressive external ophtalmoplegia, mitochondrial myopathy etc., (Amati-Bonneau et al., 
2008). Rouzier et al., (2011) reported a large family carrying mutation in Mfn2, representing 
autosomal dominant optic atrophy ‘plus’ phenotype, a phenotype usually linked to mutations 
in OPA1. Mitochondrial DNA deletions, respiratory chain deficiencies in fibroblasts from the 
patients, mitochondrial network fragmentation and MFN2 depletion classify MFN2 and 
mitochondrial fusion as responsible for mtDNA stability (Rouzier et al., 2011). All these facts 
lead to the current assumption that impaired mitochondrial fusion leads to instability of the 
mitochondrial genome, insufficient mitochondrial content mixing and incapability for recovery 
after oxidative stress (Rouzier et al., 2011; Chen and Chan, 2010).  
Alterations in mitochondria, such as changes in their structure, decline in their 
respiratory function, mtDNA mutation accumulation and increasing oxidative stress, and 
subsequent oxidative damage are also signs of the ongoing process of aging. Multiple 
mitochondrial deletions are detectable in patients with idiopathic Parkinson’s disease. They 
are wide spread in the substantia nigra pars compacta. In consensus with the development 
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of Parkinson’s disease with advancing of the age, mitochondrial deletions are accumulating 
in the process of aging (Bender et al., 2006; Kraytsberg et al., 2006). The accumulated 
deletions in these neurons are triggering neuroprotective compensatory mechanisms in the 
mitochondria, leading to higher pathogenic threshold in the dopaminergic neurons (Perier et 
al., 2013). 
Swerdlow et al., (2004) proposed the Alzheimer's disease “mitochondrial cascade 
hypothesis” for its late onset. Alzheimer's disease is characterized by dementia, extracellular 
amyloid protein aggregations, and intracytoplasmic tau protein aggregations. Mitochondrial 
dysfunction, such as impaired energy metabolism, electron transport chain enzyme 
dysfunction and ROS production appear to be an early sign of Alzheimer's disease (Chen 
and Yan et al., 2010).  
Campbell et al., (2011) gave evidence that mitochondrial dysfunction is involved as 
well in multiple sclerosis and is part of the pathomechanism of the disease, plus the chronic 
inflammation in its progressive stages. In amyotrophic lateral sclerosis (ALS) mitochondrial 
transport in the axons was shown to be disrupted as well as the mitochondrial fission and 
fusion (Shi et al., 2010). Morphological changes in mitochondria were found in both humans 
and animal models of ALS. Patients with secondary progressive multiple sclerosis (SPMS) 
represent respiratory chain deficiency of complexes II and IV in comparison to aged controls. 
This pathology is result of the formation of clonally expanding multiple mitochondrial 
deletions inducible by inflammation and their impaired repair. The deletions have breakpoints 
in the major arc as in other neurodegenerative diseases (Campbell et al., 2011). 
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1. 8 Goals 
 
The focus of this PhD thesis was to gain insight into the different pathological mechanisms 
that lead to mitochondrial dysfunction through an impairment in mtDNA maintenance. (i) I 
was investigating the novel mitochondrial exonuclease MGME1 that we have discovered in 
three families with mtDNA maintenance disorder. Mutation in MGME1 leads to decreased 
mtDNA copy number and generation of unusual large rearrangments. The exact function and 
the molecular consequences of MGME1 deficiency has been investigated in detail. (ii) Defect 
of other genes, not directly involved in mtDNA replication, can also have an effect on mtDNA 
maintenance. Mitofusin 2 is known to play a crucial role in fusion of mitochondria. Proper 
mitochondrial dynamics are required for adequate content mixing, i.e. complementation of 
impaired proteins, RNA and DNA molecules through their healthy counterparts. We aimed to 
show that dysfunction of mitofusin 2 can lead to insufficient mtDNA replication and the 
formation of deletions. (iii) Alterations of the mitochondrial genome have been demonstrated 
in epilepsy, especially in the hippocampus, the seizure focus of temporal lobe epilepsy (TLE) 
patients with AHS. So far, it is not clear whether mtDNA damage and hippocampal 
neurodegeneration is a cause or result of the epilepsy. By investigating the complex mixture 
of multiple deletions in brain samples of patients having different forms of TLE, we aimed to 
identify specific mechanisms relevant for chronification of epilepsy.   
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2. Materials and Methods 
 
2. 1.  Synthetic oligonucleotides 
 
The following oligonucleotides used in different PCR reactions for the nuclear single copy 
gene Kir4.1, for the mitochondrial genome (mtDNA) and ligation-mediated PCR, were 
designed by using software ‘Primer’ and were purchased from Thermo Fisher Scientific 
GmbH (Ulm, Germany) and MWG Biotech AG (Ebersberg, Germany). They are listed in 
Tables 1, 2, 3 and 4. F, forward primer; R, reverse primer; TM, TaqMann probe; number in 
the name indicates the 5′ nucleotide of the primer. 
 
Locus Name Lenght Sequence 
Kir4.1 KIR835F 19 5’-GCGCAAAAGCCTCCTCATT-3’ 
Kir4.1 KIR857TM 27 5’-FAM-TGCCAGGTGAACAGGAAAACTG CTTCAG-TAMRA-3’     
Kir4.1 KIR903R 19 5’-CCTTCCTTGGTTTGGTGGG-3’ 
 
Table 1   Oligonucleotides for the nuclear gene Kir4.1. 
 
 
Locus Name Lenght Sequence 
synthetic sequence LMP25 25 5’-GCGGTGACCCGGGAGATCTGTATTC-3’ 
synthetic sequence LMP11 11 5’-GAATACAGATC-3’ 
 
Table 2   Oligonucleotides used for linker synthesis. 
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Locus          Name         Lenght   Sequence 
mtDNA       16,557TM 25 5’-FAM-AGACATCACGATGGATCACAGGTCT-TAMRA-3’ 
mtDNA 10F 30 5’- TCTATCACCCTATTAACCACTCACGGGAGC-3’ 
mtDNA 108F 22 5’-AGCACCCTATGTCGCAGTATCT-3’ 
mtDNA 174F 27 5’-CAATATTACAGGCGAACATACTTA CTA-3’ 
mtDNA  379F 25 5’-AGCCTAACCAGATTTCAAATTTTAT-3’ 
mtDNA 521F 21 5’-ACACCGCTGCTAACCCCATAC-3’ 
mtDNA 16,074F 23 5’-ATCAACAACCGCTATGTATTTCG-3’ 
mtDNA 16,099F 23 5’-CATTACTGCCAGCCACCATGA-3’ 
mtDNA 16,196F 23 5’-GCTTACAAGCAAGTACAGCAATC-3’ 
mtDNA 16,285F 25 5’-ACCTACCCACCCTTAACAGTACATA-3’ 
mtDNA 16,520F 24 5’-CATAAAGCCTAAATAGCCCACACG-3’ 
mtDNA 16,525F 21 5’-AGCCTAAATAGCCCACACGTT-3’ 
mtDNA  35R 24 5’-CCGTGAGTGGTTAATAGGGTGATA-3’ 
mtDNA 45R 22 5’-TGGAGAGCTCCCGTGAGTGGTT-3’ 
mtDNA 67R 21 5’-CCAGACGAAAATACCAAATGC-3’ 
mtDNA 136R 21 5’-CAAAGACAGATACTGCGACAT-3’ 
mtDNA 208R 26 5’-ACACACTTTAGTAAGTATGTTCGCCT-3’ 
mtDNA 288R 25 5’-TTTGTTATGATGTCTGTGTGGAAAG-3’ 
mtDNA 485R 25 5’-ATGAGATTAGTAGTATGGGAGTGGG-3’ 
mtDNA          16,075R 22 5’-ATGGGTGAGTCAATACTTGGGT-3’ 
mtDNA          16,115R 21 5’-GGTGGCTGGCAGTAATGTACG-3’ 
mtDNA          16,148R 25 5’-GGTCAAGTATTTATGGTACCGTACA-3’ 
mtDNA          16,185R 21 5’-GGTTTTGATGTGGATTGGGTT-3’ 
mtDNA         16,263R 18 5’-AGGGGTGGCTTTGGAGTT-3’ 
mtDNA          16,282R 21 5’-GTTGGTATCCTAGTGGGTGAG-3’ 
mtDNA         16,308R 24 5’-ATGTACTGTTAAGGGTGGGTAGGT-3’ 
mtDNA        16,413R 19 5’-ACGGAGGATGGTGGTCAAG-3’ 
mtDNA         16,496R 32 5’-CGGATACAGTTCACTTTAGCTACCCCC AAGTG-3’ 
mtDNA          16,503R 23 5’-CAGATGTCGGATACAGTTCACTT-3’ 
 
Table 3   mtDNA primers in the D-loop. 
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Locus                  Name         Lenght     Sequence 
mtDNA            1056F 22 5’-AGCTAAGACCCAAACTGGGATT-3’ 
mtDNA           2101F 22 5’CAAAGAGGAACAGCTCTTTGGA-3’ 
mtDNA           3137F 26 5’-GAGAAATAAGGCCTACTTCACAAAGC-3’ 
mtDNA           3150F 20 5’-TACTTCACAAAGCGCCTTCC-3’ 
mtDNA            3922F 25 5’-GAACTAGTCTCAGGCTTCAACATCG-3’ 
mtDNA           5462F 28 5’-CCTTACCACGCTACTCCTACCTATCTC C-3’ 
mtDNA           7027F 25 5’-CCCACTTCCACTATGTCCTATCAAT-3’ 
mtDNA           8282F 20 5’-CCCCTCTAGAGCCCACTGTA-3’ 
mtDNA           11,226F 20 5’-GCTCCCTTCCCCTACTCATC-3’ 
mtDNA           12,062F 21 5’-ACCCTCATGTTCATACACCTA-3’ 
mtDNA           14,588F 24 5’-CCCCCATAAATAGGAGAAGGCTTA-3’ 
mtDNA 15,081F 21 5’-CCTGAAACATCGGCATTATCC-3’ 
mtDNA 15,965F 25 5’-AAGTCTTTAACTCCAACCATTAGCAC-3’ 
mtDNA 15,974F 23 5’-ACTCCACCATTAGCACCCAAAGC-3’ 
mtDNA 638R 22 5’-GGTGATGTGAGCCCGTCTAAAC-3’ 
mtDNA 1144R 22 5’-AGTGTTCTGGCGAGCAGTTTTG-3’ 
mtDNA 2223R 22 5’-TAGTGGGTGTTGAGCTTGAACG-3’ 
mtDNA 3246R 22 5’-GGCTCTGCCATCTTAACAAACC-3’ 
mtDNA 4036R 26 5’-CTAGGAAGATTGTAGTGGTGAGGGTG-3’ 
mtDNA 4833R 24 5’-TGCCTTGGGTAACCTCTGGGACTC-3’ 
mtDNA 5985R 25 5’-CTCCAGCTCATGCGCCGAATAATAG-3’ 
mtDNA           12,135R 20 5’-GAGGAAAACCCGGTAATGAT-3’ 
mtDNA           13,684R 24 5’-GGGTGGGGTTATTTTCGTTAATGT-3’ 
mtDNA           14,695R 20 5’-GGTTGTAGTCCGTGCGAGAA-3’ 
mtDNA           15,180R 20 5’-ACTGTGGCCCCTCAGAATGA-3’ 
mtDNA         15,623R 20 5’-CAAGGACGCCTCCTAGTTTG-3’ 
 
Table 4   Primers in the mtDNA coding region. 
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2. 2 Enzymes, chemicals and solutions 
 
All enzymes were provided with their commercial reaction buffers.  
 
Enzyme Company Headquater 
iTaq DNA polymerase BIO-RAD Hercules, California, U. S. 
JumpStart AccuTaq LA polymerase Sigma-Aldrich St. Louis, USA 
JumpStart Taq polymerase Sigma-Aldrich St. Louis, USA 
LongAmp Taq DNA polymerase New England Biolabs Ipswich, United Kingdo 
Ranger DNA polymerase BIOLINE GmbH  Berlin-Brandenburg, Germany 
TaKaRa LA Taq
 
HS TAKARA BIO INC Ōtsu, Shiga, Japan 
Mung Bean Nuclease New England Biolabs Ipswich, United Kingdo 
T4 DNA ligase New England Biolabs Ipswich, United Kingdo 
T4 DNA polymerase New England Biolabs Ipswich, United Kingdo 
Proteinase K QIAGEN N.V. Venlo, Netherlands 
Trypsin PAA Laboratories GmbH Pasching, Austria 
 
Table 5    Enzymes. 
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Chemical Company Headquater 
Acrylamide/Bis Solution, 40%, 37.5:1 BIO-RAD Hercules, USA 
Agarose Sigma-Aldrich St. Louis, USA 
Ammonium persulfate Carl Roth GmbH & Co. KG Karlsruhe, Germany 
Bromophenol blue Sigma-Aldrich St. Louis, USA 
Bovine serum albumin Sigma-Aldrich St. Louis, USA 
2’-3’-dideoxycytidine Sigma-Aldrich St. Louis, USA 
Digitonin Serva Electrophoresis GmbH Heidelberg, Germany 
dNTPs Sigma-Aldrich St. Louis, USA 
DMSO Merck Darmstadt, Germany 
DMEM PAA Laboratories GmbH Pasching, Austria 
Double distilled water Sigma-Aldrich St. Louis, USA 
EDTA Sigma-Aldrich St. Louis, USA 
EGTA Sigma-Aldrich St. Louis, USA 
Ethidium bromide Sigma-Aldrich St. Louis, USA 
FBS Invitrogen Corporation Carlsbad, USA 
Glycerol Sigma-Aldrich St. Louis, USA 
HEPES Sigma-Aldrich St. Louis, USA 
Hydrogen peroxide solution Sigma-Aldrich St. Louis, USA 
Mannitol  Sigma-Aldrich St. Louis, USA 
MgCl2 Sigma-Aldrich St. Louis, USA 
Nagarse  Sigma-Aldrich St. Louis, USA 
N,N,N′,N′-Tetramethylethylenediamine Sigma-Aldrich St. Louis, USA 
PBS pH 7.4 Invitrogen Corporation Carlsbad, USA 
Penicillin Streptomycin  Invitrogen Corporation Carlsbad, USA 
ROX Reference Dye Invitrogen Corporation Carlsbad, USA 
Sucrose AppliChem GmbH Darmstadt, Germany 
SYBR Green I nucleic acid gel stain Sigma-Aldrich St. Louis, USA 
TBE Sigma-Aldrich St. Louis, USA 
Tris-EDTA buffer solution Sigma-Aldrich St. Louis, USA 
Uridine Sigma-Aldrich St. Louis, USA 
Xylene cyanol Merck Darmstadt, Germany 
1 kb DNA Ladder New England Biolabs Ipswich, United Kingdo 
2-Log DNA Ladder (0.1-10.0 kb) New England Biolabs Ipswich, United Kingdo 
25 bp DNA Ladder Invitrogen Corporation Carlsbad, USA 
 
Table 6   Chemicals. 
 
Materials and Methods 
                                                                                                                                                       37 
Solution Ingredients 
Cell freezing media 90% [v/v] FBS, 10% [v/v] DMSO 
Fibroblasts media DMEM (4.5g/l glucose, GlutaMAXTM , 1mM sodium pyruvate),  
 10%[v/v] FBS, uridine (0,005g/l), penicillin (100 000 U/l),  
 Streptomycin (0.1g/l) 
Loading Dye 1×TBE buffer, 30% [v/v] glycerol, 0.04%  [w/v] bromphenol blue,  
 0.4% [w/v] xylene cyanol 
MSE solution 225 mm mannitol, 75 mm sucrose, 1 mm EGTA, 5 mm HEPES,  
 1 mg/ml BSA, pH 7.4 
MSE-nagarse solution 0.05% nagarse in MSE solution 
MSE-digitonin solution 0.02% digitonin in MSE solution 
 
Table 7   Solutions. 
 
2. 3 Kits 
 
Kit Company Headquater 
iQ™ SYBR® Green Supermix BIO-RAD Hercules, USA  
QIAamp DNA Mini Kit QIAGEN N.V. Venlo, Netherlands 
QIAquick Gel Extraction Kit QIAGEN N.V. Venlo, Netherlands 
QIAquick PCR Purification Kit QIAGEN N.V. Venlo, Netherlands 
Quick Blunting™ Kit New England Biolabs Ipswich, United Kingdo 
 
Table 8   Kits. 
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2. 4 Equipment and software 
 
Electronic equipment  Model Company Headquater 
Analytical balance TE214S Sartorius Elk Grove, USA 
Camera 3CCD Color  Sony Corporation Minato, Japan 
 Video Camera,   
 Model DXC-9100P   
Gel-electrophoresis chamber Sub-Cell GT BIO-RAD Hercules, USA 
 System   
Haemocytometer BLAUBRAND®, BRAND GMBH  Wertheim, Germany 
 Neubauer, IVD & Co K.G  
Phase contrast Axiovert 40C Carl Zeiss AG Jena, Germany 
microscope    
PCR thermocycler GeneAmp® Applied Carlsbad, USA 
 PCR system 9700 Biosystems  
PCR thermocycler MJ Research  GMI, Inc. Ramsey, USA 
 PTC-100   
PCR thermocycler MJ Research  GMI, Inc. Ramsey, USA 
Quantitative real time PCR iCycler iQ™ BIO-RAD Hercules, USA 
(qPCR) thermocycler cycler   
Spectrophotometer  Cary 50 scan Varian, Inc. Palo Alto, USA 
 PTC-200   
UV-illuminator GeldocTM XR BIO-RAD Hercules, USA 
 
Table 9   Equipment. 
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Application Software Company Headquater  
Vector graphic editing Corel Draw Corel Corporation Ottawa, Canada 
Image processing and analysis ImageJ Wayne Rasband NIH public domain 
Image acquisition Quantity One 1-D  BIO-RAD Hercules, USA 
 Analysis Software   
Plotting and data imaging Sigma Plot 2001 Sysat Software Inc. San Jose, USA 
Primer design  Primer   
qPCR MyiQ™ BIO-RAD Hercules, USA 
qPCR iQ5 BIO-RAD Hercules, USA 
Spectrophotometry CaryWinUV Varian, Inc. Palo Alto, USA 
Sequence analysis scftk  Dr. Zsurka in house  
 
Table 10   Software. 
  
2. 5 Patients and samples 
 
All experiments with human samples were performed according to the guidelines of the 
University Ethical Comission. All patients or their care attendants gave written informed 
consent for the scientific use of their anonymized data and samples. The clinical information 
needed was provided by the Departments of Epileptology and Neurology, University Bonn.  
All muscle samples were obtained after routine diagnostic skeletal muscle biopsy and 
all brain samples after therapeutical hippocampectomy of patients with drug resistant 
temporal lobe epilepsy. The samples were used either for direct DNA isolation and 
biochemical analysis, or were frozen in liquid nitrogen. When enough tissue material was 
available from the selected samples, they were used for mitochondrial purification and 
isolation of mitochondrial DNA enriched samples.  
When possible, DNA was isolated as well from urine, blood samples and skin 
fibroblast from the patients and their relatives. Aliquotes cultured skin fibroblasts were frozen 
in liquid nitrogen.  
All control samples used in this study were from age matched individuals without 
mitochondrial diseases.  
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2. 6 Cell culture 
 
Skin fibroblasts from control patients, patients with mitochondria maintenance disorders and 
Charcot–Marie–Tooth neuropathy were grown in cell culture. The fibroblast samples were 
stored in liquid nitrogen (at -195°C) in cryo reaction tubes. They were taken into culture, after 
quick thawing at 37°C. The cells were grown into tissue culture flasks (with size of 25 cm², 75 
cm² and 175 cm²) in high-glucose DMEM medium containing 10% FBS, 200 µM uridine and 
1% penicillin-streptomycin. After the cells have attached to the flask the medium was 
exchanged with fresh one. The cells were grown in humid CO2 incubator at 37°C and 5% 
CO2.  
 
2. 6. 1 Cell passaging 
 
By 95% density of the cells in the flask they were split for further breeding. The old fibroblast 
media was discarded by aspiration and the cells were washed with 1× PBS. To detach the 
cells from the 175 cm² flask 5 ml (1 ml for 25 cm² and 3 ml for 75 cm² flsks) of 2.5 mg/ml 
trypsin solution was used for 5 minutes at 37°C. The trypsinization was controlled under 
microscope. After the cells were detached, the activity of the trypsin was blocked with the 
addition of fibroblast media, and the cells were alliquoted into new tissue culture flasks with 
fresh media. 
 
2. 6. 2 Cell counting 
 
Detached cells resuspended in 20 µl medium were counted on Neubauer haemocytometer 
under light microscope. The counted cells from three repeats of eight type A squares of the 
haemocytometer, with volume 1 mm3 (or 1 µl = 0.001 ml) each, were averaged and the data 
was used to calculate the amount of cells with the formula:  
 
Concentration of cells/ml = (total cells counted/ # of squares used)(104 ×dilution factor) 
 
2. 6. 3 Freezing of cells 
 
Trypsinized cells resuspended in desired amount of media were centrifuged for 5 minutes at 
1000× g. The supernatant was discarded by aspiration and the cell pellet was resuspended 
in ice cold freezing media. The cells were alliquoted in cryo reaction tubes. At first they were 
stored at -20°C for an hour and subsequently at -80°C for 24 hours. Finally, the cells were 
transferred to liquid nitrogen.  
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2. 6. 4 Cell pelleting 
 
Cells were trypsinized as for passaging (2. 3. 1) and were transferred into a Falcon tube, and 
PBS was filled in up to 50 ml final volume. At this step the cells were checked for vitality and 
counted. After spinning the cells for 5 minutes at 3000 rpm, the pellet was resuspended in  
750 µl PBS and transferred to an Eppendorf tube to which PBS was added up to 
approximately 1500 µl. The tubes were centrifuged for 5 minutes at 3000 rpm and following 
50 seconds at 10,000 rpm. The supernatant was discarded by pipeting and the pellet was 
frozen directly at -20°C or was directly used for DNA extraction, or enzymatic measurements 
(Siddiqui et al., 2012). 
 
2. 7 Depletion and repopulation experiments 
 
The mtDNA depletion experiments were performed over 32 days. 16 flasks (75 cm²) derived 
from a single passage were used for the experiments. Samples were collected on the first 
day before depletion and afterwards every second day. The depletion was achieved by 
adding  
2’, 3’-dideoxycytidine (ddC) with final concentration of 20 µM. The ddC was exchanged with 
fresh one every second day. The ddC treatment continued 12 days for mtDNA depletion, on 
the 14th day the ddC containing medium was discarded and the cells were left for mtDNA 
recovery in fresh fibroblasts medium, which afterwards was exchanged every second day. 
Cells were counted every time when a sample was collected (Brown and Clayton, 2002). The 
cell pellets were frozen directly at -20°C for further DNA extraction.  
 
2. 8 Hydrogen peroxide treatment of fibroblasts 
 
To examine the effect of oxidative stress, hydrogen peroxide treatment experiments were 
carried on control fibroblast cell line. The cells were 70% confluent at the start of the 
experiments. After washing of the cells with PBS, medium containing the desired 
concentration of H2O2 (stock solution contains 30 wt. % in water) – 250 µM, 500 µM and 750 
µM, was added to the flasks. For each concentration of the H2O2 treatment there were three 
repeats, and a control flask, incubated only with medium. After 10 minutes incubation the 
medium was discarded and the cells were washed with PBS and trypsinized. The cells were 
pelleted as in 2. 3. 5 and the pellet was used for DNA isolation. 
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2. 9 Purification of mitochondria from human brain samples 
 
The protocol used for mitochondria purification is adapted from Kudin et al., 2004. The 
solutions used in this protocol are MSE solution, MSE-nagarse solution and MSE-digitonin 
solution; they were all chilled before the experiment. 
Fresh tissue sample was obtained after brain surgery of epileptic patients and the 
brain slice was immediately transferred into MSE solution. After mincing the brain with a 
sterile scalpel, ice-cold MSE-nagarse solution was added and the tissue was homogenized 
at 600 rpm by potter homogenizer. Nagarse is a protease having strong and unspecific 
proteolytic activity (Picard et al., 2011). As a next step 20 ml of ice-cold MSE solution was 
added to the homogenate and it was centrifuged for 4 minutes at 2000× g in order to remove 
the nuclei. The mitochondria rich supernatant was filtered through cheesecloth and 
centrifuged for 9 minutes at 12,000× g. The pellet was dissolved in 10 ml ice-cold MSE-
digitonin solution in order to permeabilize the synaptosomes. The prepared solution was 
homogenized 8 to 10 times in glass-homogenizer, until having homogenous suspension. As 
a final step it was centrifuged at 12,000× g for 11 min and the pellet was dissolved in 300 µl 
of MSE buffer. The suspension contained purified mitochondria, confirmed by biorespiration 
measurement of respiratory control (RC) value, performed by Dr. Kudin in our lab. 
The RC value is calculated as a ratio between state 3 of respiration of the 
mitochondria (triggered by addition of 250 µM ADP to the mitochondrial suspension) and 
resting state 4 of the mitochondria. The higher the RC value, the better the quality of the 
mitochondria in the suspension. Afterwards, the protein content was determined 
spectrophotometrically (about  
20 mg protein/ml), by Loury method (Kudin et al., 2004). The samples were directly used for 
mitochondrial DNA isolation or were stored in liquid nitrogen. The mtDNA enrichment 
obtained from isolated mitochondria has been checked by qPCR and was found to be at 
least 10 fold higher as compared to the total DNA.  
 
2. 10 Mitochondria purification from human muscle samples 
 
The purification of mitochondria from muscle was performed by Dr. Kudin in our laboratory, 
applying the protocol described by Kudin et al., 2005. 
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2. 11 DNA isolation with QIAamp DNA Mini Kit 
 
Column purification of DNA was performed as described in the manual of QIAamp DNA Mini 
Kit (QIAGEN N.V., Venlo, Netherlands). Each sample was eluted twice in 200 µl elution 
buffer provided with the kit and was stored without freezing at 4°C. 
 
2. 12 DNA concentration quantitation 
 
The concentration and purity of the isolated DNA were estimated by measurement of its 
optical density (OD) with a spectrophotometer. Double-stranded DNA shows ultraviolet light 
absorption maximum at wavelength λ = 260 nm, while the proteins absorption maximum is at 
wavelength 
λ = 280 nm. The DNA concentration (C) in ng/µl is calculated by the formula: 
 
C = [–36.0(OD280nm–OD320nm) + 62.9(OD260nm–OD320nm)] × dilution factor  
The total yield of the isolated DNA (µg) is calculated by multiplying the DNA 
concentration C by the purified sample volume (ml). The ratio OD260nm/OD280nm provides an 
estimate of the degree of purity of the DNA. The quality of the DNA was considered suitable 
when the ratio was between 1.8 and 2. The DNA purity can be estimated by correcting for 
impurities detected at λ = 320 nm, OD320nm  with the formula:  
 
DNA purity = (OD260nm– OD320nm)/(OD280nm–OD320nm) 
 
2. 13 Gel electrophoresis 
 
All PCR products with expected size bigger then 500 bp were visualized by agarose gel (1%) 
electrophoresis.  
PCR products smaller then 500 bp were electrophoretically separated by 
polyacrylamyde gel electrophoresis, PAGE. The PCR products from all primer pairs used in 
the qPCR were optimized and checked for purity and size on PAGE gels. Multiplex PCR 
products, with size smaller then 500 bp were loaded on 3% agarose gels.  
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Reagents Volume (ml) 
5× TBE 2 
Acrylamide 2.5 
10% APS 0.1 
TEMED 0.01 
dd water up to 10 ml  
 
Table 11   Mixture for PAGE gel. 
 
2. 14 Long-Range PCR (LR-PCR) 
 
LR-PCR was used for the amplification of large fragments of DNA, up to 27–30 kb. LR-PCR 
was performed with TaKaRa LA Taq Hot Start (HS) or JumpStart AccuTaq LA enzymes 
(Table 12). They contain LA TaqTM (LA, long and accurate) polymerase mixture constituted 
by a highly processive thermostable polymerase and second thermostable polymerase with 
3’→5’ exonuclease activity (proofreading activity), which leads to strong reduction of the 
misincorporation errors, and supports the production of longer PCR amplicons, with greater 
accuracy. The TAKARA LA Taq HS kit contains a monoclonal antibody specific for the  
LA TaqTM, which binds to it and inhibits the polymerase activity until the temperature 
escalates. In this way mis-priming and formation of primer dimmers during temperature 
elevation is being avoided. The antibody is being denatured in the first step of DNA 
denaturation. The PCR program (Table 13) and PCR mixtures (Table 12) were optimized by 
modifying the original protocols provided by the producer (TAKARA BIO INC and Sigma 
Aldrich). 
 
Reagent  Volume (µl) 
10× TaKaRa reaction buffer  2.5 
TaKaRa dNTPs (2.5 mM) 2.5 
FW primer (25 pmol/µl) 0.2 
RW primer (25 pmol/µl) 0.2 
TaKaRa LA Taq (HS) / AccuTaq LA 0.125 / 0.25 
DNA (2 ng/µl) 10 
ddH2O                                                           up to 25 µl 
 
Table 12   TaKaRa LA Taq (HS) and JumpStart AccuTaq LA LR PCR mixture. 
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PCR program  
1. 95°C, 2:30 min  
2. 92°C, 0:20 min 
3. 68°C, 14:00 min 
          
      10× 
4. 92°C, 0:25 min 
5. 68°C, 16:00 min 
            
      20× 
6. 72°C, 10:00 min  
7. 15°C for ever  
 
Table 13   LR-PCR program.   
 
5 µl of the PCR products with 5 µl loading buffer were mixed and loaded on 1% 
agarose gel, and 1 kb DNA ladder or 2-log ladder for band identification. After 
electrophoresis at 180V for 1h, of the gel picture was visualized and captured with 3CCD 
Video Camera with 4 megapixels resolution, with UV-illuminator GeldocTM XR with excitatory 
wavelength between 254 and 365 nm. Deleted molecules were detected as bands of 
decreased size.  
 
2. 15 Single-molecule PCR (smPCR) 
 
In order to avoid laborious cloning procedures and to capture and analyze single-molecules 
of DNA and map their deletions, I have established a modified version of the single-molecule 
PCR (smPCR) described by Kraytsberg et al., 2008 (Tables 14 and 15). 
 
Reagent  Volume (µl) 
10× TaKaRa reaction buffer  2.5 
TaKaRa dNTPs (2.5 mM) 2.5 
FW primer (50 pmol/µl) 0.1 
RW primer (50 pmol/µl) 0.1 
TaKaRa LA Taq (HS) 0.125  
Diluted DNA* 1 
ddH2O                                                             up to 25 µl 
*diluted 10×, 100×, 1000× etc. mtDNA 
Table 14   TaKaRa LA Taq (HS) smPCR mixture. 
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PCR program  
1. 95°C, 2:30 min  
2. 92°C, 0:20 min 
3. 68°C, 14:00 min 
          
      10× 
4. 92°C, 0:25 min 
5. 68°C, 16:00 min 
            
      32× 
6. 72°C, 10:00 min  
7. 15°C for ever  
 
Table 15   Single-molecule PCR program. 
 
 The DNA used in the smPCR is diluted to such an extent that in a set of repeats of 
the same sample only part of the repeat reactions would give a product. Firstly, a pilot 
experiment was performed for each analyzed sample (Figure 13a). The pilot experiment 
includes serial dilutions of the DNA in five repeats for each dilution, to adjust the right mtDNA 
concentration in order to detect single mtDNA molecules. On Figure 13a, a pilot experiment 
depicts the effect of serial mtDNA dilution and the decrease in the number of molecules 
detected in every step. For this sample at 1000× dilution there are still multiple bands in a 
single lane, therefore the right mtDNA single molecule concentration should be checked at 
even higher dilution (10,000×). For each gel electrophoresis a line with PCR product from 
undiluted mtDNA from the same sample was used as a PCR positive control (marked with C 
on Figure 13a). After determination of the right mtDNA dilution, a smPCR with a larger set of 
repeats (15–20) was performed (Figure 13b).   
After successful amplification of single-molecule amplicons, they were either cut out 
of the agarose gel (Figure 13, red rectangles), the DNA was purified with QIAquick Gel 
Extraction Kit and reamplified; or PCR product, 30 fold diluted in double distilled water, was 
used for the re-amplification. The primers used in the re-amplification PCR were located 
within the amplified region and by ‘walking’ from both ends in the amplified product with 
different primers we aimed flanking of each deletion as close as possible, to size not 
exceeding 1500 bp. The reamplified PCR products were purified with QIAquick PCR 
Purification Kit and the exact breakpoints were determined by sequencing.  
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a 
 
 b 
 
 
Figure 13   Single-molecule PCR. (a) smPCR pilot experiment for adjusting the right concentration of 
the mtDNA, for capturing single molecules, (b) smPCR in a big set of 16 repeats with optimized 
mtDNA concentration; C, undiluted sample; w, water control; red box, gel cut outs used for 
sequencing.  
 
 
2. 15. 1 mtDNA deletions quantification by smPCR 
 
In order to estimate the amount of deletions in a sample, two smPCRs with two different 
primer combinations were performed. The first PCR primer pair is amplifying either almost 
the whole mtDNA genome (10F/16,496R) or just the mtDNA major arc (3137F/45R), that is 
prone to deletion formation. The second primer pair amplifies a shorter region of the small 
arc (16,520F/4833R), which usually does not contain deletions and should be giving an 
estimate of the total amount of wild-type molecules. The ratio of deletions is calculated by 
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comparison of the number of positive PCR reactions and the degree of dilution of the total 
and deleted mtDNA molecules (Zsurka et al., 2008; Vielhaber et al., 2013; Kornblum et al., 
2013). Both PCRs were performed with TaKaRa LA Taq (HS). The reaction mix and PCR 
program for total mtDNA estimation are the same as the ones used for the long product, but 
with 3 minutes elongation time (Table 14 and 15). 
 
2. 16 Long extension PCR 
 
Duplicated mtDNA molecules were detected by using a long extension PCR method modified 
from Williams et al., 2010. Primers 1057F and 1144R were used to amplify a short mtDNA 
fragment and additional extended elongation time enabled the polymerase to amplify 
fragments of several thousand base pairs in size. This kind of long molecules can be 
amplified along the short fragments, if more than one copies of the primer-binding region are 
present on some of the mtDNA molecules. The reaction mix and PCR program for long 
extension PCR are the same as the ones used for single-molecule PCR (2.12). All PCR 
products were analysed on agarose gel. 
 
2. 17 mtDNA copy number determination 
 
The mitochondrial DNA copy number was evaluated by quantitative Real-Time PCR (qPCR), 
a modified PCR method allowing the monitoring of targeted mtDNA amplification in status 
nascendi. For the detection of DNA products in qPCR either the fluorescent dye SYBR® 
Green I or sequence-specific DNA probes (oligonucleotides) labelled with a fluorescent 
reporter, such as TaqMan® Probe were used. In both cases the qPCR was performed with 
three different concentrations of the DNA sample – 5 ng/µl, 10 ng/µl or 20 ng/µl, with three 
repeats for each dilution. All primer pairs were optimized and checked by PAGE. 
 
2. 17. 1 SYBR® Green I qPCR 
 
The cyanine dye SYBR Green I binds preferentially to dsDNA and intercalates between the 
DNA strands and therefore stains the DNA in a not sequence specific way. The formed 
DNA/dye-complex absorbs blue light at λmax = 488 nm and emits green light at  
λmax = 522 nm. This increase in fluorescence intensity, which is measured at each PCR 
cycle, allows the DNA concentrations to be quantified. The primers used for total mtDNA 
determination were 3922F and 4036R. The primers used to detect the 7S DNA levels were 
16,520F and 35R.  
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Reagent  Volume (µl)  
iQ™ SYBR® Green Supermix 11.9 
FW / RW primer mix  (12.5 pmol/µl each ) 0.6 
DNA* (ng/µl) 12.5 
* 1.6 ng/µl, 0.8 ng/µl or 0.4 ng/µl   
 
Table 16   SYBR® Green qPCR mixture.  
 
In order to verify the specificity of the product, a melting curve analysis was 
performed at the end of the qPCR. During it the temperature increases constantly from 55°C 
to 95°C, leading to melting of the DNA. At a specific temperature the dsDNA denatures and 
at that point the SYBR Green I is set free leading to decrease in the fluorescence. In case 
the PCR is specific only one high fluorescence peak should be observed. In table 17 this 
analytical phase corresponds to step 6. 
 
PCR program  
1. 95°C, 7:00 min  
2. 95°C, 0:15 min 
3. **°C, 1:00 min 
          
      45× 
4. 95°C, 1:00 min 
5. 55°C, 1:00 min 
            
       
6. 55°C, 0:10 min 
    + 0.5°C per cycle 
        
      80× 
7. 15°C for ever  
** primer specific annealing temperature (in the range of 55°C to 70°C) 
 
Table 17 SYBR Green qPCR program. 
 
 
2. 17. 2 TaqMan® qPCR 
 
Specific probes as TaqMan® assure higher specificity of the method, as they permit 
detection only after hybridization of the probe with its complementary DNA target (Holland et 
al., 1991). The TaqMan probe has fluorescence reporter on one end and a quencher of 
fluorescence on the opposite end. The close proximity of the reporter to the quencher 
prevents the detection of fluorescence. The probe anneals to the complementary DNA strand 
and when the Taq Polymerase is synthesizing the new strand, it is fulfilling as well its 5’→3’ 
exonuclease activity and it breaks down the probe and the unquenched emission of 
fluorescence gets free. Due to breakdown of the probe and release of its reporter in every 
cycle of the PCR, the increase of the targeted product can be detected. 
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Reagent  Volume (µl)  
10× JumpStart reaction buffer 2.5 
containing 1.5% Triton X-100  
MgCl2 2.5 
DMSO 0.38 
dNTPs (25 mM) 0.2 
50× ROX reference dye 0.13 
FW primer (12.5 pmol/µl) 0.3 
RW primer (12.5 pmol/µl) 0.3 
TaqMann® Probe (12.5 pmol/µl) 0.2 
JumpStart Taq polymerase 0.13 
DNA* (ng/µl) 12 
ddH2O                                              up to 25 µl 
*1.6 ng/µl, 0.8 ng/µl, 0.4 ng/µl  
 
Table 18   TaqMann® qPCR mixture.  
 
The PCR program used for Taqman qPCR is the same as for SYBR Green qPCR  
(Table 17). 
 
2. 17. 3 Analysis of qPCR data 
 
Data collected with qPCR were analyzed by SigmaPlot and were fitted with a sigmoidal 
regression curve, Chapman curve (Zhao and Fernald, 2005). The sigmoidal regression curve 
has four parameters – y0 , a, b and c,  determining its shape and the degree of exponential 
function. The parameters are provided by the software from the equation:  
 
y = y0+a(1-e
-bx )c 
 
The Ct value is calculated at the inflection point of the fluorescence sigmoidal curve 
from the equation: 
 
Ct = ln(c)/b 
 
As each sample was in triplicate the standard deviation was calculated. The Ct values 
for Kir4.1 (reference gene), single nuclear gene, were used for calculation of the mtDNA 
copy number (Zsurka et al., 2008). Firstly, the cycle number difference was calculated by 
subtracting the Ct values of the mtDNA fragment (Ctmito) of interest from the Ct values of the 
reference gene (Ctnuc): Ctnuc–Ctmito. This value was used to calculate the mtDNA copy number 
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(CN). The relation between the diploid single nuclear gene and a mitochondrial sequence 
was calculated as follows:  
 
CN = 2×2 Ctnuc–Ctmito 
 
The serial dilution (three different concentrations) of the measured Ct values of each 
DNA sample was plotted against their initial concentration in a semilogaritmic scale. The total 
amount of DNA is being duplicated in each PCR reaction cycle if the efficiency of the process 
was 100%. The negative correlation slope and the intercept should have a value of -1 and 
the slope s and the efficiency E are related to each other as following: 
 
E = (1/s)(–100) 
 
2. 18 Evaluation of mtDNA integrity 
 
A qPCR-based method was used for detection of presence or absence of strand breaks 
between chosen primer positions, and evaluation of mtDNA integrity and quality. The method 
includes two PCRs performed on the same 96-well qPCR plate (assuring the same PCR 
conditions), for the same sample. Triplets of two different mtDNA dilutions, 20 ng and 10 ng 
DNA, were used. The first PCR amplifies a short product, flanked by primers 1057F and 
1144R, with size of 88 bp and the second PCR amplifies a long 5379 bp PCR product, 
amplified by primers 11,226F and 35R. The method compares the amplification of the big 
mtDNA fragment to that of the small fragment of the mtDNA, with the later representing the 
overall amount of mtDNA. Any damage in the mtDNA would prevent the polymerase to 
amplify a full-length product. The further away the primers, the higher the chance that 
blocking damage occurs between them. Cycle number differences between the two PCRs 
(dependent on the short and the long product quality) were measured in the qPCR reactions 
and the data from the control untreated samples was used as reference. For all samples, 
first, the relative amplifiability difference was calculated by subtracting the Ct values for the 
long product from the wild-type mtDNA Ct values. Then the control sample amplifiability was 
taken as reference, to which the treated samples were compared in a ratio. In this case the 
control sample represents a value of 1, all treated samples containing less intact mtDNA 
should show a value smaller than 1. The calculations are performed as described previously.  
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Reagent  Volume (µl)  
5× Ranger reaction buffer containing dNTPs 5 
50× ROX reference dye 0.128 
Ranger DNA polymerase 0.156 
FW/ RW primer mix (12.5 pmol/µl) 0.6 
500× diluted SYBR Green (in DMSO) 0.12 
DNA (1.6 ng/µl or 0.8 ng/µl) 12 
ddH2O 7 
 
Table 19    Ranger qPCR mixture.  
 
The PCR program for mtDNA integrity determination is the same as described 
previously in Table 17, with elongation time of 14 min, at step 3. 
 
2. 19 Ligation-Mediated PCR (LM-PCR) 
 
I have established a modified version of the ligation-mediated PCR (LM-PCR) described 
originally by Kang et al. (1997), for detection of free DNA ends. In opposite to the original 
paper, blunt ends required for linker ligation were created by treating the DNA samples with 
Quick Blunting Kit (NEB) or Mung Bean nuclease for detection of free 5’ or 3’ ends, 
accordingly.  
The Quick Blunting Kit contains T4 polymerase that is having 5’ to 3’ polymerase 
activity and 3’ to 5’ exonuclease activity. The kit contains T4 Polynucleotide Kinase for 
phosphorylation of the 5’ end of the blunted molecules and its subsequent ligation.  
The Mung Bean nuclease is a single-strand specific DNA endonuclease, which 
degrades all 3’ and 5’ single-stranded overhangs, leaving 5’-phosphorylated blunt ends.  
After filling in or removing overhangs, the molecules represent blunt ends that are 
ready to be ligated. The ligation was done by using a T4-ligase and a linker. The linker 
‘adaptor’ used in the LM-PCR has non-biological sequence and is prepared by the annealing 
of two complementary oligonucleotides, LMP25 and LMP11, with 25 bp and 11 bp length 
accordingly:  
 
5’–GCGGTGACCCGGGAGATCTGTATTC–3’ 
                                    3’–CTAGACATAAG–5’ 
 
The different length of the primers allows the formation of blunt end only on one side 
of the linker, which would prevent double sided ligation in the later steps (Kang et al., 1997).  
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Reagent  Final Concentration  PCR program  
LMP25  25 pmol/µl 1. 95°C x 3:00 min 
LMP11 25 pmol/µl 2. 95°C x 1:00 min         
      
       185× 
 
TE Buffer       -0.5°C per cycle   
 
Table 20   Linker annealing mixture and conditions. 
 
After ligation the reaction mix was used in blunt-end ligation-mediated PCR, to which I 
am going to refer to as LM-PCR, as in the original protocol by Kang et al., 1997; taking in 
account the introduced changes in the protocol. The LM-PCR reaction is using one primer 
complementary to the linker and a specific primer on the mtDNA for the 5’ end detection. For 
detection of the 3’ end the mtDNA primer should be a reverse one. The amplified products 
were purified and the free ends were determined by sequencing.  
 
2. 19. 1 T4 polymerase blunting of mtDNA 
 
Quick Blunting™ Kit was used to perform T4 polymerase blunting of mtDNA. The  
T4 DNA polymerase has both 3’→5’ exonuclease activity, removing 3’ overhangs and 5’→3’ 
polymerase activity, filling 5’ overhangs, in this way it creates blunt ends at the site of the 
original 5’ end of one strand. The kit contains a T4 polynucleotide kinase which provides a 
phosphorylation of the 5’ end, important for the following ligation of the linker ‘adaptor’. 
The Blunt Enzyme Mix is supplied from the company in: 100 mM KCl, 10 mM Tris-HCl 
(pH 7.4), 0.1 mM EDTA, 1 mM dithiothreitol, 0.1% Triton X-100 and 50% Glycerol. The 1X 
Blunting Buffer contains: 100 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl2, 0.025% Triton X-
100, and 5 mM dithiothreitol, with pH 7.5 at 25°C. 
 
Mix  Volume (µl) Incubation Inactivation 
DNA – 0.2 µg   
10× Blunting buffer 2.5  
 
1mM dNTPs 2.5 30 min at RT°C 10 min at 70°C 
Blunt Enzyme Mix 1   
ddH2O up to 25 µl   
   
Table 21   Quick Blunting Kit treatment.  
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2. 19. 2 Mung Bean Nuclease blunting of mtDNA 
 
The Mung Bean Nuclease removes single stranded ends in both orientations and leaves a 
phosphorylated 5’ end. The Mung Bean Nuclease Reaction Buffer contains: 30 mM NaCl, 50 
mM sodium acetate, 1 mM ZnSO4, with pH 5 at 25°C. 
 
Mix  Volume (µl) Incubation Inactivation 
DNA – 0.2 µg (in water) 30   
10× Mung Bean buffer 4 
Mung Bean Nuclease 0.2 
30 min at 30°C 
Purification with 
QIAamp DNA Mini Kit 
ddH2O up to 40 µl   
   
Table 22   Mung Bean Nuclease treatment. 
 
2. 19. 3 S1 nuclease treatment of mtDNA 
 
S1 nuclease degrades single stranded DNA and RNA and removes 3’ and 5’ overhangs, by 
leaving phosphorylated 5’ end. It recognizes nicks and single nucleotide lesions on the 
nucleic acids and cuts them.  
 
Mix  Volume (µl) Incubation Inactivation 
DNA – 0.2 µg (in water) 30  
10× S1 reaction buffer 4 
S1 nuclease 0.2 
30 min at 30°C 
ddH2O up to 40 µl  
Heat deactivation at  
70°C + 1 µl EDTA (optional); 
purification with 
QIAamp DNA Mini Kit 
 
Table 23   S1 nuclease treatment. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
                                                                                                                                                       55 
2. 19. 4 Ligation of linker 
 
The blunt-ended mtDNA samples were ligated with the linker ‘adaptor’ via T4 ligase in the 
following reaction: 
 
Mix  Volume (µl) Incubation Inactivation 
DNA – 0.2 µg blunted 50  
Linker 5 
10× T4 ligase buffer 6.2 
O/N at RT°C 
T4 ligase 1  
10 min at 65°C  
 
Table 24   Linker ligation.  
  
2. 19. 5 Amplification of linker ligated ends 
 
The blunt-end LM-PCR was performed always with LMP25 primer and a mitochondrial 
primer with specific location and orientation. 
 
Reagent  Volume (µl)  
5x Ranger Reaction buffer  5 
containing dNTPs  
LMP25 (25 pmol/µl) 0.3 
FW/RW primer (25 pmol/µl) 0.3 
Ligated DNA 1 
Ranger DNA Polymerase 0.156 
ddH2O up to 25µl 
  
Table 25   LM-PCR mixture.  
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PCR program  
1. 95°C, 2:30 min  
2. 92°C, 0:20 min 
3. 63°C, 1:00 min 
          
      10× 
4. 92°C, 0:25 min 
5. 68°C, 1:00 min 
            
      25× 
6. 72°C, 1:00 min  
7. 15°C for ever  
 
Table 26   LM-PCR program. 
 
2. 19. 6 Single-molecule LM-PCR 
 
In order to determine the ends of the detected molecules, a single-molecule LM-PCR was 
performed, following the same principles as in smPCR, but with linker specific primer in 
combination with mitochondria specific primer.  
 
Reagent  Volume (µl)  
5× Ranger Reaction buffer  5 
containing dNTPs  
LMP25 (50 pmol/µl) 0.6 
FW/RW primer (50 pmol/µl) 0.6 
Ligated DNA 1 
Ranger DNA Polymerase 0.3 
ddH2O up to 25 µl 
  
Table 27 Single-molecule LM-PCR mixture.  
 
PCR program  
1. 95°C, 2:30 min  
2. 92°C, 0:20 min 
3. 63°C, 1:00 min 
          
      10× 
4. 92°C, 0:25 min 
5. 68°C, 1:00 min 
            
      32× 
6. 72°C, 1:00 min  
7. 15°C for ever  
  
Table 28   Program for single-molecule LM-PCR.  
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The captured single molecules were cut out from the gel and were purified with 
QIAquick Gel Extraction Kit. Each purified PCR product was reamplified once with a LMP25 
and a different mitochondrial primer within the fragment, to assure the amplification of 
mitochondrial, but not nuclear PCR product. And second, the product was checked by 
reamplification with double amount of LMP25 primer, to exclude short non-mitochondrial 
fragments ligated with LMP25 on both of their ends. 
 
2. 20 Multiplex PCR   
 
Multiplex PCR was used for the detection of two different deletions (the common deletion 
and a deletion of interest, simultaneously), on 3% agarose gel. The acquired data images 
were analyzed by ImageJ (Chapter 2. 21). 
 
Reagent  Volume (µl)  
10× TaKaRa reaction buffer  2.5 
TaKaRa dNTPs (2.5mM) 2.5 
FW primer (25 pmol/µl) 0.8 
RW primer 1 (25 pmol/µl) 0.6 
RW primer 2 (25 pmol/µl) 0.2 
TaKaRa La Taq (HS) 0.125 
DNA (2 ng/µl) 10 
ddH2O up to 25 µl 
 
Table 29   TaKaRa LA Taq (HS) multiplex PCR mixture. 
 
PCR program  
1. 95°C, 2:30 min  
2. 94°C, 0:20 min 
3. 68°C, 3:00 min 
          
      10× 
4. 94°C, 0:20 min 
5. 68°C, 3:00 min 
            
      32× 
6. 72°C, 7:00 min  
7. 15°C for ever  
 
Table 30   PCR program for multiplex PCR. 
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2. 21 Sequencing PCR 
 
The PCR used for re-amplification of smPCR products was performed with LongAmp Taq 
DNA polymerase. 
 
Reagent  Volume (µl)  
5× LongAmp reaction buffer  5 
dNTPs (2.5 mM) 2.5 
FW primer (25 pmol/µl) 0.2 
RW primer (25 pmol/µl) 0.2 
LongAmp Taq 0.25 
DNA* 1 
ddH2O up to 25µl 
*1:30 diluted smPCR product or gel isolated smPCR product 
 
Table 31   LongAmp PCR mixture.  
 
PCR program  
1. 95°C, 2:30 min  
2. 94°C, 0:20 min 
3. 63°C, 2:50 min 
          
      10× 
4. 92°C, 0:25 min 
5. 68°C, 3:00 min 
            
      25× 
6. 72°C, 1:00 min  
7. 15°C for ever  
 
Table 32   PCR program for sequencing PCR.  
 
2. 22 PCR purification 
 
The PCR product column purification was performed according to the recomendation of the 
manufacturer (QIAquick PCR Purification Kit; QIAGEN N.V., Venlo, Netherlands). The PCR 
product purification after excision from agarose gel was performed as described in the 
manual of QIAquick Gel Extraction Kit (QIAGEN N.V., Venlo, Netherlands). 
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2. 23 Sequencing 
 
After PCR purification, the DNA concentration of the amplicons was estimated with 
spectrophotometer and the samples were send for sequencing, performed by a commercial 
sequencing service at Eurofins MWG / Operon, Ebersberg, Germany. The sequencing 
primers mainly were identical with the PCR primers. 
 
2. 24 ImageJ analysis 
 
Semiquantitative analysis for deletions was performed by using Java-based image 
processing program ImageJ. The region of interest (ROI) on each LR-PCR picture was 
selected for every sample. The ROI included the wild-type (wt) band and the region under it, 
containing deleted molecules, the same ROI was used for all samples. By using the plotting 
option of ImageJ a two-dimensional graph of the intensities of pixels along the ROI was 
displayed. The X-axis represents distance along the ROI and the Y-axis is the pixel intensity. 
The peak amplitude corresponds to the intensity of the bands in the ROI. In this case, the wt 
band has the highest peak of intensity. A ratio between the wt band peak and the summed 
deletion peaks was calculated, and used for semiquantitative measurement of the deletions 
present in each sample. The background intensity was subtracted in the calculations. The 
same method was used for analysis of the images obtained by multiplex PCR, but in this 
case the intensity for the common deletion was compared to the intensity of the deletion of 
interest. 
 
2. 24 Statistical analysis 
 
Microsoft Office Excel was used for applying the unpaired, two-sided student’s t-test in order 
to determine significant difference between pairs of data sets. It was used to calculate the 
probability of occurrence of a positive zero hypothesis, which is determined by the identity of 
two empirical determined mean values belonging to two sample populations. The level of 
significance was set to p<0.05 or smaller.  
One-way analysis of variance (ANOVA) was used to analyse differences between the 
mean values of multiple (more then two) groups of data sets. ANOVA is based as well on the 
null hypothesis; in case of null hypothesis, all samples are random samples of the same 
population. Once a group of samples was identified as not random, a Dunnett’s post-hoc test 
was applied to check which means differ. The ANOVA test and the Dunnett’s post-hoc test 
were performed by Dr. Zsurka. 
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3. Results 
 
3. 1 MGME1  
 
Multiple mitochondrial deletions and mtDNA depletion syndromes (MDS) constitute a group 
of diseases known as mtDNA maintenance disorders (Blakely, 2012). The pathological 
changes and clinical manifestations in these diseases may affect single tissues or the 
function of the whole organism. They appear in different ages and have diverse impact on 
the patients (El-Hattab, 2013). The pathologic mechanisms in this group of diseases affect 
either the salvage pathway of deoxyribonucleoside 5'-triphosphates for mtDNA synthesis or 
the mtDNA replication. Mutations in POLG, POLG2 and C10orf2 genes, all components of 
the replication machinery, were previously described to be involved in the disruption of the 
mtDNA replication and disease. Recently, DNA2 (Ronchi et al., 2013) and a truncated 
version of protein encoded from the nuclear FEN1 gene (FENMIT) (Kazak et al., 2013) have 
been added to the group of genes possibly involved in mitochondrial maintenance, by 
influencing its repair and replication. Nevertheless, many patients remain poorly diagnosed 
and problematic for treatment, as the exact molecular mechanisms and system damage are 
not clear (Kornblum et al., 2013).  
 
3. 1. 1 Patients with mtDNA maintenance disorders (MMDs) 
 
Respiratory chain deficiency is the main biochemical trait in mitochondrial disorders. As the 
muscle is very rich of mitochondria, it is commonly used in the diagnostics for checking the 
mitochondrial function. Muscle containing dysfunctional mitochondria often displays 
accumulation of highly proliferating mitochondria or so called ragged-red fibers (RRF). I was 
working with samples from a Lebanese family having three children affected by MMD 
(P1976, P2061 and P3737) and unknown cause of the disease. The three patients showed 
respiratory chain insufficiency, confirmed by skeletal muscle histochemical staining and by 
biochemical measurements in fibroblasts (data not shown), performed by Dr. Schoeler. All 
affected children have similar symptoms since early childhood and have multisystemic 
mitochondrial disorder. The clinical symptoms include ptosis and mild PEO, mental 
retardation, respiratory distress and skeletal muscle waste. The family pedigree is shown on 
Figure 14a. 
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Figure 14   Pedigrees of MGME1 patients. (a) Lebanese Family (Family I) carrying MGME1 mutation. 
This family carries c.456G>A (p.Trp152*) mutation in MGME1 gene; (b) Pedigree of Italian Family 
(Family II) carrying MGME1 mutation. This family carries c.456G>A (p.Trp152*) mutation in MGME1 
gene. Open symbols indicate healthy individuals; closed symbols indicate affected members of the 
family. Diagonal bar through the symbol denotes deceased individuals (Kornblum et al., 2013). 
 
Mutations in POLG, POLG2 and C10orf2, for the three patients, were excluded by 
Sanger sequencing, performed by Susanne Beyer, in our lab. As the patients did not carry 
any mutation in the well studied nuclear genes known to cause MMD, thereafter, in 
collaboration with the Institute of Human Genetics, in Munich, exome sequencing (Haack et 
al., 2012) of P1976 sample, was performed. 
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The results from the exome sequencing of P1976, assuming the autosomal recessive 
inheritance of the disease and the possible mitochondrial targeting of the protein, pointed 
towards two genes, SPTLC3 and C20orf72, as possible candidates. Both genes encode 
proteins targeted to mitochondria. Unlike SPTLC3, the C20orf72 gene revealed c.456G>A 
(p.Trp152*) nonsense mutation in P1976. Following Sanger sequencing of the C20orf72 
gene, in the affected siblings’ samples, confirmed the segregation of the mutation; all of them 
were carrying the c.456G>A (p.Trp152*) mutation in the gene. The healthy siblings were 
homozygous wild-type for the mutation and the parents were heterozygous carriers.  
By targeted MitoExome sequencing (Calvo et al., 2012) performed by our 
collaborators, another affected Italian family (P4050, P4052) carrying the same mutation and 
clinical manifestation (Figure 14b) was discovered. The list of samples with mutations in the 
C20orf72 gene was additionally extended with one sporadic patient from Germany (P931), 
which was added from our laboratory, by sequencing of the gene in a set of PEO samples, 
performed by Kerstin Hallman, MSc. Opposite to the other samples, this patient carried a 
different mutation, c.698A>G (p.Tyr233Cys) in the same gene.  
Investigation over the affected protein’s primary structure showed that it belongs to 
the PD-(D/E)XK nuclease super-family, whose members possess various nucleic acid 
cleavage activities. The c.456G>A (p.Trp152) mutation, discovered in the Lebanese and the 
Italian family, is placed before the PD-(D/E)XK motif, which would suggest non-functionality 
of the protein. The mutation discovered in the sporadic case from Germany affects a 
conservative amino acid residue.  
We have decided to rename the enzyme and call it MGME1, standing for 
mitochondrial genome maintenance exonuclease 1. 
 
3. 1. 2 In vivo consequences of MGME1 mutations 
 
To clarify the molecular consequences of mutation in the MGME1 gene, all muscle samples 
from the patients were analyzed by LR-PCR (Figure 15 lower panel). A second sample from 
patient P4052, taken one year after the first biopsy, was included in the set. One POLG 
muscle sample, carrying the homozygous mutation p.Ala467Thr in the POLG gene was 
included in the study, as a sample rich of mtDNA deletions. LR-PCR was performed also with 
urine sediment and blood DNA samples from the Lebanese family. Two blood samples from 
the unaffected father and sister from this family were also included in the panel of samples 
(Figure 15 upper panel).   The primers used for this experiment were primer pair 5462F/45R, 
amplifying a wild-type 11,153 bp product, covering the mtDNA major arc (Figure 15 upper 
panel), and primer pair 15,974F/15,623R, amplifying 16,219 bp product, which covers almost 
the entire mtDNA (16,569 bp) (Figure 15 lower panel).   
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Figure 15   LR-PCR amplification of mtDNA from MGME1 patients. Upper panel, LR-PCR (primer pair 
5462F/45R; 11,153 bp wt product) of blood (BL) and urine sediment (UR) samples from Family I. 
Blood samples from unaffected father and sister from the family were also included in the set. Lower 
panel, LR-PCR (primer pair 15,974F/15,623R; 16,219 bp wt product) of mtDNA isolated from muscle 
biopsy (MB) from all affected MGME1 patients included in this study. PG, POLG patient (carrying the 
homozygous mutation p.Ala467Thr in the POLG gene); C, control muscle (30 years old); wt, wild-type 
sized amplicon; del, deletion-specific PCR products. Thick line unclosed circle (close to the panels) 
indicates the PCR amplified region of the mtDNA (thin line closed circle). All samples from affected 
MGME1 patients contain apparent unusually large mtDNA rearrangments. The PG patient shows 
typical range of deletions. All unaffected members of the family and the controls show only wild-type 
molecules (Kornblum et al., 2013).  
 
Both LR-PCRs detected an increased amount of rearrangements in different tissues 
from the MGME1 patients. In comparison to the POLG patient (PG) sample, in which most of 
the deletions were small and visible as high smear, close to the wild-type molecules, the 
MGME1 samples showed much shorter bands, representing specific pattern for the disease 
(Figure 15). In the MGME1 patients, the PCR products were small and were lacking most of 
the mtDNA.  
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The muscle from P931 carried very high amount of rearrangements, which is in 
correlation with the most advanced age of that patient at the time of biopsy, compared to the 
rest of the patients (Table 33).  
The quantity of the rearranged mtDNA molecules was estimated by using a modified 
version of smPCR. In the smPCR the primers 10F and 16,496R were used to amplify a big 
mtDNA fragment, which amplifies almost the entire mtDNA. Simultaneously, a second 
smPCR for total mtDNA amount was performed, to amplify part of the minor arc of the 
mtDNA lying between primers 16,520F and 4833R. In both PCRs the DNA was diluted to 
such extent that a PCR product would be a result from the amplification of a single molecule. 
In successful case, half of the repeats would be positive. Most of the samples were screened 
for deletion amount also by using primer pair 3137F/45R (Table 33). 
To calculate the rearrangements amount, the dilution used for getting single 
molecules was used to calculate the number of single molecules detected for both fragments 
at the same DNA concentration, and a ratio between the two was calculated. For example, if 
a sample shows 8 positive PCR bands out of 16 repeats for the wild-type mtDNA fragment at 
dilution 10-4, at the starting concentration the sample shall contain 8×10,000 or 80,000 PCR 
products in 16 repeats. If the same sample, for the larger PCR product shows 7 
rearrangements out of 16 repeats, at concentration 10-1, the non diluted sample should 
contain 7×10 bands or 70 bands, and the ratio 70/80,000 would give a result of 0.000875 or 
0.0875% deletions.  
The quantification showed increased amount of rearrangements in the MGME1 
patients, in the range from 0.4% to 1.5% (Table 33). The amount of rearrangements is 
comparable to the amount of deletions detected in the POLG patient. In MGME1 patients the 
rearrangements load was much higher when the quantification was performed with the 
primer pair amplifying almost the entire mtDNA. Thereafter, the observed MGME1 
rearrangements are present all over the mtDNA. P931 had the highest amount of deletions, 
confirming the results from the LR-PCR pictures and this can be explained with the advanced 
age of the patient and the accumulation of deletions due to aging. 
Amplified products from single rearranged mtDNA molecules were mapped and their 
breakpoints were determined by sequencing. Detected breakpoints are shown schematically 
on Figure 16a, and a list with the exact breakpoints can be found in Appendix I. As 
comparison,  
I determined additionally deletion breakpoints in the POLG patient, Figure 16b (the exact 
breakpoints can be found in Appendix II). The POLG patient was having deletions affecting 
predominantly the major arc of the mtDNA and these rearrangements are visibly shorter then 
the ones observed in MGME1 patients.  
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Apart from the bigger size of the rearrangements in the MGME1 patients, many of the 
molecules did not contain their light strand promoter (LSP) or have lost their light or heavy 
strand replication origin (OL or OH) and were missing more then 2/3 of the mitochondrial 
genome.  
 
Patients Primer pairs 
Samples Age at biopsy 3137F/45R 10F/16496R 
MB 1976 10 n.d 4.4 × 10-4 ± 1.9 × 10-4 
MB 3737 23 5.0 × 10-4 ± 5.0 × 10-5 4.7 × 10-3 ± 2.0 × 10-4 
MB 2061 17 7.5 × 10-5 ± 1.5 × 10-5 3.7 × 10-4 ± 3.5 × 10-5 
MB 931 57 1.5 × 10-3 ± 7.9 × 10-4 1.5 × 10-2 ± 1.0 × 10-3 
MB 4050 31 3.7 × 10-4 ± 1.9 × 10-4 2.6 × 10-3 ± 1.4 × 10-3 
MB 4052 36 5.9 × 10-4 ± 4.2 × 10-4 3.7 × 10-3 ± 2.3 × 10-3 
MB 4052a 37 1.4 × 10-3 ± 1.0 × 10-4 3.8 × 10-3 ± 1.2 × 10-3 
MB PG 19 n.d 4.8 × 10-4 ± 0.9 × 10-5 
MB Control 30 9.0 × 10-7 ± 0.0 × 10-7 4.2 × 10-5 ± 2.6 × 10-5 
 
Table 33   Amount of deletions in MGME1 muscle biopsy (MB) samples, control muscle and POLG 
muscle (PG). The quantification was performed by smPCR. All MGME1 patients showed higher 
amounts of mtDNA rearrangments, in comparison to the control MB. In MGME1 patients the amount 
of rearrnagments was approximately 10 fold higher when the deletions were estimated with the primer 
pair covering the entire mtDNA, which confirms the existence of apparent large deletions longer then 
the major arc.  
 
Out of the 131 detected breakpoints in MGME1 patients, only one was having both 
breakpoints into the major arc, where most of the deletions are expected. The end positions 
of the detected rearrangements were laying between 13,000 and 16,000 bp position, as most 
described classical deletions, but their starting point was located in the minor arc, between 
the heavy strand origin of replication (OH) and the heavy strand promoter (HSP), in the 12S 
ribosomal RNA gene; or downstream of the transcription termination factor mTERF1 binding 
site (Terzioglu et al., 2013). As the OL is important for the mtDNA maintenance and 
molecules that are not having it are supposed to be incapable of replicating (Wanrooij et al., 
2012). However, almost all affected individuals had specific breakpoint detected repeatedly, 
which would suggest their clonal propagation.  
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Figure 16   mtDNA rearrangements in MGME1 and POLG patients. Arcs represent retained parts of 
the mitochondrial genome. (a) mtDNA rearrangements in MGME1 patients. In red are marked 
deletions which are having at least one of the breakpoints between the light strand promoter (LSP) 
and termination-associated sequence (TAS); (b) mapped deletions in POLG patient. OH, heavy strand 
replication origin; OL, light strand replication origin.  
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Figure 16   (c) Partially duplicated mtDNA molecules in skeletal muscle of MGME1 patients as 
detected by long extension PCR. Bands at the bottom represent the short PCR fragment. If a second 
copy of the corresponding region is present on the same molecule, longer PCR products are 
additionally observed. The upper bands, bigger then 10 kb, picture complete duplications and partial 
duplications are visible as lower bands under them. In healthy controls C1 and C2 and in samples with 
pathogenic POLG mutations (PG) no mtDNA rearrangements were detectable (Nichols et al., in 
preparation). 
 
As the detected rearrangments were missing important for their replication origins, 
alternatively, we assume that these breakpoints might be result from the detection of 
complex structures of partial duplications or concatamers. To address the issue whether 
breakpoints in the MGME1 patients could represent partial duplications instead of true 
deletions, long extension PCR was performed. This experiment showed that in addition to 
the expected short PCR product, with size of 88 bp, additional large products were also 
detectable in skeletal muscle samples of MGME1 patients (Figure 16c). Therefore, the short 
primer-binding region was present at least twice on the same mtDNA molecule, which is a 
hallmark of duplications and multiplications. In control skeletal muscle samples or in POLG 
samples rich of deletions no such products were detectable (Figure 16c).  
Additionally, sequencing of the mtDNA of P931 revealed presence of insertions of 
small D-loop multimers in that patient (Table 34).  
As patient P931 has different mutation than all the other MGME1 patients it was of 
interest to check if any of the other patients contains such multimers. Indeed, in P3737 such 
multimers appeared to be detectable. Such structures were previously described in humans 
(Wei et al., 1996) and in POLG mouse model (Williams et al., 2010), but the duplications 
described in that papers were much longer (150 to 880 bp), then the ones observed in the 
two MGME1 patients, between 13 and 200 base pairs. 
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Sample FW primer RW primer Breakpoints (indicated by slash) 
M3737 16,099F 136R –16,122/16,070–16,125/16,267–16,553/29– 
M3737 16,099F 136R –16,245/16,083–16,132/16,348– 
M931 3137F 45R –3272/16,072–16,137/16,069–16,336/16,311– 
M931 3137F 45R –3272/16,072–16,137/16,069–16,336/16,311– 
M931 3137F 45R –3272/16,072–16,137/16,069– 
M931 3137F 45R –3272/16,072–16,137/16,069– 
M931 3137F 45R –3265/16,079–16,134/16,084– 
M931 3137F 45R –3610/16,077–16,151/16,074– 
M931 10F 16,496R –898/16,116–16,149/16,075– 
M931 10F 16,496R –898/16,080–16,117/16,082– 
M931 10F 16,496R –898/16,116–16,128/16,082– 
 
Table 34   Small direct multimers in the D-loop of MGME1 patients. Highest number were detected in 
the sporadic case M931 that carries mutation c.698A>G (p.Tyr233Cys) in a conservative domain of 
the MGME1 and carries highest amount of mtDNA rearrangments in comparison to the other patients. 
With appropriate primers the repeats were detected also in M3737.  
 
3. 1. 3 mtDNA depletion in MGME1 patients 
 
Patients with MMD are characterized by mtDNA rearrangments accumulation or mtDNA 
depletion, or both simultaneously. As in MGME1 patients the amount of detected 
rearrangments present in muscle samples is insufficient to explain the mitochondrial 
dysfunction, it was essential to find out if the patients suffer from mtDNA depletion as well. 
To this end, the mtDNA copy number was determined by qPCR in the muscle samples. The 
copy number values were normalized to control value, obtained from eleven healthy control 
muscles of age of 18 to 33 years. All MGME1 patients showed depletion of the mtDNA in 
comparison to controls, with exception of P1976 (Figure 17a, grey bars). The observed 
normal copy numbers in that patient can be explained with the early age at which the sample 
was obtained (10 years old); at this age the patient also represented only mild clinical 
symptoms. 
While performing the qPCRs for copy number determination I noticed difference in the 
copy numbers detected when using primers placed inside or outside of the D-loop region of 
the mtDNA (Figure 17). This phenomenon was detectable only in the MGME1 patients and 
was not visible to such extent in none of the control patients.  
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Figure 17   Relative mtDNA copy numbers in muscle and fibroblasts of MGME1 patients. (a) Relative 
mtDNA copy numbers in muscle, the data is result from three independent qPCR reactions and is 
normalized to a control value, which on the graph appears as 1. The control value was obtained from 
eleven control patient muscle samples in the age from 18 to 33. The control samples show 8146–
11,416 mtDNA molecules per nucleus (Kornblum et al., 2013). (b) Relative mtDNA copy number in 
fibroblast sample from P1976 in comparison to control fibroblast cell line. The data is normalized to the 
control value, which on the graph appears as 1. Grey bars display the mtDNA relative copy number 
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outside the 7S DNA; black bars represent the relative copy number in the 7S DNA region; error bars 
are indicating the SD(+); * indicates the significance of the experiment; *p<0,05, ***p<0,001; two-tailed 
Student’s t test (Kornblum et al., 2013). 
 
7S DNA is a single stranded DNA belonging to the D-loop. It is proposed that the 7S 
DNA is a prematurely terminated product from mtDNA replication of the H-strand. The ratios 
of the 7S DNA to the total amount of mtDNA were different between the patients but varied 
between twofold and eightfold increase (Figure 17a black bars). A 1,5 fold increase is 
accepted as maximal theorethical accumulation of 7S DNA in healthy cells, if 100% of the 
mtDNA has 7S DNA. This finding suggests that MGME1 might participate in the turnover of 
7S DNA.  
In conclusion, the mtDNA in muscle from MGME1 patients is depleted and contains 
highly increased amounts of 7S DNA. If we assume that the 7S DNA accumulation is a result 
of prematurely terminated replication, its accumulation in these patients would suggest the 
direct involvement of MGME1 in mtDNA replication and its control of the 7S DNA turnover. 
To find out if this 7S DNA accumulation is present also in other tissues than muscle, 
qPCRs were performed also with fibroblast sample from P1976 with the same primer pairs. 
The 7S DNA effect was clearly visible in the fibroblasts from P1976 in comparison to control 
(Figure 17b). The values are normalized to the control sample.  
To confirm that blood is also a good source for detection of the 7S DNA effects, 
qPCRs were performed in the same conditions as in the previous experiments on blood 
samples from P2061 and P3737. The 7S DNA increase was also significant in both blood 
samples, which may be important for non invasive diagnostics. In consistence with the 
literature, the muscle contained the highest amount of total mtDNA, then the fibroblast and 
the mtDNA content was lowest in the blood.  
In order to confirm that the copy number increase is detectable in the entire 7S DNA 
region, I optimized fourteen different primer pairs with SybrGreen qPCR, by which I could 
display the changes in the mtDNA copy numbers inside and outside the 7S DNA. As the 7S 
DNA increase was detectable in blood samples, the PCRs were performed with blood DNA 
from P1976, P2061 and P3737, as well as with one control blood sample (Figure 18).  
All three samples showed similar pattern of high copy numbers in the entire 7S DNA 
region between np191 and 16,106, with strongest 7S DNA effect in P3737.  
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Figure 18   Relative mtDNA copy numbers, with eleven primer pairs outside and inside the 7S DNA 
region. Blood samples (BL) from three affected members from the Lebanese family, and a control 
sample were included in the experiment. The 7S DNA region starts from np 191 to np 16,106. The 
values are normalized to the BL control. All samples from affected members of the Lebanese family 
show elevated levels of 7S DNA in comparison to the control BL sample.  
 
3. 1. 4 Overexpression of wild-type MGME1  
 
Our collaborators in Munich have transfected fibroblast from P1976 with lentiviral wild-type 
MGME1 expression construct, in order to examine whether rescue experiment would 
compensate the lack of MGME1. I used isolated DNA from that cell line to detect the 7S DNA 
levels and the total mtDNA amount. A possible compensatory effect would confirm the 
causative role of the MGME1.  
Two weeks expression of the wild-type MGME1 had decreased significantly the 7S 
DNA amount in the fibroblast from P1976 (Figure 19). Overxpression of MGME1 led to 
decrease in the overall amount of the mtDNA in the transfected cells, in comparison to 
controls and the non-transduced P1976 fibroblasts. Simillar effect on the 7S DNA and the 
overall amount of mtDNA was visible as well in the control cell line, after transduction with 
the wild-type construct (Figure 19a). This experiment is in line with the suggested 
exonuclease activity of the enzyme and its direct effect on the 7S DNA turnover.  
To check the total mtDNA and 7S DNA decrease in the complemented cells, in 
comparison to the non-transduced P1976 fibroblasts, I have detected by qPCR the variation 
in the copy number inside and outside the 7S DNA with eleven primer pairs, as already 
shown for the blood samples of the MGME1 patients. The decrease in the 7S DNA was 
clearly visible and getting stronger with the increase of the lentivirus titer applied (Figure 
19b).  
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Figure 19   mtDNA copy number in fibroblasts from P1976, transduced with a viral construct 
overexpressing MGME1, compared to control and POLG patients. (a) mtDNA copy number in 
fibroblast sample from P1976 (FB1976) with and without overexpression of wild-type MGME1, in 
comparison to control fibroblast cell line. Grey bars represent the mtDNA relative copy number outside 
the 7S DNA; black bars represent the relative copy number within the 7S DNA region; error bars are 
indicating the SD (+); * indicates significance difference, *p<0,05, **p<0,01; two-tailed Student’s t test 
(Kornblum et al., 2013). (b) Copy number representations with eleven primer pairs outside and inside 
the 7S DNA region in fibroblast samples from one control (FB Control), P1976 (FB 1976) with and 
without transduction with wild-type MGME1 and one POLG patient (PG). The 7S DNA region spans 
from np 191 to np 16,106. +, fibroblast transduced with low titer of lentivirus; +++, fibroblast 
transduced with high titer of lentivirus.  
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The depletion of the mtDNA due to the overexpression of the wild-type gene is also 
visible on Figure 19b. The cells treated with higher titer of the lentivirus are almost loosing 
their 7S DNA, the experiment was confirmed as well by Southern blot by our collaborators in 
Cambridge.  
 
3. 1. 5 mtDNA depletion and repopulation of MGME1 fibroblasts 
 
To investigate the influence of mutated MGME1 on mtDNA replication, mtDNA ddC depletion 
and repopulation experiments were performed in fibroblast cell cultures from patient P1976 
(Kornblum et al., 2013), the Italian patient P4052 and controls (Figure 20). ddC acts as 
competitive inhibitor of POLG and as a terminator of nascent strand elongation (Stewart et 
al., 2011). 12 days treatment of control and patient fibroblasts with the nucleotide equivalent 
ddC, led to mtDNA depleteion with mtDNA falling to less then 10% of the untreated steady 
state level. The results from the ddC treatment experiment revealed severely impaired 
mtDNA repopulation in MGME1 mutated cells. Only 8% of control mtDNA copy number in 
P1976 was reached after 16 days of repopulation without ddC. This demonstrates perturbed 
mtDNA replication, akin to the one observed in POLG patients (Wanrooij et al., 2007). In 
P4052 after withdrawal of ddC, the copy numbers reached 55% of the control copy numbers, 
but still could not recover completely. Both patients showed inability to recover their mtDNA 
levels after mtDNA depletion. 
 
 
Figure 20   Changes in mtDNA copy numbers during induced mtDNA depletion and repopulation of 
fibroblasts from P1976, P4052 and a control. Arrow indicates the withdrawal of ddC. The mtDNA copy 
numbers were determined by qPCR. The data point for mtDNA copy numbers in the control is 
considered as 100% and the rest of the data points are normalized to it. The qPCR was performed by 
using the mitochondrial primers 3922F and 4036R.  
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3. 1. 6 Detection of 7S DNA ends in MGME1 patients 
 
Our collaborators in Cambridge performed series of experiments confirming the function of 
MGME1 and its exonuclease activity (Kornblum et al., 2013). MGME1 showed 5’ end 
exonuclease activity, it prefers single stranded DNA substrates, and can process flap 
structures, that may also contain RNA on their 5’ end. Its 3’ end processing activity is weak. 
As it is dysfunctional in MGME1 patients, and the patients show high amount of 7S DNA, it 
was interesting to check for free ends of the 7S DNA, and determine them in MGME1 
patients, and preferentially the 5’ end.  
In order to detect single stranded free ends, without the need of radioactive labeling, I 
established a modified version of the ligation-mediated PCR (LM-PCR) described originally 
by Kang et al. in 1997. The method is simple enough to be used for screening of large 
numbers of samples and can successfully detect free 5’ ends and 3’ ends (Figure 21). 
In order to visualize the 5’ end of the 7S DNA, first, the DNA sample was treated with 
Quick Blunting Kit (NEB), containing T4 polymerase, having 5’ to 3’ polymerase activity and 
3’ to 5’ exonuclease activity. The 5’ end in this reaction does not lose any nucleotides. The kit 
contains dNTPs and T4 Polynucleotide Kinase for phosphorylation of the 5’ end of the 
blunted molecules and its subsequent ligation.  
Although, the 3’ processing activity of MGME1 is weak, in vitro, I have checked for 
alterations also of the 3’-end of the 7S DNA. To this end the mtDNA was treated with Mung 
Bean nuclease (Figure 21), which is a single-strand specific DNA endonuclease, which 
degrades all 3’ and 5’ single stranded overhangs and leaving 5’-phosphorylated blunt ends.  
After filling in or cutting out the overhangs, the molecules should have blunt ends 
suitable for ligation to the blunt-end linker. The linker serves as adaptor; it has a non-
biological sequence consisting of two complementary primers LMP25 and LMP11, which 
form a blunt end only on one side of the adaptor. As the primers used for the linker synthesis 
are not phosphorylated but contain only a hydroxyl group at both ends, only one of the two 
strands will be ligated. Through the asymmetry of the linker, it will be ligated only 
unidirectionally to a free double-stranded blunt end, by the available 5’ phosphate on the 7S 
DNA  and the 3’ hydroxyl group on the primer. The LM-PCR reaction is performed with the 
LMP25 primer used for the synthesis of the linker and a specific primer on the mtDNA for the 
5’-end detection. For detection of the 3’ end of the 7S DNA the mtDNA primer should be a 
reverse one.  
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Figure 21   Schematic representation of LM-PCR for detection of free mtDNA ends. 
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At first, to test the specificity of the technique I performed LM-PCR with LMP25 primer 
annealing to the linker and five different forward primers annealing to the 7S DNA. There 
were prominent PCR products with the expected size, amplifying the 5’ end of the 7S DNA 
(Figure 22a). On the gel picture one can notice that the products in the fibroblasts sample 
from P1976 are slightly longer then the ones in the control. To be sure that there were no 
PCR artifacts due to the ligation and the nuclease treatment of the DNA, I performed ligation 
incubations without adding linker or T4 ligase, and in both cases the PCRs did not amplify a 
product (Figure 22b). Additionally, I performed ligation of the DNA from P1976 and a control 
with only one primer (LMP25) (data not shown). There was no detectable PCR product, 
which confirmed that the observed reactions are amplifying mitochondrial blunt end 
molecules.  
In MGME1 patients, for detection of the 5’ 7S DNA end with nucleotide position 191 
(Clayton, 1996), a linker primer LMP25 and mitochondrial primer 10F ware used, in LM-PCR 
(Figure 23 upper panel). If the 5’ end of the 7S DNA is at np 191, the LM-PCR would give a 
product of 181 bp, which is indeed the observed PCR product in the fibroblast controls 1 and 
2 (Figure 23). In both MGME1 patients the LM-PCR resulted in slightly longer products. 
For detection of the 3’ 7S DNA end at position 16,104–16,106 (Clayton, 1996) a linker 
primer LMP25 and mito primer 16,413R ware used in LM-PCR (Figure 23 middle panel). If 
the 3’ end of the 7S DNA is at np 16,106, the LM-PCR would give a product of 307 bp, which 
was the observed PCR product in both MGME1 patients and controls. No changes in the 3’ 
7S DNA end were observed in MGME1 patients in comparison to controls. To confirm my 
results, I have treated the mtDNA from P1976 with S1 nuclease. It has single strand 
nuclease activity and also leaves phosphorylated 5’ ends, but opposite to Mung Bean 
nuclease it cuts the DNA in single-stranded regions caused by a nick, gap, mismatch or loop. 
The results from the LM-PCR were the same as those with Mung Bean treatment and it was 
confirmed as well by sequencing (Figure 23 lower panel). 
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Figure 22   LM-PCR visualization of the 5’ end of the 7S DNA. (a) Determination of 5’ 7S DNA end 
with linker primer LMP25 and seven different forward primers in fibroblasts from P1976 (FB 1976) and 
a control (FB Control). (b) LM-PCR with mtDNA from human muscle mitochondria, and primers 
LMP25T7/108F, when either the linker or the T4-ligase is missing the reaction does not amplify a 
product.  
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Figure 23   LM-PCR after T4-polymerase (T4), Mung Bean nuclease (MuB) and S1 treatment of 
fibroblasts from patients with MGME1 mutation and controls. The 5’ 7S DNA end in the MGME1 
patients (FB 1976 and FB 4052) is slightly longer then the one detected in controls (C1 and C2). The 
3’ 7S DNA end seems unaltered in both controls and MGME1 patients.  
 
To detect the exact ends of the 7S DNA, I have performed a smPCR with the ligated 
mtDNA. For the 5’ end, I have used the T4 polymerase treated DNA and for the 3’end the 
Mung Bean nuclease treated DNA. By Sanger sequencing, the sequence of the linker can be 
easily recognized from the mtDNA fragment and the exact nucleotide position of the 7S DNA 
end can be detected. To assure the amplification of mitochondrial DNA and also to exclude 
the sequencing of short non-mitochondrial ligated on their both ends fragments, each 
detected single molecule was re-amplified with the linker primer and another mitochondrial 
primer inside the amplified molecule. In this way I screened the fibroblasts sample from 
P1976 and one control fibroblasts cell line. The result revealed various 5’ ends, which were 
longer in the MGME1 patient in comparison to the known size of the 7S DNA (Figure 24).  
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a 
Sample 5’ end (QBK) 3’ end (MuB) 
P1976 170; 183; 186; 191; 194; 197; 16,106 
 200; 204; 205; 206; 207; 215 
 229; 238; 298; 301 
 
FB Control 151; 191 16,104 
 
b 
 
 
Figure 24   7S DNA ends mapped by single-molecule LM-PCR. (a) Free 7S DNA ends detected in 
fibroblast from P1976 and fibroblasts control cell line (FB Control). The 5’ ends were detected after 
Quick blunting kit (QBK) treatment of the mtDNA, LM-PCR and sequencing. The 3’ ends were 
detected after Mung Bean (MuB) nuclease treatment, LM-PCR and sequencing. In red are marked the 
7S DNA ends known from the literature. (b) Example of six detected by smLM-PCR ends in fibroblasts 
from P1976. The linker is marked in red and the arrows indicate the free 5’ and 3’ end point. 
 
The results in the control fibroblasts are in consistence with previous findings. The 5’ 
end of the 7S DNA is at np 191 (Clayton, 1996) and the 3’ end is at np 16,104. Several 5’ 
ends have been described and they are all extending up to 191 np, for example, in controls 
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one of these ends was detected, at position 151. In opposite to controls, in the MGME1 
patient P1976 there were many and various 5’ ends of the 7S DNA, which were with ends 
predominantly above np 191. A scheme of some of the mapped free ends is shown in Figure 
24b.  
According to Clayton the 3’ end of the 7S DNA is at positions 16,104 to 16,106. The 
3’ end of the 7S DNA seems to be unaltered in patients with MGME1 mutation. The 3’ 7S 
DNA end in P4052 was also checked with Mung Bean treatment and represented the same 
end point of 16,104–16,106. 
 
3. 1. 6. 1 Light strand origin of replication and free ends 
 
As the ligation-mediated method is detecting free DNA ends, it should be able to detect any 
kind of double-stranded free ends and not exclusively only the 7S DNA ends. Therefore, I 
performed screening for free ends over the entire mitochondrial genome of P1976 fibroblasts 
sample and one control sample. I used thirteen different reverse mtDNA primers and the 
linker primer LMP25. In P1976 the LM-PCR with primer 5985R has amplified a free end, 
which is localized at the origin of replication of the light strand (OL) and was not detectable in 
the controls. As OL is covering a region from np 5721 till 5798, by using reverse primer at 
position 5985, a free end at OL shall give a product with size between 212–289 bp (between 
the LMP25 and 5985R) (Figure 25).  
The free OL end was confirmed by sequencing of smLM-PCR products, the exact np 
position of the free end is 5771–5772, within OL. The same free end was detectable as well 
in the Italian patient P4052. Therefore, it appears that loss of MGME1 causes accumulation 
of free double-stranded ends around the light strand replication origin or accumulation of 
patient specific linear fragments. The data was confirmed also by Southern blot (experiment 
provided by our collaborators in Cambridge).  
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Figure 25   LM-PCR showing free end at the OL of MGME1 patients. LMP25 and 5985R primer 
amplify a short product signifying free end around the origin of replication of the light strand (OL). The 
product has size of 213–214 bp. Equal amounts of DNA were used for the reaction. The exact 
breakpoints were determined by single-molecule LM-PCR (Nicholls et al., in preparation). 
 
 
3. 2 Mitofusin 2 and Charcot–Marie–Tooth neuropathy 
 
One of the most common neuropathies, affecting the peripheral nerves and associated with 
mitochondrial dysfunction, is Charcot–Marie–Tooth neuropathy (CMT). CMT type 2A 
(CMT2A) is an autosomal dominant disease, found to be associated with mutations in the 
nuclear gene encoding for mitofusin 2 (MFN2). MFN2 is targeted to mitochondria and 
belongs to the family of dynamin GTPases and plays crucial role in the process of outer 
mitochondrial membrane tethering during fusion of mitochondria (Koshiba, 2004). In this part 
of my doctoral work I investigated the functional effects of different MFN2 mutations on 
mtDNA stability and maintenance, in skeletal muscle and fibroblasts samples from four 
different patients. 
 
3. 2. 1 Patients  
 
Four patients were diagnosed for CMT2A by direct sequencing of the MFN2 gene. The 
sequencing was performed by Susanne Beyer in our lab, and in the lab of Dr. Vielhaber in 
Magdeburg. Each of the four patients (Patient 1 to Patient 4) carried different mutation in the 
MFN2 gene, all affecting different protein domains (Figure 26). Patient 1 harbored a 
heterozygous single nucleotide substitution in exon 11 of the MFN2 gene – c.1126A>G. The 
mutation affects highly conserved amino acid of the protein, in undescribed till now domain. 
As the patient was adopted at newborn age no investigation could be performed in the 
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parents. Patient 2 carried a heterozygous mutation in exon 18 of the gene – c.2120G>C, also 
affecting a conservative region of the MFN2 gene in the HR2 domain. The parents of the 
patient did not show the mutation; therefore, it is a result of de novo mutational event. 
Patients 3 revealed a heterozygous in-frame deletion c.677_688del12 in exon 2 of the MFN2 
gene, encoding for the GTPase domain of the protein. Other affected relatives in the family 
carried the same heterozygous mutation. Patient 4 carried a heterozygous mutation in exon 
4 – c.221A>G, at the P-loop nucleoside triphosphate hydrolase domain, not detectable in the 
mother and the brother of the patient. The mutations in P3 and P4 have not been described 
until now. The mutation in P2, has been recently published (Sitarz et al., 2012).  
 
 
 
Figure 26   Partial sequences representing MFN2 mutations in four patients with CMT2A. Patient 1 (a) 
(reverse sequence), Patient 2 (b), Patient 3 (c) and Patient 4 (d) (reverse sequence); arrow is 
indicating the mutation in each sequence (Vielhaber et al., 2013). 
 
Skeletal muscle biopsies from Patient 1 and Patient 3 were investigated for COX 
activity. Due to strong fatty muscle degeneration, the skeletal muscle of Patient 2 was 
unsuitable for histological examination, and no muscle sample was available from P4. The 
histological investigation from Patient 1 and Patient 3, performed by our collaborators 
(Vielhaber et al., 2013), revealed mild changes and although no COX-negative fibers were 
visible, the mitochondria had an abnormal distribution in the fibers.  
As a disease control patient, a sample from Charcot–Marie–Tooth type 1A (CMT1A) 
neuropathy patient was used. In this case the cause of the disease is a mutation in the gene 
a b 
d c 
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PMP22 causing subsequent demyelination of neurons, thereafter any changes in skeletal 
muscle in this form of the disease are consequences of neurogenic atrophy. As CMT2A is 
caused by a primary mitochondrial dysfunction, all alterations of mitochondrial function are 
expected to be specific, apart from signs of neurogenic atrophy. The appearance of the 
mitochondria in the CMT2A patients under electron microscopy (performed by our 
collaborators, Vielhaber et al., 2013) was very different than the one in the disease control 
patient. The mitochondria appeared swollen, with smaller sizes and visible paucity. The 
results from the histological analysis suggested respiratory disturbances due to the changes 
in the mitochondria. Biochemical analysis in the fibroblasts and muscle from the patients 
performed by Dr. Schoeler showed only increased sensitivity of the respiration to COX 
inhibitor azide (data not shown). The MFN2 mutations appeared to have only mild effect on 
the respiration rate in the samples (data not shown). To elucidate the question how disturbed 
fusion of the mitochondria can affect the phenotype in these patients, I have performed 
genetic investigations of their mtDNA.  
 
3. 2. 2 Copy number determination 
 
The copy number of the mtDNA was measured by qPCR and the samples showed reduced 
copy number of the mtDNA in comparison to the healthy and the diseased controls (Table 
35). 
 
Sample Skeletal muscle Fibroblasts 
Controls 
16,045±8817 
n=15 
1297±188 
n=8 
CMT1A disease control 9116±891 942±87 
CMT2A Patient 1 6211±571* 411±19** 
CMT2A Patient 2 654 ±44* 889±73** 
CMT2A Patient 3 11,440±632 798±64** 
CMT2A Patient 4 no data 633±103** 
 
Table 35   mtDNA copy numbers determined in four CMT2A patients, one diseased control patient 
with CMT1A and controls. The copy numbers were measured in fibroblasts and muscle DNA samples. 
The values were normalized to the values for the single nuclear gene Kir4.1. Standard deviation was 
calculated from three separate experiments. *p<0.05; **p<0.001; Student’s t-test; n, number of 
samples. 
 
 
The absolute copy numbers in tissue samples from all CMT2A patients showed a 
significant, almost twofold decrease, in comparison to both controls. Only Patient 3 had an 
insignificant decrease in the copy number. The highly reduced values in muscle sample from 
Results 
 
 84 
Patient 2 can be explained with the fatty muscle substitution in that sample. As mtDNA 
depletion is often caused by mutations in the POLG gene, all patients were checked for 
mutation in it and all were negative (experiment performed by Susanne Bayer). As mtDNA 
depletion was not observed in the CMT1A disease control patient, the depletion was not 
result of neurogenic degradation, and this reveals new insight into the pathological effect of 
MFN2 mutations and might point to a potential causative role of mtDNA depletion in CMT2A 
neuropathy. To confirm that, a fibroblasts mtDNA depletion experiment with ethidium 
bromide, a strong mtDNA replication inhibitor, was performed by Dr. Schoeler and the data 
showed linear correlation between the reduction of mtDNA copy number and lower 
respiration (Vielhaber et al., 2013). Altered mitochondrial dynamics lead to disturbed mtDNA 
maintenance.  
 
3. 2. 3 mtDNA deletions in CMT2A neuropathy 
 
To investigate the deletion load in MFN2 patients, I performed a common LR-PCR with 
primers 7027F and 45R. All samples showed accumulation of multiple deletions (Figure 27a). 
Deletion quantification was performed in skeletal muscle and fibroblasts from the patients by 
using smPCR. All samples showed accumulation of deletions (Figure 27b and c). 
Particularly, the skeletal muscle from Patient 3 had significantly increased amounts of 
deletions in comparison to controls. This patient showed previously less pronounced 
depletion in comparison to the other patients with CMT2A. Patient 3 is also the only one who 
has a deletion in the MFN2 gene, affecting the GTPase domain of the protein; which might 
be relevant to the slightly different mtDNA status in comparison to the other patients. From 
this result it was evident that MFN2 mutations not only influence the copy number, but also 
cause accumulation of mtDNA deletions. 
The deletion quantification showed approximately 8-fold more deletions in CMT2A 
skeletal muscle and 15-fold more deletions in CMT2A fibroblasts (Figure 27b) in comparison 
to age matched controls. The total level of deletions between 0.0006 and 0.0012 %, was only 
about 0.001 % of total mtDNA (Figure 27b), and therefore, the deletions were unlikely to 
explain the marked decrease of in vivo COX activity.  
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Figure 27   Deletions in CMT2A patients. (a) LR-PCR with CMT2A fibroblast (F) and muscle (M) 
samples from Patients 1 to 4 (P1–P4) and a control sample. Wt, wild-type amplicon; del, deletion 
specific PCR products. Deletion quantification in CMT2A muscle (b) and fibroblast (c) samples (P1–
P4), as well as in one diseased control patient with CMT1A (CX) and a control patient (C). Error bars 
show the SEM from two independent experiments; the significance level was *p<0.05 or **p<0.005 
(Vielhaber et al., 2013). 
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Figure 28   Mapped mtDNA deletion breakpoints in CMT2A patients. On the figure are shown retained 
mtDNA regions. (a) Mapped deletions in the major arc of CMT2A. The graph shows the amplified 
deleted molecules, missing parts of their major arc. In red are shown deletions which are missing their 
OL or are spanning the TAS region of the mtDNA. (b) The graph represents the amplified deleted 
molecules missing parts of their minor arc. In red are shown deletions missing their LSP or OH.  
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All single molecules amplified during the quantification were sequenced and their 
deletion breakpoints were determined (Appendix III). Surprisingly, there were deletion 
species lacking the heavy strand origin of replication (OH), the light strand promoter (LSP), or 
their 3’ breakpoint was spanning over the TAS region (Figure 28). These molecules probably 
cannot replicate and are unlikely to propagate by clonal expansion. They are most probably 
resulting from ongoing mtDNA mutagenesis. This is supporting also the finding that most of 
the mapped deletions were detectable only once and most likely are not clonally proliferating. 
After performing smPCR and detecting the deletions’ breakpoints, it appeared that all 
samples contain deletions also in the small arc of the mtDNA (Figure 28b).  
These non-conventional deletions in the mtDNA minor arc as well as deletions 
removing regions crutial for mtDNA replication might be related to elevated oxidative damage 
and double-strand breakage. To check if such deletions are detectable in samples exposed 
to high oxidative stress, I performed hydrogen peroxide (H2O2) treatment of healthy human 
fibroblast (Spitz, 2010). In order to detect the proportion of damaged mtDNA molecules 
correlating to the increase of oxidative stress caused by the treatment of the cells with H2O2, 
I established a qPCR method, for mtDNA integrity estimation (Figure 29). The method 
combines two PCRs, the first PCR amplifies a short product, flanked by primers 1057F and 
1144R. The lenght of this PCR product is 88 bp and the probability of detecting a breakpoint 
in such small amplicon would be very low, therefore, the detected Ct value would show the 
total amount of mtDNA molecules. The second PCR amplifies a long 5379 bp PCR product, 
amplified by primers 11,226F and 35R. The difference between the two PCR Ct values would 
delineate the intactness of the mtDNA, by comparison of the short and the long PCR product 
amplifiability, which depends on the mtDNA quality. Cycle number differences between the 
two PCRs were measured in the qPCR reactions and the data from the control untreated 
samples were used as reference. For all samples, first, the Ct values for the long product 
were subtracted from the wild-type mtDNA Ct values. Then the control sample Ct difference 
was taken as reference, to which the treated samples were compared in a ratio. In this case 
the control sample represents a value of 1, all treated samples containing less intact mtDNA 
should give a value smaller than 1 (Figure 29).  
 
Results 
 
 88 
 
Figure 29   mtDNA damage upon oxidative stress by H2O2. The mtDNA damage is increasing in  
correlation with increase in the oxidative stress, by treatment with different concentrations of H2O2. 
The error bars indicate SEM (+) from three independent experiments. 
 
Multiple deletions in the hydrogen peroxide treated samples were detected by 
smPCR. Breakpoints mapping unveiled that indeed deletions in the minor arc were 
detectable in H2O2 treated fibroblasts and some of them were removing the replication origin 
for the heavy strand at position 191 (Table 36). In the H2O2 treated fibroblasts, I detected as 
well deletions spanning the classical 3’ deletion breakpoint at 16,000–16,100 np and entering 
into the 7S DNA (Table 36).  
 
Deletions in H2O2 -treated fibroblasts 
Minor arc deletions    Major arc deletions 
129–4306 
980–4646 
674–4147 
24–2760 
129–3922 
333–4216 
 
7486–16,247 
6248–16,046 
8104–16,319 
6297–16,192 
 
 
Table 36   mtDNA deletions mapped by smPCR in H2O2 treated human fibroblasts. The deletions 
marked in red in the minor arc are removing the origin of H-strand replication. The deletions in red in 
the major arc are spanning the 16,070–16,090 region of the mtDNA, and are non-conventional 
deletions. 
 
 These non-conventional deletions detected in MFN2 patients and in H2O2-treated 
fibroblasts, cannot replicate and expand clonally due to the missing replication origins and 
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are most probably created de novo. In conclusion, higher oxidative stress might contribute to 
the elevated deletion formation in MFN2 patients. 
 
3. 3 mtDNA deletions in Ammon’s horn sclerosis 
 
ROS production and oxidative stress are implicated as well in the pathology of TLE and 
mitochondrial dysfunction is suggested to play an important pathogenic role in the seizure 
generation and epilepsy. To characterize the dysfunction of mitochondria in temporal lobe 
epilepsy (TLE), I explored the mtDNA from 18 hippocampal brain samples, from patients with 
Ammon’s horn sclerosis (AHS). AHS is characterized with extensive loss of neurons in the 
CA1 and CA3 regions of the hippocampus, and less damage in the AD and the PH regions 
(Margerison and Corsellis, 1966). As a control group, I selected 5 TLE brain samples, with no 
hippocampal sclerosis, and close brain lesion or tumor to the temporal lobe as primary cause 
of the epilepsy (lesion control group). It is known that deletions in the mtDNA accumulate 
with age (Linnane et al., 1989; Bua et al., 2006); therefore, in this study the age of the 
patients was limited between 20 and 40 years, and the detection of high levels of deletions 
due to advanced age was excluded. All samples were obtained from surgery of the 
hippocampus in pharmacologically intractable form of the disease. mtDNA from four different 
regions of the hippocampus – CA1, CA3, AD and PH were checked for deletions by LR-PCR. 
The primers used to perform the LR-PCR amplify large part of the major arc of the mtDNA, 
which is known to be highly prone to deletion formation in different pathological conditions 
(Shoffner, 1989). I used primer pair 5462F/16,115R, which amplifies a wild-type product with 
size 10,654 bp. Mutated molecules containing deletions appear as bands or smear under the 
wild-type sized molecules (Figure 30). All samples were semiquantitatively analyzed for 
deletions content by using ImageJ processing and analysis of the gel pictures. A ratio 
between the wild-type band peak and the summed deletion peaks was calculated, and used 
for semiquantitative measurement of the deletions present in each sample. The background 
intensity was subtracted in the calculations. 
From the LR-PCR reactions of all the 18 AHS patients it was visible that the patients 
with hippocampal sclerosis show higher overall amount of deletions in the hippocampus in 
comparison to the lesion control patients (Figure 30a).  
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Figure 30   LR-PCR and semiquantitative analysis of mtDNA deletions content in TLE patients. (a) 
LR-PCR with mtDNA from CA3 hippocampal region from five AHS and five lesion samples, with primer 
pair 5462F/16,115R; left panel, AHS patients; right panel, lesion patients; C, blood control negative for 
deletions. The group of AHS samples shows higher amount of deletions in comparison to the lesion 
group of samples. (b) mtDNA deletion percentage in four different regions of the hippocampus of AHS 
and lesion patients with TLE. Primers used in the LR-PCR: 5462F/16,115R; AD, area dentate; CA1, 
cornu Ammonis 1; CA3, cornu Ammonis 3; PH, parahippocampus. Error bars indicate SEM (+). 
Standard student’s t-test was used to indicate significant difference; * indicates p< 0.005. There is a 
significantly higher amount of deletions present in AD and CA3 regions of AHS patients in comparison 
to lesion patients. 
 
The group of AHS patients showed accumulation in the CA3 region of the 
hippocampus, whereas the lesion controls had no detectable deletion. Furthermore, in 
comparison to the lesion TLE patients almost twelve fold higher amount of deletions was 
detected in the AD region of the AHS patients  (p<0.005, a standard student’s t-test was 
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used to test the significance of the difference) (Figure 30b). In the CA1 region both groups 
showed almost equal amounts of deletions. In the PH region the amount of deletions was 
very low in the AHS group and not detectable in the lesion TLE patients. This finding 
demonstrates that in difference to lesion TLE patients, significant amount of mtDNA deletions 
are accumulating in AD and CA3 regions of the hippocampus in AHS patients. 
Both groups of patients suffer from TLE, but only the AHS group shows specific 
accumulation of higher amount of deletions in the most affected by the disease region CA3, 
this fact points to the causative function of the mtDNA deletions in TLE with AHS.  
I compared the mtDNA deletion accumulation in four different hippocampal regions in 
11 AHS samples in the age of 20–30 years and a control group of 3 lesion samples in the 
same age (Figure 31). 
 
 
Figure 31   mtDNA deletion amounts in AHS and lesion patients, dependent on age. Primers used in 
the PCR, 5462F/16,115R; AD, area dentate; CA1, cornu Ammonis 1; CA3, cornu Ammonis 3; PH, 
parahippocampus. Error bars indicate SEM (+). Standard student’s t-test was used to indicate 
significant difference; * indicates p< 0.005 between the two marked groups. There is high amount of 
deletions in the AD region of AHS patients, detectable in early age. There are significantly more 
deletions in AD region of AHS patients in comparison to lesion patients in the same age group (20–
30).  
 
Comparison between AHS and lesion patients at the age between 20 and 30 years, 
showed significant difference (p< 0.005) with 21% of deletions in AD region of AHS patients 
vs. 1.3 % deletions in lesion patients (Figure 31). This result demonstrates that specifically in 
AD regions of AHS patients high amount of deletions can be detected in very early stage of 
life.  
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3. 3. 1 Breakpoint ‘hotspot’ for TLE patients with AHS 
  
In AHS patients, classical deletions of the mtDNA tend to have their 3’ end breakpoint at 
nucleotide position 16,070–16,090 (Zeviani, 1989; Guo, 2010). These deletions are 
suggested to result from the attack of reactive oxygen species, due to impaired function of 
the mitochondrial respiratory chain (Baron, 2007; Imlay, 1988). To check if these deletions 
are the main fraction of deletions in AHS patients I performed screening for deletion content 
of the same set of patients with primer pair 5462F/15,623R, in the AD region. The location of 
the reverse primer is excluding the 16,070–16,090 region covered with the previously used 
primer 16,115R.  
 
 
Figure 32   Comparison of relative deletion percentage in AD region, in AHS patients, with two 
different primer pairs. 5462/16,115, including the 16,070–16,090 region and 5462/15,623 excluding it. 
Error bars indicate SEM (+). Standard student’s t-test was used to indicate significant difference; * 
indicates p< 0.005 between the two marked groups. 
 
 The change in the primer pair influenced the amount of detectable deletions in the 
AD region of AHS patients (Figure 32). In AHS patients, a great amount of the deletions 
seem to be deletions with 3’ breakpoints in the 16,070–16,090 region. Change of the primer 
in lesion patients had no effect on the deletion / wild-type ratio. Overall, these results suggest 
a different pathological mechanism leading to deletions in AHS patients in comparison to 
lesion patients.    
Previous single-molecule PCRs of AHS samples, performed in our lab have 
frequently detected one specific species of large scale deletion with np 8649–16,084 deleting 
a 7436 bp (7.4 kb) long part of the mtDNA, flanked by two 12 nt of long perfect direct 
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repeats. This deletion, with 3’ breakpoint in the 16,070–16,090 region, has been described in 
different diseases such as cancer, endocrine disorders, and chronic disorders (Nicolino, 
1997; Yamamoto, 1992) and its detection can be relevant indicator for underlying processes 
specific for AHS. Therefore, I checked its distribution among 66 AHS samples and 22 lesion 
TLE samples. All mtDNA samples were isolated from the CA3 region of the hippocampus. As 
a reference I amplified the ubiquitous ‘common deletion’ – 4977 bp, found to be surrounded 
by 13 nt direct repeats, and have compared its intensity with the intensity of the 7.4 kb  
deletion by ImageJ evaluation. The common deletion is frequently used as a biological 
marker for aging and has been used since long time as an indicator of ongoing mutagenesis 
of the mtDNA (Shoffner et al., 1989; Berneburg et al., 1999). 
I detected the 7.4 kb deletion by using primers 8282F and 16,115R that flank the 
deletional breakpoints, when the deletion is present the amplified product has size of 398 bp. 
The ‘common deletion’ has breakpoints at 8482 and 13,459 bp position and is 4977 bp long. 
For its detection I have used primers: 8282F and 13,684R, when the deletion is present the 
PCR product has size of 426 bp. I set up a multiplex PCR, which can detect both deletions 
simultaneously (Figure 33). It is a PCR containing all three primers 8282F:13,684R:16,115R 
in ratio 4:3:1, optimized to increase the specificity of the PCR, assuring the detection of the 
common deletion even at lower levels. The PCR products of both deletions appear as two 
close bands, from which the upper band is the common deletion and the lower band is the 
specific deletion.  After acquiring the images they were evaluated with ImageJ and ratio 
between the intensities of the two deletions was calculated. When the intensity ratio between 
the specific and the common deletion was higher then zero the sample was considered 
positive for the 7.4 kb deletion. 
 
 
Figure 33   Multiplex PCR of AHS and lesion TLE samples. The upper panel includes 15 AHS 
samples and the lower panel 15 lesion  samples, from the hippocampal CA3 region. Reaction 
products were loaded on 3% agarose gel. The upper 426 bp band represents the common deletion, 
4977 bp; the lower 398 bp band represents the 7436 bp deletion (7.4 kb deletion); (++) positive control 
for both deletions.  
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In the experiment I included double positive brain sample, that reproducibly showed 
the same pattern. The positive sample was checked by sequencing of DNA extracted from 
excised from the gel product. 
The analysis of the CA3 region of all 66 AHS samples and 22 lesion samples 
revealed that 63% of the AHS samples contained both the common deletion and the 7.4 kb 
deletion, in comparison to 9% of the lesion samples. This result confirms that deletion 8649–
16,084 is more often detectable in AHS samples and is more specific for TLE with 
hippocampal sclerosis then lesion based TLE. 86% of the lesion samples contained only the 
common deletion, which confirms it as one of the most often described deletions in 
degenerative tissues. There was no sample containing only the specific deletion, neither in 
the AHS nor in the lesion group of patients. 
After confirming the 7.4 kb deletion as one prominent deletion species from the 
16,070–16,090 cluster, typical for CA3 region of AHS samples, it was interesting to find out if 
it is characteristic for other hippocampal regions of the AHS patients. I performed a screening 
of another 121 AHS samples, from which 25 samples from CA3, 46 samples from PH, 30 
samples from CA1 and 20 samples from AD region. In the lesion group I checked 31 new 
samples, from which 7 samples from CA3, 12 samples from PH, 9 samples from CA1 and 3 
samples from AD region. The result showed very high frequency of the 7.4 kb deletion in 
AHS samples in comparison to lesion samples. The deletion is characteristic for all brain 
regions in AHS samples with lowest frequency in the PH region, which is comparable to the 
lesion group of patients. Above 70% of the samples from CA1, AD and CA3 region were 
positive for the deletion. This result confirms the importance of 7.4 kb deletion and raises the 
question for its frequency and plausible function in seizure development or degeneration of 
the hippocampus in AHS patients.  
AHS brain sample sequenced by Next Generation Sequencing in our group 
demonstrated plenty of classical deleted molecules carrying 5’ breakpoint at position 5786 
and 3’ breakpoint at position 16,078, also layng in the hotspot region of 16,070–16,090 np. 
To check its segregation in other AHS samples I optimized a multiplex PCR for its detection, 
by using primers 5462F and 16,503R. I checked for the frequency of that deletion in 24 AHS 
and 16 lesion brain samples. 62.5% of the AHS samples were positive in comparison to 
12.5% in the lesion samples. This result again points at the specificity of clonally expanding 
deletions in AHS brain. The absence of these types of deletions in lesion patients confirms 
the theory that clonally expanding deletions are having pathologic role in TLE with AHS and 
these deletions described above might be as well hotspots for deletion formation in TLE 
patients with AHS. 
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4. Discussion 
 
4. 1 Exonucleases in mtDNA replication, repair and recombination 
 
The processes of replication, repair and recombination rely, among others, on the activity of 
nucleases. Very little is known about the nucleases localized to mitochondria that act on the 
mtDNA. In humans, helicase/nuclease DNA2 was suggested to localize both to the nucleus 
and the mitochondria (Duxin et al., 2009) and recently, another endonuclease FENMIT, a 
mitochondria localized truncated isoform of FEN1 was described in humans (Kazak et al., 
2013). FENMIT binds preferentially to flap structures containing 5' RNA flap and is recruited 
to RNA-DNA hybrids in conditions of inhibited replication. FEN1 is a 5'-flap endonuclease 
and 5'→3' exonuclease known to function together with DNA2 in the nucleus (Budd and 
Campbell, 1977). Similar to the function of DNA2 and FEN1 in the nucleus, it was suggested 
that in mitochondria they participate in the processing of flap structures and forked substrates 
in mtDNA repair through LP-BER and in mtDNA replication. Nevertheless, the knock down 
neither of FEN1 nor DNA2 disturbs the process of mtDNA replication (Ruhanen et al., 2011). 
Apart from FEN1 and DNA2, which have double localization, a third unique 5′-
exo/endonuclease EXOG was also found to function in mtDNA repair. The involvement in 
mtDNA replication of FEN1, DNA2 and EXOG is not clear. Altogether, the knowledge over 
the mitochondrial nucleases is very poor and probably many nucleases are yet to be 
discovered. For example, the turnover of the mitochondrial 7S DNA molecule is very fast, but 
the enzyme involved in its degradation is unknown. Recently, we identified a novel 5’-
exonuclease, MGME1 that might be involved directly in the processing of the 7S DNA 
molecule and its degradation.  
MGME1 was shown to localize to mitochondria via immunohistochemical subcellular 
localization, by GFP-tagging and cell fractionation, performed by our collaborators in 
Cambridge (Kornblum et al., 2013). They performed detailed investigation of the enzymatic 
properties of MGME1, which revealed that it cleaves ssDNA, but not ssRNA or RNA-DNA 
hybrids. It has strong preference for ssDNA over dsDNA, and processes more efficiently 5’ 
DNA ends then 3’ ends (Kornblum et al., 2013). Such single stranded DNA is the 7S DNA, 
that can be substrate of MGME1. 
There are several theories over the formation of the 7S DNA and its function. It was 
suggested that the 7S DNA participates in the priming of the heavy strand replication of the 
mtDNA and if it is true, its level has to be kept high in order to respond fast to the needs of 
the cell; or it is a result of replication stalling at the TAS region (Doda et al., 1981). On the 
other hand, in the strand-displacement model of replication, the formation of the 7S DNA 
fragment is being suggested to be the last step of the H-strand replication and formed by its 
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termination at the TAS region (Berk and Clayton, 1974) Another theory claims that 7S DNA is 
needed for maintaining the dNTPs pools, as with the increase of the dNTPs the 7S DNA 
levels as well elevate, but the mtDNA copy number does not change. Thus, the 7S DNA 
levels are changing in the different phases of the cell cycle in response to the needs of the 
cell (Antes et al., 2010). However, its generation, function and turnover are a matter of 
dispute.  
Samples from MGME1 patients appeared to contain a huge amount of 7S DNA 
(Figure 17 black bars, Figure 18), far exceeding the broadly accepted 1.1 fold 7S DNA 
accumulation detected in healthy individuals. If 100% of the mtDNA molecules contain  
7S DNA, the maximal theoretical accumulation of 7S DNA should not exceed 1.5 folds. In 
muscle from the MGME1 patients, the ratios of 7S DNA to the total amount of mtDNA were 
two to eight folds higher then in age matched controls, in five of the six investigated patients 
(Figure 17a). High 7S DNA level was detectable as well in the fibroblasts from the patients 
and was missing in the control fibroblasts cell line (Figure 17b). Blood samples and cells with 
MGME1 function down-regulated by siRNA (experiment provided by our collaborators in 
Cambridge) showed as well 7S DNA accumulation (Kornblum et al., 2013). In blood samples 
the elevated amount of 7S DNA was confirmed by qPCRs with different primers spanning the 
whole 7S DNA region (Figure 18).  The accumulation of 7S DNA in MGME1 deficient 
samples, would suggest that MGME1 participates in the turnover of the 7S DNA. In support 
to that hypothesis, 7S DNA had elongated half life under mtDNA replication inhibition 
(performed by our collaborators in Cambridge) with fibroblasts from MGME1 patients. 
However, one should mention that strong MGME1 overexpression leads not only to 7S DNA 
degradation but also to overall mtDNA depletion, in MGME1 patients and in controls (Figure 
19).  
 
 
 
Figure 34   Structure of the D-loop containing the 7S DNA. In green is shown the 7S DNA; L, light;  
H, heavy; LSP, light strand promoter; HSP, heavy strand promoter; CSB, conserved sequence block; 
OH, heavy strand origin of replication; TAS, termination associated sequence (modified according to 
Zhang and Pommier et al., 2008 and from our paper in preparation Nicholls et al.). 
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It has been shown that there are several types of 7S DNA (Figure 34), which differ in 
length, with 191 as the longest 5’ end reported in the literature, defining as well the H-strand 
origin of replication (Clayton, 1996; Bogenhagen and Clayton, 1977). This fact might be 
related to the theory of 7S DNA playing priming role in H-strand replication. 
Additionally to 191, np 168, 151 and 110 are the only identified 5’ end positions listed 
in the literature until now (Crews et al., 1979; Kang et al., 1997; Pham et al., 2006). 
According to the literature the 3’ end of the 7S DNA is at position 16,104–16,106, and it 
contains the termination associated sequence TAS (16,157–16,172). No variations were 
registered until now at the 3’ end of the 7S DNA molecule (Clayton, 1996; Doda et al., 1981). 
As MGME1 is involved in the turnover of 7S DNA and it is a 5’-exonuclease 
processing single stranded DNA, a question raised if MGME1 performs processing of the 5’ 
end of the 7S DNA molecule, and if so, how does this end look like in MGME1 deficiency. 
One has to remember that MGME1 activity on 7S DNA is possible only if the 7S DNA 
molecules are not completely annealed to the template DNA and a free 5’ end is available 
(based on the in vitro data). The exact state of annealing of the 7S DNA was not studied until 
now. The formation of such 5’ flap end close to the 191 np can be result of replication 
termination of the heavy strand of the mtDNA, which when fully replicated would displace the 
7S DNA and create the 5’ end flap. The formation of 5’ 7S DNA flap end might as well occur 
due to the formation of secondary structures in the D-loop. It was suggested that the 
sequence of the D-loop at its 5’ end allows the formation of a cloverleaf-like structure, which 
when folding would incorporate the CSB1 sequence and all major 5’ 7S DNA ends. If this 
cloverleaf-like structure forms in the template L-strand subsequent to D-loop synthesis, the 
7S DNA will not be able to anneal and will retain 5’ free end, in the form a large flap (Brown 
et al., 1986). 
By establishing a single-molecule blunt-end ligation-mediated PCR technique (Figure 
21), using T4 polymerase blunting for detection of the 5’ end of the 7S DNA and Mung Bean 
nuclease blunting for the 3’ end, I confirmed the expected nucleotide positions, 191 (and 
shorter) and 16,104 for both ends of the 7S DNA in controls. In opposite to controls, MGME1 
fibroblasts from P1976 had varying 5’ 7S DNA ends, often exceeding position 191, and an 
unchanged 3’ end (Figure 24). Most molecules detected in the MGME1 patients revealed 
longer 5’ end of the 7S DNA. This result is in consensus with the impaired 5’-exonuclease 
activity of MGME1 in the patients. Thus, we conclude that the mutation in the MGME1 gene 
led to accumulation of 7S DNA molecules inefficiently processed at their 5’ end. One 
possibility is that the longer 7S DNA molecules can be a result from aberrant RNA-DNA 
transitions. The longest detected 5’ 7S DNA end is at position 301, which is close to the 
beginning of the CSB2 (299–315) (Figure 34), and the site of transcription termination and 
primer formation of the mtDNA (Pham et al., 2006). However, as shown by our collaborators 
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in Cambridge, treatment with RNase did not change the detectable 7S DNA ends; therefore, 
the RNA-DNA transitions are not affected in MGME1-null cells. In this case in the next step 
after the RNA-DNA transitions at the CSBs, the 5’ DNA end of the 7S DNA precursor 
molecules has to be processed additionally by MGME1 to the known positions of the 7S DNA 
(191 and shorter) (Nicholls et al., paper in preparation). These findings are very important, as 
previously, it was not clear that the 5’ end of the 7S DNA has to be processed, apart from 
removing the RNA primers. However, in MGME1 patients, this process is disrupted, which 
would explain the accumulation of longer 7S DNA molecules in these patients. In agreement 
with this, longer 7S DNA molecules were found to have greater stability and longest half-lives 
in mouse models for D-loop synthesis kinetics determination (Bogenhagen and Clayton, 
1978), which might explain the accumulation of 7S DNA in MGME1 patients, eventually 
based on its slower degradation.  
LM-PCR is a very powerful technique to detect free DNA ends; therefore, I checked 
the entire mtDNA genome for such free ends in controls and MGME1 fibroblasts. 
Surprisingly, in addition to the 7S DNA ends one other free end species was visible in the 
MGME1 patients and sequencing revealed a free end of a patient-specific linear mtDNA 
fragment at position 5771 and 5772. This position is located within the light strand origin of 
replication. Another free dsDNA end was as well detected at the OH, by native DNA ligation 
(data not shown). Such free ends were not present in controls (Figure 25). A linear product 
with these ends would have size of around 11-kb and would include the entire mtDNA major 
arc. The formation of such 11-kb molecule between the two origins of replication was 
described in the POLG-deficient ‘mutator mouse’. It was suggested that such fragments are 
being formed by spontaneous nicking of single stranded DNA at arrested replication forks 
near OH and OL (Bailey et al., 2009). S1 treatment, as well, can generate these fragments, as 
the junctions near the origins of replication are very prone to nicking (Bailey et al., 2009). A 
chromosome breakage of a theta replication intermediate with ends at both replication origins 
might generate also such linear fragments. This is the first time that such DNA linear 
molecules are described in human mitochondrial pathology. As MGME1 acts preferentially 
on ssDNA in vitro, its putative role in the degradation of this blunt-end double-stranded 
mtDNA fragment is less probable; therefore, these molecules might be indeed product of 
replication stalling or a product of replication pausing at the origins of replication, providing a 
checkpoint of the replication process. Indeed, the restart of a stalled replication is known to 
be bound to the function of 5’→3’ exonucleases, therefore, MGME1 might support the 
replication fork to pass the replication checkpoint; in such scenario, MGME1 absence would 
lead to lasting stuck replication and eventually to chromosomal breakage.  
In this study, I showed that dysfunction of MGME1 protein leads also to the 
accumulation of mtDNA rearrangements, detectable with long-range PCRs in muscle 
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biopsies, blood and urine samples from all the affected patients (Figure 15). The 
rearrangements in the MMD patients were very big and atypical for other mitochondrial 
diseases, for example in comparison to the deletions observed in a POLG patient, which 
might be important for the easier diagnostics of MMD patients’ carring MGME1 mutation 
(Figure 15). The amount of mtDNA rearrangements in MGME1 patients was in the range 
from 0.4% to 1.5% (Table 33). The amount of rearrangements detected in the MGME1 
patients was higher in comparison to age matched controls and comparable to the amount of 
deletions detected in a POLG patient harboring a p.Ala467Thr mutation in the POLG gene. 
P931 showed the highest amount of rearrangements, which can be explained with the 
advanced age (57 years) at the time of biopsy in comparison to the other patients (10–37 
years).  
As the amount of deletions in POLG and rearrangements in MGME1 patients was 
similar, but the pattern of MGME1 rearrangements was very distinct, it was important to 
characterize and compare the breakpoints spectra in both pathological conditions. POLG 
patients showed mostly deletions affecting the mtDNA major arc between the two replication 
origins (Figure 16). MGME1 patients were missing the classical major arc deletions and the 
starting positions of the detected breakpoints were clustered in the minor arc around the 
tRNAPhe gene, in the 12S ribosomal RNA gene and near to the tRNALeuUUR gene. In 
difference to the POLG patients MGME1 patients harbored multiple rearrangements erasing 
2/3 of the mtDNA molecule, including the light strand origin of replication (Figure 16). The 
absence of light strand origin of replication makes these molecules unable to propagate. 
However, many of them were detectable repeatedly in the individual patients. One possible 
explanation could be, if the detected breakpoints are not actual deletions, but complex 
structures, such as partial duplications. Detailed analysis revealed that the detected 
breakpoints indeed originated mainly from partial duplications (Figure 16c). This finding can 
explain the clonality of these rearranged molecules missing apperantly their light strand 
origin of replication. In support to that finding, sequencing of the mtDNA of P931 and P3737 
revealed presence of insertions of small D-loop multimers in these two patients (Table 34) 
and they can be result from the detection of more perplexing structures of the mtDNA. Such 
multimers were observed in the ‘mutator mouse’ (Williams et al., 2010) and it was suggested 
that they might indicate the ineffective replication termination, which needs the exonuclease 
activity of POLG (Brown et al., 2005; Williams et al., 2010). In this case, our results would 
point out to the additional involvement of MGME1 in replication termination.  
The 11-kb fragment might play role in the generation of these non-standard 
rearrangements, as free ends are widely accepted as precursors for deletion formation. Such 
precursors can be formed after double-strand break (DSB) at replication stalling sites. The 
repair of these DSBs is based on the mechanism of homologous recombination. However, 
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breakpoints close to the OL were missing, therefore, the linear fragment detected with  
LM-PCR does not participate in recombination, or the mechanism of homologous 
recombination is not functioning properly, which actually can explain the missing major arc 
deletions, in MGME1 patients. These assumptions would suggest, that MGME1 is needed for 
the process of homologous recombination. 
Three-dimensional modeling of the MGME1 active site and alignment comparison 
performed by our collaborators, showed high homology of MGME1 with the RecB catalytic 
residues of the RecBCD enzyme of E. Coli (Kornblum et al., 2013). Homology modeling of 
MGME1 active site based on the crystal structure of RecB in E. coli revealed very similar 
structure of the key catalytic residues of MGME1 (Kornblum et al., 2013). RecB is involved in 
end-processing in the process of recombination, which might be the case as well for 
MGME1. The homology of MGME1 to RecB is another confirmation of its function as an 
exonuclease that might be involved in recombination, and would turn MGME1 into the first 
described mitochondrial exonuclease directly involved in the processes of replication and 
recombination. The non-standard breakpoints detected in the MGME1 patients might occur 
by alternative forms of single-strand generation, in the absence of MGME1, in order 
homologous recombination to take place. The clustering of two of the breakpoints hotspots 
close to the D-loop might be explained by the higher probability for that region to be in a 
single-stranded state. And the third hotspot at tRNALeuUUR is a mitochondrial transcription 
termination factor (mTERF1) binding site, which might lead as well to the formation of single-
stranded regions, required during homologous recombination.  
Analysis of the breakpoints detected in the MGME1 patients showed equal amount of 
both type of rearrangements, with and without direct repeats (with minimal length of 5 nt) 
(Appendix I), similarly to the analyzed deletions in the POLG patient (Appendix II), which 
does not point to a specific mechanism of the breakpoints formation in POLG and in MGME1 
patients. 
Besides mtDNA rearrangements, mtDNA depletion is common feature for MMD 
patients, it was interesting to find out weather this is the case in MGME1 patients. Substantial 
depletion was observed in all affected patients (Figure 17 grey bars), except in muscle from 
P1976, which might be in connection with the fact that the muscle biopsy was taken at the 
age of 10 and at that time the patient was mildly symptomatic. The fact that the MGME1 
patients carry multiple mtDNA rearrangements and represent mtDNA depletion suggests that 
the primary cause of the disease in MGME1 patients is mtDNA maintenance perturbation 
and points to the importance of MGME1 in mtDNA maintenance.  
In mtDNA depletion and repopulation experiments in fibroblast cell lines from patients 
P1976 and P4052 and a control fibroblasts cell line, we used 2’-3’-dideoxycytidine (ddC) that 
competes with the natural substrate deoxycytidine for DNA incorporation (Waqar et al., 1984) 
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and causes replication termination due to missing 3’-oxygen of the ddC (Mitsuya et al., 
1987). Polymerase alpha, which is the main nuclear active polymerase, has low affinity to 
ddC which insures the low cytotoxicity of the method, whereas polymerase gamma in the 
mitochondria can use it as a substrate. In this way, only the replication in mitochondria is 
being specifically affected (Lee et al., 2009). 12 days treatment of control and patient 
fibroblasts with ddC, followed by 16 days of repopulation without ddC, led to recovery of only 
5% of control mtDNA copy numbers in P1976 and 55% in P4052 (Figure 20). These results 
revealed severely impaired mtDNA repopulation in MGME1 mutated cells.  
Figure 35 depicts our hypothesis over the function of MGME1 in mtDNA 
maintenance. 
 
 
Figure 35   Proposed function of MGME1 in mtDNA maintenance (adapted from Kornblum et al., 
2013). Replication intermediates are accumulating due to mutation in MGME1 or siRNA, which leads 
to mtDNA depletion and 7S DNA accumulation (right black arrow up). Overexpression of MGME1 
leads to 7S DNA degradation and overall mtDNA depletion (right black arrow down). 
 
Shortly after our publication, Szczesny et al. (2013) have described the same 
nuclease, and they have called it Ddk1 based on its predicted catalytic residues. They have 
shown that Ddk1 is metal-dependent nuclease, targeted to mitochondria, involved in the 
regulation of 7S DNA turnover, with single DNA strand affinity, and requiring free ends to 
fulfill its function. In contrast to our findings, the authors claimed that Ddk1 had a putative 
3’→5' exonuclease function, which was not supported by later findings. In consensus with 
our findings, Ddk1 binds to the free end of a substrate and moves along it until hydrolysable 
site is reached, in this way it differs from all other DNAases described until now. This ability 
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of the enzyme to slide over RNA, might suggest involvement of Ddk1 in other mtDNA 
transactions (Szczesny et al., 2013). 
In conclusion, we have discovered a novel gene encoding for the protein MGME1, a 
5’-exonuclease located to mitochondria. Its loss of function leads to the formation and 
accumulation of unusually large partial duplications. mtDNA depletion and accumulation of 
replication intermediates, such as the 7S DNA. It is the first dedicated mitochondrial 
exonuclease proven to be directly involved with the process of mtDNA replication. MGME1 is 
able to process DNA flap structures, as well as flap structures containing RNA at their 5’ end. 
Nucleases described until now that function in mitochondria FEN1, DNA2 and ExoG have 
functions more focused on repair of the mtDNA, but their involvement in replication was not 
reported, and MGME1 seems a good candidate for flap processing of intermediates during 
mtDNA replication, for example of displaced DNA containing Okazaki fragments during 
lagging strand synthesis or in LP-BER (Kornblum et al., 2013). 
Figure 36 sums up our knowledge for mtDNA replication; and in Figure 37 are 
summarized all findings over the dysfunction of MGME1 and its hypothetical involvement in 
replication and repair, as well as description of the possible 5’ flap ends formations, which 
are substrates for its function. 
 
 
Figure 36   Replication fork at the mtDNA (adapted from nuclear replisome by Burgers and Seo, 
2006). 
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4. 2 Mitochondria dynamics and mtDNA maintenance 
 
Impairment of mitochondrial dynamics due to mutations in nuclear genes encoding for 
proteins participating in the processes of fusion and fission, is leading to different 
mitochondrial disorders with unclear molecular pathologic mechanisms. Such disease is 
Charcot–Marie–Tooth neuropathy type 2A (CMT2A). CMT2A is an autosomal dominant 
axonal form of peripheral neuropathy caused by mutations in the mitofusin 2 gene (MFN2), 
which encodes a mitochondrial outer membrane GTPase protein that promotes mitochondrial 
fusion (Züchner, 2004). 
Neurodegeneration appears to be common phenotype in mice with targeted mutation 
in MFN2 and cells lacking mitochondrial fusion show severe defect in their respiratory 
capacity (Chen, 2005). MFN-null mice for either of the mitofusins die during the embryonic 
development due to placenta defects, and show fragmented mitochondria in fibroblast (Chen 
et al., 2003). MFN2 deletion mutant missing two transmembrane spans blocks mitochondrial 
fusion and represents phenotype as a dominant-negative mutant. Its overexpression leads to 
loss of membrane potential, which suggests function of MFN2 in maintaining it (Honda et al., 
2005). Knock out of MFN2 increases the distance between mitochondria and ER. In MEF 
and HEK cells, depolarization of the inner mitochondrial membrane, through protein junction 
transduces a signal to the outer membrane which is being bridged by MFN2 to the STIM1 
protein (dynamic calcium signal transducer) and leads to activation of the CRAC channels  
(calcium release activated channels) responsible for the replenish of calcium into the ER. 
Disrupted connection between ER and mitochondria is found to be relevant in heart failure 
and heart myocites damage (Dorn and Maack, 2013). Dysfunction of the mitofusins (MFN1 
and MFN2) leads to disruption of the mitochondrial network and the process of mitochondrial 
fusion. 
An interesting hypothesis claims that by fusion and fission the process of effective 
complementation between the mutated mtDNA molecules, proteins and RNA allows the cell 
to tolerate higher levels of pathogenic mtDNA (Chen, 2010). In support to that studies 
showed that the process of mitochondrial fusion seems to be up-regulated in the presence of 
oxidated gluthation in the cells, which is a main oxidative stress indicator, and most probably 
the mitochondrial fusion is coupled as well to cellular stress response (Shutt et al., 2012). All 
these studies show the importance of mitochondrial dynamics for their proper function, but 
until now, it remains unclear how the mitochondrial fusion dynamics affects the mitochondrial 
function. 
Big part of my PhD work was devoted to characterization of the mitochondrial 
phenotype in CMT2A patients carrying mutations in Mfn2 in order to shed a light on the 
pathomechanism leading to disease. Our study included four CMT2A patients caring four 
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different mutations localized in different domains of the MFN2 gene, two of which were not 
described before (Figure 26). We investigated the mutation effect on mitochondrial function 
in skeletal muscle and cultured fibroblasts. As CMT2A is caused by a primary mitochondrial 
dysfunction, all alterations of mitochondrial function would be expected to be specific for 
CMT2A, when different to signs of neurogenic atrophy. Therefore, a disease control patient 
sample from Charcot–Marie–Tooth type 1A (CMT1A) was included in the study, as all 
changes in the muscle and mitochondria in this patient are consequences of neurogenic 
atrophy, the potential mitochondrial alterations would be secondary. 
In mice, the complete loss of function of both mitofusins led to severe respiratory 
deficiency in brain and muscle, while knocking out of only one of the mitofusins resulted in no 
specific phenotype (Chen et al., 2005; 2007; 2010). All of the patients in our study carry a 
missense mutation on only one allele of MFN2, which would suggest that humans are much 
more sensitive to mild impairment in the mitochondrial dynamics or dominant negative effect 
of the mutations. Until now, oxidative phosphorylation impairment has been investigated only 
in fibroblasts from CMT2A and the results were very contradicting. Although one study on 
patients caring a mutation in the GTPase domain did not show any respiratory dysfunction 
(Amiott et al., 2008), a complex IV deficiency was detected in fibroblasts from patients with 
an unusual for MFN2 mutation phenotype (Rouzier et al., 2012).  
In our study, skeletal muscle histology analysis of two of the patients revealed 
abnormal mitochondrial distribution within the type 2A skeletal muscle fibers. Cytochrome c 
oxidase staining showed paucity of intermyofibrillar mitochondria that was confirmed by 
electron microscopy (from our collaborators in Magdeburg). The mitochondria were having 
reduced size and number, with abnormal slightly swollen appearance (Vielhaber et al., 
2013). The cristae in the mitochondria were resembling reduced folding and empty 
appearance. The affected mitochondrial distribution and morphology is in consensus with 
previous studies in mice lacking both mitofusins (Chen et al., 2010).  
Our data provided direct evidence for the functional impairment of oxidative 
phosphorylation in skeletal muscle and fibroblasts of CMT2A patients harboring different 
mutations in the MFN2 gene. Mitochondrial respiration measurements and enzymatic activity 
determination in muscle and fibroblasts from all four patients revealed slightly reduced 
maximal respiration rate and increased respiration sensitivity to azide treatment, with 
consequent decrease of cytochrome c activity in the mitochondria (all the data was provided 
by Dr. Schöler). The only patient without respiratory chain function impairment was carrying 
mutation in the GTPase domain of MFN2, which was in accordance with the results of Amiott 
et al., (2008). Our data revealed that a potential reason for the observed decreased 
cytochrome c oxidase activity is a twofold decrease in mtDNA copy number (Table 35). 
mtDNA copy number determination in muscle and fibroblast from the patients showed that 
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the absolute copy numbers were two-fold reduced in the CMT2A patients in comparison to 
controls. Only one of the patients had non-significant decrease in the copy number, but was 
showing high accumulation of deletions (Table 35 and Figure 27). The observed depletion of 
mtDNA might be due to impaired mtDNA replication as it has been observed in patients 
carrying mutations in the OPA1 gene (Amati-Bonneau et al., 2008). It was previously 
described that the rate of oxidative phosphorylation is in linear connection to the mtDNA total 
amount (Kudin et al., 2002; Rocher et al., 2008). Thereafter, the mtDNA depletion is 
sufficient to explain the observed mitochondrial dysfunction. 
The impaired content mixing would suggest accumulation of mtDNA deletions, due to 
impaired functional complementation of the heteroplasmic molecules (Nakada et al., 2009); 
indeed, muscle and fibroblast samples from all four MFN2 patients show multiple deletions 
(Figure 27). Although, the deletion amount was higher then in age matched controls, their 
level was not as high to be responsible for the impaired mitochondrial function (not higher 
then 0.2 %). However, the patient who did not show mtDNA depletion was harboring 0.18% 
of deletions and was the only patient caring a deletion in the GTPase domain of MFN2. Our 
result is in apparent contrast with another study performed by Rouzier et al., 2012, where 
they have detected 49% deletions in skeletal muscle of one patient. This difference between 
the results can be due to the advanced age of the patient used in the Rouzier et al. study. 
These results demonstrate the diversity in mitochondrial functional alterations due to different 
mutations in the MFN2 gene, which can explain the diversity in the results from previous 
studies. 
The breakpoint analysis by smPCR revealed that some of the deletions observed in 
the patients were untypical; lacking the heavy strand replication origin or the light strand 
promoter, or their 3’ end breakpoint spans the replication termination site. 13 deletions of that 
type were detected (Figure 28). Until now deletions erasing DNA above 16,268 np were not 
described in the literature and only 4 deletions were registered to span the 16,085 np 
(Samuels et al., 2004). This kind of deletions lack parts of the mtDNA that are important for 
replication initiation. Accordingly, they cannot be result of clonal expansion, but rather a 
result from ongoing mutagenesis and impaired mtDNA repair. Out of the 69 mapped 
deletions, 56 were detected only once in the smPCR reactions, which is in consensus with 
the absence of clonality. In the MFN2 patients I detected deletions in the small arc of the 
mtDNA, which might be disease specific (Figure 28). Some of the deletions were spanning 
the np 16,100 going over the TAS region into the 7S (Figure 28). Deletions expanding over 
the 16,100 np are rarely described in the literature. To confirm the formation of these 
deletions, exceeding the TAS region, I checked for the presence of such deletions in 
fibroblasts treated with high doses of hydrogen peroxide. To follow the impairment of the 
mtDNA with the increase of hydrogen peroxide dose, I optimized a qPCR which can be used 
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for determination of the relative amplifiability of the mtDNA and evaluation of its integrity 
(Figure 29). By applying this method I could confirm the progressive mtDNA damage in linear 
dependence from the H2O2 treatment with increasing concentrations. In the H2O2 treated 
fibroblasts I detected deletions spanning the classical 3’ deletion breakpoint at 16,000–
16,100 np and entering into the 7S as well as small arc deletions (Table 36), as the ones 
observed in MFN2 patients. The appearance of such deletions due to oxidative stress, might 
point to ongoing oxidative stress in MFN2 patients. Furthermore, the impaired content 
mixing, might explain the absence of clonally expanding deletions and the accumulation of 
de novo mutations. 
Impaired mtDNA replication and mtDNA maintenance are most likely the reason for 
lowered mtDNA content and accumulation of multiple mtDNA deletions in CMT2A patients, 
with imparied mitochondrial dynamics. The insufficient content mixing would lead as well to 
insufficient substrates for efficient mtDNA replication and repair of ongoing mtDNA injury.  
 
4. 3 mtDNA deletions in TLE 
 
mtDNA polymerase errors, replication machinery failure and replication fork stalling during 
the process of mtDNA synthesis can lead to the formation of mtDNA mutations. mtDNA 
damage can arise as well form different factors such as exposure to environmental mutagens 
and specifically high vulnerability to ROS activity, due to its endogenous formation during 
mitochondrial respiration (Shokolenko et al., 2009) (Figure 38). The fate of the damaged 
mtDNA molecules (marked with a star on Figure 38) is crucial for the fate of the mitochondria 
and the cell itself. Damaged mtDNA molecules can either undergo repair or be degraded. 
The repair might end with the complete restoration of the mtDNA in its original state or might 
end in the formation of stable molecules with altered information, mutant molecules. Mutated 
molecules that are not missing parts of the DNA important for mtDNA replication can expand 
clonally, and because of their smaller size they might replicate faster than the wild-type 
mtDNA molecules. Mutation segregation and clonal expansion lead to the development of a 
pathological phenotype. However, as mitochondria are very dynamic organelles constantly 
involved in processes of fusion and fission and balanced mitochondrial content mixing, the 
damaged or mutated mtDNA is constantly complemented; therefore, the accumulation of 
deleted mtDNA molecules must reach certain threshold in order to cause pathological 
changes in the cells.  
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Figure 38   mtDNA mutagenesis. BER, base excision repair; MMR, mismatch repair; DSBR, double-
strand break repair; ROS, reactive oxygen species; *, damaged mtDNA molecules, (adapted from 
Zsurka and Kunz, 2013). 
 
As mitochondria are the main source of ATP in the neurons, failure of their respiratory 
chain function would lead to neuronal dysfunction and eventually to cell death. Most probably 
the local insufficiency of ATP in the neurons, for example, in the presynaptic terminal, is 
causative for the neuronal dysfunction rather then a general energy drop in the cell (Zsurka 
and Kunz, 2013). Mitochondria were shown to participate in modulating the neuronal 
excitability and the synaptic transmission (Tang and Zucker, 1997). 
Most likely, the local ATP shortage in combination with clonally expanding somatic 
mtDNA deletions leads to the slow progression of the disease (Zsurka and Kunz, 2013). This 
mitochondrial dysfunction was shown to play important pathogenic role in the seizure 
generation and epilepsy, and particularly in temporal lobe epilepsy (TLE) with Ammon’s horn 
sclerosis (AHS) (Kudin et al., 2009, Guo et al., 2010). mtDNA depletion and accumulation of 
mtDNA deletions through clonal expansion were described in TLE with AHS (Guo et al., 
2010). Neuronal cells, such as the interneurons or the pyramidal cells, containing more 
mitochondria are more prone to damage due to ATP shortage, in comparison to other 
neuronal cell types, such as the hippocampal granule cells, that have lower amounts of 
mitochondria (Gulyás et al., 2006, Zsurka and Kunz, 2013). These cells being rich of 
mitochondria are also more vulnerable to injury, due to their dependence on the ATP 
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production. The hippocampus is having lower seizure threshold and patients with TLE with 
AHS show segmental neuronal cell loss of pyramidal neurons in the CA1, CA3 and CA4 
regions of the hippocampus and almost no injury in the granular cell layer. This cell loss 
accumulates during the years and is considered as causative for the medicamentation 
resistance of patients suffering from seizures generated in the temporal lobes and for their 
severe memory impairment (Kudin et al., 2009). Figure 39 shows schematic overview of the 
pathological mechanisms and a postulated “vicious circle” of mitochondria damage, leading 
to epilepsy.  
 
 
 
Figure 39   Overview of the accumulation of mutated mtDNA, respiratory failure, and insufficient ATP 
supply leading to disease (adapted from Zsurka and Kunz, 2013).  
 
Comparison of the amounts of mtDNA rearrangements in the hippocampal brain 
regions CA1, CA3, AD and PH in samples from TLE patients with AHS, demonstrated that 
AHS patients show overall higher accumulation of deletions in all four investigated brain 
regions in comparison to hippocampal brain samples from the same regions in patients with 
TLE, resulting form brain lesion and with no hippocampal sclerosis, (Figure 30). Significant 
difference between the two sets of samples, with p<0.005 was detected in the CA3 and the 
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AD hippocampal regions. This finding is in consensus with the literature, as in the AHS 
pathology the CA3 region is one of the most affected brain regions. In the AD region the 
differences between the AHS and lesion groups was even more dramatic, with the AHS 
patients showing 12 fold higher level of deletion accumulation in comparison to the lesion 
group. The involvement of the AD region in the epileptogenesis is a matter of dispute and our 
finding of increased amount of deletions in this region in AHS patients might be relevant. It 
was shown that the AD region is involved in the first steps of the development of the epileptic 
seizure, by receiving synchronous discharges released due to neuronal cell loss in the 
cortex, in patients with injury-associated hippocampal epileptogenesis (Sloviter et al., 2012). 
Eventually, the longer survival of the granule cells in the AD region, that are not so prone to 
the seizure effects might explain the even higher amount of deletions in comparison to the 
CA3 region (Figure 30). Granule cell dispersion and changes in dendritic orientation and 
spine distribution were registered in patients with AHS (Freiman et al., 2011). Another study 
from Buckmaster and Dudek in 1997, showed functional abnormalities in the AD region of 
epileptic kainate-treated rats.  
It is not clear whether the hippocampal mtDNA deletions detected in TLE patients 
with AHS participate in the pathomechanism of the disease, or they are result from it. Our 
findings showed accumulation of deletions in all regions of the AHS brain samples in 20–30 
year old patients (Figure 31), in opposite to aged matched TLE lesion disease controls. 
Therefore, it is more likely that the mtDNA rearrangements in the AHS hippocampus are not 
age related and are causative for the disease rather then a consequence of it. These results 
suggest a different pathological mechanism leading to TLE in AHS patients, and dramatic 
and fast accumulation of deletions. In young AHS patients, the highest amount of the 
deletions was detectable in the AD region, whilst the CA3 region deletions accumulation was 
not significant. Thus, mtDNA perturbations in the AD region might be essential for the early 
stages of the disease.  
Oxidative stress and ROS production are involved in the processes of mtDNA 
damage and double-strand DNA breakage. Recently, it was suggested that DSB are 
important for the process of deletion formation (Krishnan et al., 2008).  They proposed that 
the 3’→5’ activity of an exonuclease, leads to the exposure of single stranded regions of 
mtDNA that sustain homologous binding to regions of the mtDNA with direct repeats. 
However, this model is valid only in homologous recombination. In 2009 Fukui and Moraes, 
have described a novel mouse model, in which they could trigger generation of deletions as 
consequence of DSB induction at a fixed position on the mtDNA. The model resulted in the 
formation of various in size deletions, with and without repeats, generated by homologous 
and non-homologous recombination and representing the situation in aging tissue.  It is 
known that in AHS patients, the 3’-end breakpoints of the deletions cluster at nucleotide 
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position (np) 16,070–16,090 (Zeviani, 1989; Guo, 2010), that was described as a hotspot for 
ROS activity (Zeviani et al., 1989; Srivastava and Moraes, 2005) and DSB formation 
(Bacman et al., 2009), which would suggest that this region might be the ‘fixed position’ of 
DSB occurance according to the model proposed from Fukui and Moraes, 2009. In other 
studies, the DSB generation at that region was described as result from replication fork arrest 
(Wanrooij et al., 2004) or due to its participation in homologous annealing, based on the 
single strand nature of the region (Krishnan et al., 2008). 
In order to check if deletions with 3’ breakpoints within the 16,070–16,090 region, are 
indeed present in samples included in this study, I performed comparative analysis of the 
detectable deletions amounts with primer pairs either including or excluding the  
16,070–16,090 region. The result showed that in AHS patients, great amount of the deletions 
seem to have their 3’ breakpoints within the 16,070–16,090 region (Figure 32). This result 
might signify increased ROS production as a causative feature in AHS patients with TLE. 
The presence of two specific deletions, with 3’ end within the 16,070–16,090 region, 
8649–16,084 (7.4 kb) and 5786–16,078 (10.3 kb), was examined in AHS and lesion TLE 
patients, by applying multiplex PCR. As a reference, the ubiquitous ‘common deletion’ (4977 
bp) was amplified together with the deletions of interest. According to the literatue the 4977 
bp deletion is a hallmark of degenerative phenotype, it accumulates with age in normal 
tissues and is detected at higher frequency in tissues with higher metabolic rate, such as 
brain and heart tissues (Wallace, 1992a; Bogliolo et al., 1999). In the CA3 region, more then 
60% of the AHS samples contained both the 7.4 kb and the 10.3 kb deletions. All samples 
positive for these specific deletions were containing the common deletion, too. In the lesion 
set, in 86% of the samples the common deletion was detectable, but in the absence of the 
two specific deletions. However, the two deletions of 7.4 kb and the 10.3 kb were detectable 
not only in the CA3 region, but in all four investigated brain regions of the AHS samples, with 
lowest frequency in the PH region. The detection of these two prominent deletional species 
in AHS patients supports the hypothesis of deletion formation based on the occurance of 
DSB at the 16,070–16,090 region.   
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Appendix I   
 
mtDNA deletions in skeletal muscle biopsies, fibroblasts and urine samples of MGME1 
patients. 
     
Sample Del Start Del Stop Repeat length Count 
M2061 262 16,069  2 
 461 13,522   
 529 14,382   
 3285 16,069   
 3959 15,737 7 4 
 3615 12,986 11 1 
M3737 315 16,193 10  
 499 15,028   
 508 14,808   
 512 13,925 6  
 535 14,119   
 873 15,539  5 
 886 15,972  4 
 3231 13,472   
 3296 16,034  4 
 3558 14,816  2 
 3578 14,813 8 1 
 3743 15,636  3 
 4514 14,310  4 
 5438 13,792   
 14,287 16,264 7  
M1976 3258 16,070  3 
 3846 14,701   
 4490 11,905   
 5240 13,812   
FB1976 84 16,094   
 168 16,222   
 196 15,195   
 399 16,061   
UR1976 3248 15,972   
 3272 15,541   
 3321 15,965  2 
 3346 15,971   
 3460 14,389   
 3615 12,986 11 2 
 4902 15,848 7  
 8649 16,084 12  
M931 115 12,304   
 308 13,786 5  
 310 15,539   
 462 13,788 6  
 482 14,142 6  
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continued     
     
Sample Del Start Del Stop Repeat length Count 
M931 499 14,517  2 
 506 14,346 6  
 540 4352   
 541 14,396   
 561 13,785  3 
 562 13,462  2 
 791 15,515  2 
 887 16,079   
 899 16,115 11 2 
 3266 16,078   
 3273 16,071  5 
 3280 16,032  3 
 3572 14,812   
 3578 15,546 10 1 
 3586 15,641   
 3603 14,801   
 3611 16,076  2 
 3614 14,068   
 4228 14,832   
M4050 539 14,393 10  
 561 15,529 6 5 
 1228 14,532   
 3529 15,749   
 4468 14,824   
 5742 14,586   
FB4050 971 15,212   
M4052 453 15,197  5 
 461 14,429  4 
 482 13,775   
 515 12,562 7  
 899 16,079   
 3333 14,138 9  
 3475 13,626   
 3496 13,039   
 3602 15,272 5  
 3615 12,986 11 1 
 3721 15,945  2 
 3959 15,737 7 1 
 4773 16,320   
FB4052 316 16,193   
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Appendix II 
 
mtDNA deletions in skeletal muscle biopsy of a POLG patient carrying the homozygous 
mutation p.Ala467Thr in the POLG gene. 
 
POLG muscle     
Del Start Del Stop Repeat length Count 
5477 11,061 5 2 
5484 11,056 7 2 
5491 11,061  2 
5623 13,000 11  
5788 13,922   
5788 13,067  2 
5789 13,922   
5790 13,922   
5796 13,922   
5830 13,922   
5841 13,649  2 
5841 13,923   
5842 13,922   
5918 13,344   
6135 12,302   
6219 15,538 6  
6342 14,004 11  
6366 13,635 5 2 
6440 13,841   
6544 13,843 8  
6640 13,240   
6789 14,098   
6930 13,563 10  
7132 14,533 7 2 
7515 14,594   
7516 13,799   
7695 15,386   
7752 13,346  2 
7818 16,071  2 
7819 16,070 6  
7922 16,071   
7946 15,539   
7986 16,072   
8029 15,541 5  
8498 15,612 13  
8533 12,766   
8766 16,068  2 
8929 14,530 4  
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continued    
   
Start Stop Repeat length Count 
9233 15,572   
9233 15,760   
9399 14,603   
9505 14,155   
9582 14,498 6  
9598 15,267 8  
10,292 16,070   
10,477 15,556  2 
10,874 15,572   
11,432 16,072   
11,725 15,443 5  
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Appendix III  
 
mtDNA deletions in skeletal muscle biopsies and fibroblasts of CMT2A patients. 
 
 
Sample Start Stop 
Patient 1 muscle 192 4,195 
 502* 3,498* 
 1,238* 3,601* 
 5,314 16,462 
 6,485 15,458 
 7,617 14,947 
 8,299 15,588 
 8,483 13,459 
 8,624 15,662 
 8,642 16,142 
 8,663  16,071 
 10,952 15,371 
Patient 1 fibroblasts 383 2,989 
 6,589  15,799 
 10,292 13,632 
Patient 2 muscle 464  3,575* 
 465 3,802 
 5,600 15,851 
 5,793 14,599 
 6,486 14,500 
 6,924* 14,280* 
 7,300 14,857 
 8,031* 16,069* 
 9,891 15,266 
 12,134 16,298 
Patient 2 fibroblasts 491 4,246 
 3,767 15,862 
 6,114 15,513 
 6,143 15,866 
 7,153 15,768 
 7,863 14,597 
 8,451 16,158 
 9,507 16,294 
Patient 3 muscle 220 4,570 
 561 3,896 
 548 4,442 
 556 4,001 
 790 4,527 
 985 4,739 
 1,847 4,256 
 6,326 11,683 
 6,427 11,679 
Appendix III 
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continued   
Sample Start Stop 
Patient 3 muscle 6,541 11,603 
 7,815 12,231 
 9,033 14,056 
 9,098 15,438 
 9,450* 14,443* 
 9,651* 14,602* 
 10,962 15,845 
 10,985 16,071 
 11,715 15,434 
Patient 3 fibroblasts 746 3,290 
 694 4,134 
 3,578* 15,546* 
 3,941 12,886 
 6,031* 16,071* 
 6,330 13,993 
 6,713 12,755 
 8,483* 13,459* 
 8,900 16,071 
Patient 4 fibroblasts 175 3,622 
 3,496 16,384 
 4,217 15,956 
 4,437 16,514 
 5,750* 15,613* 
 6,231* 15,434* 
 6,535* 15,397* 
 7,055 16,129 
 8,032 16,355 
 
 
 
*Repeatedly detected deletion species 
 
In red are listed deletion breakpoints lacking the replication origin OH or the L-strand promoter  
(5’-breakpoint below position 441) or with 3’-breakpoint located deep in the replication termination 
region beyond position 16,100. 
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